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Abstract 
 
Diabetes is a chronic disease that affects approximately 415 million people worldwide 
and this number is expected to rise to 642 million by the year 2040. 90% of cases of 
diabetes are type 2. Although some treatments are already available for type 2 diabetes, 
there are considerable side-effects associated with these drugs that include a risk of 
hypoglycaemia. Hence, there is an immediate need for new and more effective drugs. 
Naturally occurring flavonoids are known inhibitors of glycogen phosphorylase, which 
is a validated target for controlling hyperglycemia in type 2 diabetes. By exploiting 
computational methods such as molecular docking with Glide and post-docking binding 
free energy calculations using advanced QM/MM-PBSA calculations, we have screened 
a large library of 1239 5,7-dihydroxyflavone analogues which have the potential to bind 
at the inhibitor site of glycogen phosphorylase. We compared these results to our 
benchmark ligand chrysin, which can inhibit glycogen phosphorylase with a Ki of 19.01 
µm and identified thirteen ligands which are predicted to have better binding affinities 
exploiting a rigorous consensus scoring approach to reduce the chance of false 
positives. Favourable substituents on the predicted flavonoids included B ring hydroxyl 
and halogenated substituents in the ortho position and small hydrophobic groups on the 
meta/para positions directed towards the hydrophobic cavity of the binding site. 
Towards synthesis of these analogues, after many adjustments to the synthetic 
procedure it was identified that using methyl protection of the hydroxyls at the 5 and 7 
position in parallel with the Baker-Venkataraman re-arrangement managed to achieve 
high purity initial compounds with a relatively good yield. The procedure is now ready 
to be employed to synthesize all other predicted 5,7-dihydroxyflavone derivatives. 
Kinetics experiments will validate their potency against glycogen phosphorylase and 
structure activity relationship analysis can help further guide lead optimization 
alongside pharmacokinetics and in vivo studies, until we can achieve a more potent and 
drug-like inhibitor of glycogen phosphorylase for the treatment of type 2 diabetes. 
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Chapter 1 – Introduction 
 
1.1 – Introduction to Diabetes 
1.1.1 – Prevalence of Diabetes 
Diabetes has become a worldwide problem, which affects both high and low income 
countries; the International Diabetes Federation claims diabetes affected 382 million 
worldwide in 2013, and by 2035 for that number to rise to 592 million [1]. Diabetes is 
also a massive strain on financial resources, with the estimated global cost (direct and 
indirect) being 245 billion U.S. dollars in 2012 alone [2], which will rise due to more 
people developing the condition and inflation. 
 
Figure 1.1 - Map showing the number of people worldwide with diabetes and how 
many people are affected in different regions (taken from [3]). 
 
1.1.2 –Type 2 Diabetes 
Type-2 diabetes (T2D) or non-insulin-dependent diabetes mellitus is a heterogeneous 
disease characterized by hyperglycaemia. It is estimated that 21 million people in the 
U.S. have been diagnosed with 8.1 million undiagnosed. 90-95% of people diagnosed 
with diabetes have T2D, and are generally middle aged or older.  
2 
 
 T2D is characterised by three factors: 1) a resistance of insulin action on glucose 
uptake in tissues such as skeletal muscle, adipocytes and liver tissue, 2) relatively low 
production of insulin from the pancreas, and 3) impaired insulin action to inhibit the 
hepatic glucose production [4]. The insulin is a hormone which is created in the β-cells 
in the islets of Langerhans in the pancreas. Insulin has two major roles in the body: 
maintaining blood glucose levels and controlling glucose metabolism. It is important to 
regulate blood glucose levels in the blood, as too much glucose which is left to circulate 
in the blood (hyperglycaemia) can cause tissue damage over time [3], too little glucose 
(hypoglycaemia) can lead to tiredness, shaking and loss of consciousness [5]. Glucose 
can be regulated by insulin as insulin stimulates the translocation of the glucose 
transporter to the cell surface [6]. Glucose levels can also be regulated by decreasing 
glucose productivity, which can be achieved by decreasing glycogenolysis and 
gluconeogenesis. Both of these pathways produce glucose and are inhibited by insulin, 
however the key difference is that glycogenolysis produces glucose by breaking down 
glycogen, whereas gluconeogenesis forms glucose from pyruvate and other non-
carbohydrate substances.   
Chances of developing T2D can vary depending on several risk factors, including: 
obesity, poor diet, physical inactivity, age (>45 years), ethnicity, family history of 
diabetes and high blood glucose during pregnancy affecting the unborn child [3].  
 
1.1.3 – Type 1 Diabetes 
Type 1 diabetes (T1D) or diabetes mellitus, is an autoimmune condition which makes 
the body insulin-dependent. It’s a metabolic disorder of multiple aetiology characterized 
by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion [7]. These defects occur as the 
immune system attacks the β cells in the pancreas, which stop them producing the 
insulin. T1D has many differences to Type 2 Diabetes, as shown in Table 1.1. 
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Table 1.1 – Differences between Type 1 and Type 2 diabetes [8] 
Type 1 Diabetes Type 2 Diabetes 
Often diagnosed in childhood Usually diagnosed in adults over 30 
Not associated with obesity Usually associated with high levels of obesity 
Associated with above average ketone levels 
at diagnosis 
Associated with high blood pressure and/or 
cholesterol levels at diagnosis 
Treated with insulin injections or pumps Usually initially treated without medication 
or with tablets 
Cannot be controlled without taking insulin Sometimes possible to come off diabetes 
medication 
 
1.1.4 – Gestational Diabetes 
Gestational diabetes is the third main type of diabetes which affects roughly 18% of 
pregnant women, though it can be diagnosed during the first trimester, this type of 
diabetes doesn’t usually take effect until the second or third trimester [9]. The problem 
arises when the woman’s body produces more insulin than normal, increasing glucose 
levels in the blood, which insulin cannot bring under control. Symptoms of gestational 
diabetes are similar to T2D, with increased thirst, urination, tiredness, blurred vision 
and recurrent infections. This form of diabetes can usually be controlled with a healthy 
diet and regular exercise, however, some women require medication to keep their blood 
glucose levels under control [9]. This form of diabetes usually goes away after 
pregnancy, however, studies have shown that women who suffer from gestational 
diabetes are more likely to develop T2D in the future [10]. 
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1.2 – Signs & Symptoms 
Many people are undiagnosed with Type 2 diabetes, and can remain undiagnosed for 
many years; this may be due to how mild early symptoms are, which include symptoms 
such as being thirsty, increased appetite, increased urination, balantis [11], vomiting or 
stomach pains, lack of concentration or interest and unexplained weight loss. These 
symptoms can be very gradual taking a few years in some cases. However, when T2D 
develops symptoms become more prominent, which include: increased urination, 
feeling thirsty, fatigue, weight loss, blurry vision, itching, slow healing cuts & bruises, 
leg & feet ulcers, recurrent infections and loss of feeling or tingling in the feet [12]. 
 
 
Figure 1.2 – Symptoms of diabetes [13]. 
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1.3 – Health Conditions Exacerbated by Type 2 Diabetes 
 
People who suffer from diabetes are also at an increased risk of other avoidable medical 
complications such as angina, cardiac failure, strokes, retinopathy, renal replacement 
therapy and amputations (>100 amputations a week in the UK) [14].  
 
 
Figure 1.3 – Increase in avoidable complications between 2007 and 2012 [14]. 
 
These generally occur after several years of having T2D, and occurs due to tissue 
complications, such as in small blood vessels (microangiopathy). The frequency of 
arterial diseas such as atherosclerosis and macroangiopathy is increased in diabetics, 
leading to problems associated with coronary heart disease, strokes and peripheral 
vascular disease [15]. People with T2D are 32.0 per cent more likely to die earlier than 
the general population. It is estimated that there were around 22,060 in England and 
1,926 additional deaths in Wales due to diabetes, probably due to the increased 
prevalence of the complications mentioned in Fig 1.3 [16]. 
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1.4 – Current Treatment 
As it stands there is no known cure for type 2 diabetes. Also, given the nature of the 
condition, it is unlikely that a cure is possible any time soon, but instead effective 
lifelong treatment is currently needed. To avoid early symptoms getting worse and to 
reduce the possibility of developing extra health problems later in life, an early 
diagnoses is vital. For many people diagnosed with T2D, the first step to take is changes 
in the patient’s lifestyle, as overweight or obese people account for 80-85% of the risk 
of developing T2D [14]. So altering people’s lifestyle is the foundation of effective 
treatment. This includes a change of diet and exercise. For example with a 7% weight 
loss and at least 700 calories/week of physical activity, there is a 58% reduction in the 
incidence rate of diabetes [17].  
If lifestyle changes are impractical for the patient or they are unable to achieve and 
maintain any significant weight loss, then surgical intervention is a current treatment 
option. This involves surgically helping the patient to lose weight via procedures such 
as gastric bands and Roux-en-Y gastric bypasses (RYGB). The RYGB method usually 
results in a higher sustained weight loss of roughly 40-50%, while gastric bands only 
work 20-30% of the time, this may be due to the patients’ mentality and after care rather 
than the actual surgery. With RYGB surgery, patients with diabetes prior to surgery, 
resolution of the disease is reported in 65-90% of cases. Combined with the weight loss 
associated with post operation effects (decreased nutrient intake and changes in gut 
hormones), this can improve insulin resistance and β-cell function [18]. After RYGB 
surgery patients showed a significant decrease in blood glucose (P=0.005) and insulin 
levels (P=0.02) showing a clear effect on hormonal changes related to T2D [19]. This 
suggests that the control of diabetes may be a direct effect of the RYGB and not a 
secondary outcome [20], leading to potentially using this surgery as an early method to 
combat the onset of diabetes.  
 
1.4.1 - Oral Hypoglycaemic Agents 
As T2D is a progressive disease, eventually lifestyle changes alone will not be enough 
to control T2D. One source of treatment is oral hypoglycaemic agents such as 
metformin from the biguanide family, which acutely decreases hepatic glucose 
production. This is achieved by a mild and transient inhibition of the mitochondrial 
respiratory-chain complex 1 [21]. Metformin has also shown beneficial side effects by 
reducing LDL (Low Density Lipoprotein) cholesterol and triglyceride levels, these 
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reductions help cardiovascular problems associated with diabetes. There are some 
negative side effects, the most common is gastrointestinal upset, and more serious side 
effects include anorexia or diarrhoea. When taken in excess or by people with 
contraindications such as renal impairment, lactic acidosis (lactate build up in the blood) 
can be a problem [11]. This drug should also not be administered to people with hepatic, 
cardiac or respiratory failure or people with a history of alcohol abuse. Overall though, 
when prescribed properly, the overall risk of the drug is low and has been effectively 
used for decades, this is one reason it is generally one of the first drugs to be 
administered to the patient [18]. In principle metformin can adopt roughly 28 forms, 
depending on environment and protonation. 
NNN
N
H H
N
H
H
H
 
Figure 1.4 – Structure of Metformin [22]. 
 
1.4.2 - Sulphonylureas 
N
H
N
R2
H
OO
O
R1
S
 
Figure 1.5 – General structure of sulphonylureas. 
Sulphonylureas are generally second line treatments for patients after metformin alone 
[11]. The general scaffold is shown in Figure 1.5 and the different types currently 
marketed in Table 1.2. Sulphonylureas stimulate insulin secretion, which is achieved by 
binding to the sulphonylurea receptor (SUR-1) on the β-cell plasma membrane which 
closes the KATP channel. This causes the calcium channels, leading to an influx of 
calcium and exocytosis of insulingranules. A serious side effect to sulphonylureas is 
hypoglycaemia, particularly with glibenclamide. Side effects and effectiveness also 
dependant on a few other risk factors, such as alcohol intake, age, impaired renal 
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function and intake of drugs that displace sulphonylureas from their plasma protein 
binding sites. There is also the risk of weight gain [15]. 
Table 1.2 – Different sulphonylureas and their structures. 
Name Structure.  [23] [24] [25] 
Glibenclamide 
N
H
N
H
O
S
O
O
N
O
Cl
O
H
 
Gliclazide 
N
H
N
N
H
O
S
O
O
H
H
  
Glimepiride 
NN
O O
H
N
H
N
H
O
S
O
O
 
 
 
1.4.3 - Meglitinide Analogues 
O
O
OH N
O
H
N
 
Figure 1.6 – Structure of Repaglinide [26] 
Meglitinide analogues are very similar to sulphonylureas, as they also stimulate insulin 
secretion by inhibiting the same ATP-sensitive channels (SUR-1), however, the 
pharmacokinetic and pharmacodynamics properties are different to the sulphonylureas. 
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Meglitinide analogues such as repaglinide (Figure 1.6) are absorbed rapidly, stimulating 
the release of insulin in a matter of minutes, then being rapidly metabolised for 
excretion [27]. Side effects include greater weight loss (up to three kg in three months) 
and hypoglycaemia than metformin, but less diarrhoea [28]. 
 
1.4.4 - Insulin injections 
In the most severe cases of T2D, most patients will be advised to take a drug such as 
metformin along with the insulin injections. However, for some people this is not a 
viable option and they must take insulin alone [29]. This should always be combined 
with the lifestyle changes (diet & exercise) as much as possible, to increase 
effectiveness. There are multiple ways of administering insulin: Insulin administered 
with a syringe, insulin pens, insulin pumps and inhaled insulin. If administered properly 
in the correct areas, then insulin injections rarely cause problems, aside bruises [11]. In 
some cases lipoatrophy can occur, when injecting into the same area for long periods of 
time. This is less of a risk recently, as modern insulin is highly purified and causes a 
much smaller immune response.[15] 
 
1.5 - Synopsis  
Type 2 diabetes mellitus is a worldwide problem, accounting for 90% of all diabetes 
cases. There is a demand for more effective and safer drugs for combating such a 
widespread and problematic illness. This thesis will investigate glycogen phosphorylase 
(GP), as a target for T2D, and flavonoid analogue inhibitors of the caffeine binding site 
in particular. Flavanoids have already shown promise as GP inhibitors. Liver GP is an 
important target in T2D, as this is the enzyme that catalyses the breakdown of glycogen 
to glucose, so inhibition will reduce the amount of glucose production from the liver 
released into the blood. 
This project aims to design and synthesise analogues of 5,7-dihydroxyflavone 
derivatives which can inhibit GP more effectively than chrysin. This can be achieved by 
exploiting docking and post-docking computational methods, then, using these 
predictions to select candidates for synthesis. A synthetic protocol was optimised for 
these syntheses which ultimately led to the Baker-Venkataraman re-arrangement. The 
final products are to undergo kinetics experiments at our collaborators (University of 
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Thessaly, Greece) to determine their true potencies and X-ray crystallography to 
confirm their binding interactions with GP. This data will direct for further lead 
optimisations efforts using structure activity relationship methods, with the ultimate aim 
of designing a novel, safe and effective compound which can be used in the treatment of 
T2D. 
 
-Chapter 1 – A general introduction to diabetes, with explanations of its global effect, 
types of diabetes, the different ways it can affect people and some of the current 
methods used in treatment. 
-Chapter 2 – Glycogen Phosphorylase as a target for treatment of type two diabetes, as 
well as focus on glycogenolysis and how inhibiting this pathway can be an effective 
way to prevent hyperglycaemia. 
-Chapter 3- Flavanoids as potential agents for the inhibition of GP. Flavanoids are 
naturally occurring, low molecular-weight polyphenolic compounds [30]. These 
compounds have already shown potential to inhibit GP.  
-Chapter 4 – Computational background/theory presented, including a description of 
docking and in particular the programme Glide, from Schrödinger software, as well as 
quantum mechanics methods necessary to describe π-stacking effects of flavonoids 
binding at the GP caffeine binding site.  
-Chapter 5 – Synthetic methods and synthetic routes for compounds made, with a 
particular focus on the Baker-Venkataram rearrangement. 
-Chapter 6 – Computational results and discussions. 
-Chapter 7- Synthetic results and discussions. 
-Chapter 8 – Conclusion and future work. 
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Chapter 2 - Glycogen Phosphorylase 
 
2.1 – Glycogenolysis and Gluconeogenesis 
Glycogenolysis and gluconeogenesis are both ways in which the body produces 
glucose, which are both inhibited by insulin. However, gluconeogenesis is the 
production of glucose from the substrate pyruvate and other non-carbohydrate 
substances (Figure 2.1). Whereas glycogenesis is the production of glucose from the 
breakdown of glycogen (Figure 2.2), which is a complex carbohydrate. 
Gluconeogenesis also occurs in the kidneys, not just the liver and muscles [31, 32]. 
 
Figure 2.1. The glycogen phosphorylase dimer with the various ligand binding sites 
Gluconeogenesis is triggered when a sufficient amount of carbohydrate substrates are 
not available, for example, when starving or during intense physical exertion. 
Gluconeogenesis is the reverse process of glycolysis (breakdown of glucose for energy), 
using similar enzymes. This is made possible by three extra steps in the 
gluconeogenesis pathway, which are regulated by other enzymes.[32]  
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Figure 2.2 – The process of 
gluconeogenesis.[33] 
 
Figure 2.3–The process of                  
glycogenolysis.[33] 
 
 
2.2 – Glycogen Phosphorylase 
Glycogen Phosphorylase is an enzyme involved in glycogen metabolism 
(glycogenolysis), which catalyses the first step in the intracellular degradation of 
glycogen to give α-D-glucose-1-phosphate (G-1-P). Because of this, it has been a 
prominent target for T2D as many antihyperglycaemic agents focus on the inhibition of 
the GP’s inhibitor sites.  
 
2.3 - Structure, Function and Regulation of Glycogen Phosphorylase 
GP is the main regulatory enzyme for human carbohydrate metabolism, as it catalyses 
the breakdown of glycogen to G-1-P, which then undergoes isomerisation and 
interconversion to glucose-6-phosphate (G-6-P) by the enzyme 
phosphoglucomutase.[34] This G-6-P can then enter the glycolytic pathway or it can be 
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dephosphorylated by Glucose-6-phosphorylase to glucose and transported out of the 
cell. GP exists as a dimer of two interconvertible forms, there is a T-state and an R-state 
which exist in equilibrium, with a molecular weight of roughly 97500Da (Figure 2.3). 
The predominantly inactive T-state is the dephosphorylated form, GPb, which has low 
activity and substrate affinity. Then by either phosphorylation or AMP [35], the GPb is 
converted to the active R-state ‘ser14-phosphorylated’ form (GPa) which has a much 
higher activity and substrate affinity [36]. This reaction is reversed with the protein 
phosphate 1, which is released in response to insulin, and dephosphorylates the GPa 
back to GPb. There are also three isoforms of GP termed as “muscle”, “brain” or “liver” 
GP, depending on which tissue the isoform is preferentially expressed, each has a 
distinct physiological role.  
Muscle-GP is usually in it’s inactive GPb form. As muscles need a lot of energy, 
sometimes without a lot of warning, it is important to supply enough glucose to power 
the muscle when needed. As muscles do not have the glucose-6-phosphorylase enzyme, 
glucose is formed slightly differently, glycogen breaks down into the G-1-P and 
undergoes interconversion to G-6-P, as normal, but then the molecule enters glycolysis. 
GP itself starts in the inactive form, but as the muscle is worked ATP is used so AMP 
levels increase, this causes the GP to convert from the inactive T state to the active R 
state. This process generates the metabolic energy needed for muscle contraction. 
Brain GP exists at much lower concentrations as muscle and liver, however, it is still 
important, as small amounts of glycogen is stored in the brain (averaging 3-12 µmol/g), 
these low concentrations suggest that the GP and glycogen is not a primary energy 
source, [37] but as an emergency backup supply of glucose during times of anoxia, 
ischaemia, aglycemia or severe hypoglycaemia. 
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Figure 2.4 - Binding sites and conformational changes of glycogen phosphorylase. 
 
There are currently six sites on the GP enzyme; the catalytic site, caffeine binding site, 
glycogen storage site, AMP binding site, the indole binding site and the quercetin 
binding site (Figure 2.1). The structure of GP has been confirmed through multiple 
extensive X-ray crystallographic studies and information about the protein-inhibitor 
interactions in each binding site has been well researched [36, 38], perhaps with the 
exception of quercetin binding site, as this has only been recently discovered. These 
studies have allowed research into using these sites as targets for compounds, which 
may be able to manipulate the GP to prevent unwanted glycogenolysis under high 
glucose concentrations, which gives rise to numerous opportunities for GP 
manipulation. While the inhibitor site and quercetin binding site will be described in 
Chapter 3 due to their propensity to bind flavonoids, a brief description of other key 
binding sites on GP is given here.  
 
2.4 - Catalytic site 
The catalytic site is the active site of GP, where the glycogen is phosphorylased to G-1-
P. The site contains the essential pyridoxal 5’-phosphate (PLP) as a cofactor, located at 
the centre of the GP monomer subunit, which is accessible to bulk solvent through a 15 
Å long channel. [36] This is where domains 1 (residues 1-484) and 2 (residues 485-842) 
join. The catalytic site is inhibited by many compounds (150 have been studied in the 
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last decade) [39] and has been noted that many are glucose based analogues. When the 
inhibitor binds to the catalytic site, it stabilises the conformation at the 280s loop 
(residues 282-287) located between helices α-7 (residues 261-274) and α-8 (residues 
289-314), which blocks the substrate (glycogen) reaching the site, this promotes the 
inactive T-state conformation. This also prevents the conformational changes needed to 
form the functional catalytic site, such as the movement of Arg569 to the catalytic cleft 
to create the phosphate recognition site [40].  
When the enzyme is activated via the conversion from the T-state to the R-state, the 
280s loop becomes disordered and displaced, which creates the recognition site for the 
substrate phosphate, along with the opening of the 15 Å channel, this in turn allows the 
residue Arg569 to enter the catalytic cleft in place of Asp283, creating the phosphate 
recognition site mentioned earlier. The creation of this site allows the glycogen 
substrate to enter the catalytic site and promote a favourable electrostatic environment 
for PLP, due to the substrate phosphate site being within hydrogen bonding distance of 
the 5’-phosphate group of PLP [41].  
Whilst finding treatments for human liver GP would be ideal, most studies are carried 
out using rabbit muscle GPb (RMGPb), this is due to its availability and its ability to 
form good quality crystals. HLGPb and RMGPb share the same primary sequence as 
both the human muscle and liver phosphorylase (80%). AMP binds to both HLGPb and 
RMGPb and the residues that contact AMP are the same. There are no changes in the 
HLGPb sequence compared to RMGPb and out of the 171 amino acid difference 
between the two enzyme, 85 of them (29%) are conservative as well as the fact that 
most of the amino acid changes have no impact on the enzymes function. The active 
sites of HLGPb and RMGPb are also identical in both amino acid sequence and 
structural architecture, which means conclusions for the active site, drawn by binding 
studies with RMGPb, are applicable to HLGPb [42].  
 
Drug design for inhibitors of the catalytic site have been generally focused around 
glucose based analogues (Figure 2.4) with α- and β- substitutions on the anomeric C1 
atom. 
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Figure 2.5 – A glucose analogue, displaying 
α- positioning and β- positioning. 
 
Figure 2.5 shows the binding of glucose based analogue bound at the GPb catalytic site. 
The α- and β- substitutions have an effect on binding in the catalytic site, as this 
orientation can make binding stronger or weaker depending on sterics and 
intermolecular binding, for example, the α-D-glucose (1 in Fig 2.7) inhibits the GP at 
the catalytic site with a KI value of 1.7 µm for GPb inhibtion in rabbit muscle (RM). 
Whereas the β-D-glucose inhibitor (2 in Fig 2.7) binds to RMGPb with a Ki value of 7.4 
µm. The use of β- substituted glucose exploits the catalytic sub-site called the β-cavity, 
which is an empty space at the β-1-C configuration lined by both polar and non-polar 
groups. Due to the location of the catalytic site, the GP monomer structure is viable for 
modelling inhibitor binding at this catalytic site. [43] 
An important interaction used in inhibitor design, for the GPI catalytic site, is hydrogen 
bonding; hydrogen from the NH of ligands forms the hydrogen bond to the His377 via 
the main chain oxygen. N-Acetyl- β-D-glucopyranosylamine (NAG) (5 in Fig 2.7) also 
binds to the His377 oxygen, this inhibits RMGPb with a Ki of 32µm, which is roughly 
20 times better than α-D-glucose. NAG also binds to the catalytic site with very little 
structural conformational changes within the catalytic site and residues of the 280s loop 
are stabilised in the same conformation observed in the RMGPb - α-D-glucose complex. 
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Figure 2.6 – 1-(β-D-glucopyranosyl)-5-chlorouracil bound to the catalytic site or 
RMGPb. Hydrogen bonds represented in black. 
 
 
 
Figure 2.7 – Examples of glucose-based analogue inhibitors together, with their Ki 
values.  
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2.5 - Allosteric Site 
The allosteric site (AMP binding) site has been one of the most promising GP inhibitor 
binding site with respect to identification of potent, drug like molecules [18]. The site is 
located at the subunit, which is approximately 30 Å from the catalytic site and is 
partially exposed to solvent. The allosteric site can recognise a variety of 
phosphorylated compounds such as ATP, NADH, IMP, G-6-P, UDP-glucose, 2-deoxy-
glucose-6-P, β-glycerophosphate and inorganic phosphate. Inhibition of this site works 
by direct inhibition of AMP binding and/or indirect inhibition of substrate binding via 
stabilisation of the T or T' state conformation (superscript prime refers to the symmetry 
related monomer subunit). Compounds that activate the allosteric site, such as ATP and 
G-6-P, can change the equilibrium between the T and R-state [43]. The first potent and 
powerful AMP site inhibitors were a series of dihydropyridine dicarboxylic acids, 
shown in Table 2.1 along with the potency of the different R groups. [18] 
Table 2.1 – Potencies of selected dihydropyridine AMP site inhibitors. 
N
O
R 3
R 2
R 4
R 1
CO 2 H
 
Entry R2 R2 R3 R4 
hLGP(a) 
Ki (µM) 
Cell 
EC50 
(µM) 
1 Cl CO2H (i-Pr)-O Et 0.039 2.2 
2 H CO2H (i-Pr)-O Et 0.395 6.5 
3 Cl H (i-Pr)-O Et 15.6 NA 
4 Cl CO2H (i-Pr)-O H 0.692 11.0 
5 Cl CO2H 
(i-Pr)-
NH 
Et 9.1 NA 
6 Cl CO2H (i-Pr)-O CH2Ph 0.011 1.13 
7 Cl CO2H (i-Pr)-O Cl
 
0.002 0.48 
8 Cl CO2H (i-Pr)-O 
OMe
OMe
 
0.004 0.27 
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2.6 - Indole Site 
The indole binding site (also known as the new allosteric site) is located in the central 
cavity region of the subunit dimerization interface and is found 33 Å away from the 
catalytic site and is 50 Å from the glycogen storage site. [18] It has been found that 
when the indole site is inhibited the enzyme undergoes conformational changes induced 
by the binding of indole site inhibitors, which prevents activity. [18] 
Inhibitors of this site have been proven to be very powerful at lowering blood glucose in 
animal models of diabetes.  
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Chapter 3 – Flavonoids as Glycogen Phosphorylase Inhibitors 
 
3.1 - Introduction 
Nutraceuticals are products derived from natural sources which provide health benefits, 
along with their basic nutritional value found in foods. An area that can benefit 
tremendously from the use of nutraceuticals is T2D. T2D, which has been labelled as 
the epidemic of the 21st century, is one of the fastest growing chronic diseases globally 
and the fourth leading cause of mortality [44]. At present, preventative and therapeutic 
drug strategies for T2D do not achieve adequate control of blood glucose because they 
have limited efficacy, major mechanism-based side effects, lose their effectiveness over 
time, are not well-tolerated in some patients or may have poor risk-benefit ratios [45]. 
To prevent T2D, it is currently recommended to have a generous intake of plant 
products and reduced intake of fat from beef, pork and dairy sources, while 57% of 
diabetics pursue complementary and alternative therapies that assist in managing T2D. 
While more than 1200 plants and herbal extracts appear to affect blood glucose 
regulation, scientific evidence to support their efficacy against T2D is limited [45]. 
Research on novel antidiabetics to date has been dominated by studies on newly 
synthesised compounds and only recently have phytogenic compounds started to attract 
interest in T2D research. Phytogenic compounds have displayed a very promising 
capability to inhibit glycogen metabolism enzymes which make them promising targets 
for the treatment of T2D [42]. Despite the fact that plants have been the single most 
productive source of bioactive material for various nutraceutical applications, it is 
estimated that only 5 to 15 % of the 250,000 to 750,000 existing species of higher plants 
have been tested for bioactive compounds. Thus, the vast majority of the world’s 
structurally diverse natural compounds have not yet been tested for biological activity 
and therefore there is considerable potential for the discovery of novel bioactive 
compounds against T2D. In comparison to current pharmaceutical approaches, the study 
of plant-based remedies modulating physiological effects can provide natural effective 
oral antihyperglycaemic agents that potentially have little or no side effects for T2D 
patients. 
T2D is characterized by an excess of glucose production from the liver. One molecular 
approach aims to reduce this production, and involves inhibition of glycogenolysis as 
this process accounts for more than 70% of the glucose production, whilst most of the 
glucose formed from gluconeogenesis (de novo synthesis of glucose) is also cycled 
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through the glycogen pool [46, 47]. As described in Chapter 2, GP is an important 
enzyme in blood glucose homeostasis, catalysing the breakdown of glycogen to 
glucose-1-phosphate (Glc-1-P) which leads to the release of monomeric glucose from 
glycogen deposits [48]. GP is a validated target for the discovery of antihyperglycaemic 
agents [49, 50] since GP inhibitors can affect blood glucose levels and hepatic glycogen 
balance, as demonstrated by in vitro cell biology experiments [51] and animal studies in 
rodent models of diabetes [52-54].  
 
3.2. - Flavonoids 
Flavonoids are polyphenols and ubiquitous components in food of plant origin. 
Studies in diabetic and non-diabetic rats have shown that they do have anti-
hyperglycemic properties due to their effect on glycogen metabolism [55-57]. They are 
consumed daily as part of a healthy diet of fruit and vegetables and are recognised for 
many of their health benefits including antioxidant, antibacterial, anticancer, anti-
inflammatory and antidiabetic activities, along with protection against cardiovascular 
disease [58-61]. Data such as the United States Department of Agriculture (USDA) 
database for flavonoids facilitates the assessment of daily flavonoid intake [62-64]. 
However, the amount of flavonoids present in food is influenced by a number of factors 
and different populations have different diets. As an example, based on an analysis of 
the population’s commonly consumed foods, such as vegetables, fruits and beverages 
[65], the consumption of flavonoids in the USA has been reported as 20 mg/day, which 
is significantly different compared to Holland, which is > 70 mg/day. A study of 100 
edible fruits and vegetables consumed in Harbin city, China, revealed the predominant 
flavonoids found in all of the foods that were analysed was kaempferol, followed by 
luteolin and quercetin [66]. Red wine and teas are also rich in flavonoids, and extracts 
from these sources have been explored for their GP inhibitory potential (vide infra) [67-
69].  
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Figure 3.1 - Structural classification of flavonoids 
 
 
Structurally, flavonoids have a generic scaffold which consist of two aromatic rings (A 
and B), joined by three carbons which are usually in a heterocyclic ring C containing 
oxygen. It is the differences on the heterocyclic ring C that classifies flavonoids as 
either flavones, flavanols, flavonols, flavanones, isoflavonoids and anthocyanidins (Fig. 
3.1). The substitution patterns for different flavonoids of each type relevant to this 
discussion are shown in Table 3.1. Within the subgroups of flavonols and flavones, the 
flavonol quercetin is the most commonly found in foods. Isorhamnetin, kaempferol and 
the flavones apigenin and luteolin are also common. Thousands of structurally unique 
flavonoids have been found and databases containing their structural, biological and 
physicochemical properties are available from sources such as the National Cancer 
Institute (NCI) database (https://cactus.nci.nih.gov/ncidb2.2/) and the ZINC docking 
database (www.zinc.docking.org) [70], while the flavonoid content in selected foods are 
available from the United States Department of Agriculture (USDA) flavonoid 
database.   
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3.3 – Glycogen Phosphorylase Inhibition by Flavonoids 
In recent years, natural flavonoid derivatives from the structural classes presented in 
Figure 3.1 have been investigated as GP inhibitors [68, 69, 71-75]. The results of these 
mainly IC50 binding assay experiments against RMGPa and/or RMGPb along with some 
Ki values from kinetics experiments are shown in Table 3.2. 
The leading flavonoid inhibitors of GP are on the low µM range. Jakobs et al. found in 
their study that almost all flavonoids tested inhibited phosphorylated active RMGPa and 
unphosphorylated AMP activated GPb, however inhibition of GPa was two to four 
times stronger than inhibition for RMGPb [71]. The active form of GP is therefore more 
strongly inhibited which is favourable for the regulation of blood glucose levels in T2D 
patients. However, inhibition is very sensitive to the substitution patterns of the 
flavonoids; a number of flavonoids in each structural class demonstrate little to no 
inhibition, which is believed to be due to the substitutions. The best inhibitors from 
different studies are the flavonols quercetin (IC50(GPa) = 4.8 µM; IC50(GPb) = 20.9 
µM) [71] and quercetagetin (Ki(GPb) = 3.5 µM) [73], flavones baicalein (IC50(GPa) = 
11.2 µM; IC50(GPb) = 10.2 µM) [71], hypolaetin (IC50(GPb) = 15.7 µM) and 6-
hydroxyluteolin (IC50(GPb) = 11.6 µM) (Kato et al., 2008) [73]. The flavone chrysin 
seems to be more potent for GPb (IC50 = 15.3 µM) than GPa (IC50 > 27.5 µM) [71]. 
Unfortunately, no flavanone or isoflavone showed inhibition based on the few 
compounds tested. Of the anthocyanidins, cyanidin (IC50(GPa) = 3.0 µM; IC50(GPb) = 
9.0 µM) and delphinidin (IC50(GPa) = 3.1 µM; IC50(GPb) = 10.7 µM) were the most 
potent [71], while for the catechins the best inhibitors of GPa were EGCG (IC50(GPa) = 
7.7 µM; IC50(GPb) = 34 µM) and ECG (IC50(GPa) = 12.5 µM; IC50(GPb) ≥ 27 µM) [68, 
71], while GCG has also exhibited low µM inhibition for GPb (IC50 = 34 µM) [68]. 
Recently, binding of gallic acid as well as its dimer ellagic acid to GPb were studied by 
crystallography (vide infra) and kinetics. Ellagic acid is a potent inhibitor of GPb (IC50 
= 12.1; Ki =13.4 µM) as determined by two studies [71, 76] and approximately 2-4 
times more potent for GPa (IC50 = 3.2 µM; Ki =3900 µM) [71]. On the other hand gallic 
acid demonstrated poor inhibitory potential in comparison [71, 76].  
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Table 3.1. Substitution patterns of relevant flavonoids. Numbering of substituents according to 
the basic structure given below 
A C
B
3
45
6
7
8
2'
3'
4'
5'
6'
O
 
Basic Structurea 
  3 5 7 3’ 4’ +OH +OCH3 
Flavones         
DHF     OH OH   
Chrysin   OH OH     
Apigenin   OH OH  OH   
Luteolin   OH OH OH OH   
Tricin   OH OH OCH3 OH  5’ 
Baicalein   OH OH   6  
Hypolaetin   OH OH OH OH 8  
6-hydroxyluteolin   OH OH OH OH 6  
Isoscullarein   OH OH  OH 8  
Flavonols         
Quercetin  OH OH OH OH OH   
Quercetagetin  OH OH OH OH OH 6  
(-)-Epicatechin (EC)  OH OH OH OH OH   
Isorhamnetin  OH OH OH OCH3 OH   
Kaempferol  OH OH OH  OH   
Flavanones         
Naringenin   OH OH  OH   
Hesperitin   OH OH OH OCH3   
Eriodictyol   OH OH OH OH   
Isoflavones         
Daidzein    OH  OH   
Genistein   OH OH  OH   
Catechins         
(+)-Catechin  OH OH OH OH OH   
(-)-Epicatechin  OH OH OH OH OH   
(EGC)b  OH OH OH OH OH 5’  
(ECG) (2S,3S)c  Galloyl OH OH OH OH   
(EGCG) (2S,3S)d  Galloyl OH OH OH OH 5’  
(GCG) (2R,3S)e  Galloyl OH OH OH OH 5’  
(CG) (2R,3S)f  Galloyl OH OH OH OH   
Anthocyanidins         
Pelargonidin  OH OH OH  OH   
Cyanidin  OH OH OH OH OH   
Delphinidin  OH OH OH OH OH 5’  
Peonidin  OH OH OH OCH3 OH   
Malvidin  OH OH OH OCH3 OH  5’ 
a) Refer to Fig 3.1. for the different structural classes. b) Epigallocatechin. c) Epicatechin 3-gallate. d) 
Epigallocatechin 3-gallate. e) Gallocatechin gallate. f) Catechin 3-gallate. 
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Table 3.2. IC50 values (µM) for inhibition of GPa and GPb of flavonoids tested in concentrations up 
to 50 µM. 
Compound IC50 GPa (µM) IC50 GPb (µM) 
 
Compound IC50 GPa (µM) 
IC50 GPb 
(µM) 
Flavones    Anthocyanidins   
DHF >50 [71] >50 [71]  Pelargonidin 43.6 [71] 6.2 [71] 
Chrysin >27.5 [71] 15.3 [71]  Cyanidin 3.0 [71] 9.0 [71] 
  19.0 [76]  Delphinidin 3.1 [71] 10.7 [71] 
  19.01 (Ki) [75]  Peonidin 25.1 [71] 17.6 [71] 
Apigenin >30 [71] No effect up to 30 [71] 
 Malvidin >50 [71] >50 [71] 
Luteolin 15.6 [71] 28.8 [71]  Catechins   
  29.7 [73]  Catechin No effect [71] No effect [71] 
  31.7 [73]  Epicatechin No effect [71] No effect [71] 
Tricin >50 [71] No effect [71]    No effect [73] 
Baicalein 11.2 [71] 10.2 [71]  Epigallocatechin No effect [71] No effect [71] 
Hypolaetin  15.7 [73]    No effect [71] 
6-
hydroxyluteolin  11.6 [73]
  ECG 12.5 [71] 50 [71] 
Isoscullarein  46.1 [73]    27 [68] 
Flavonols    EGCG 7.7 [71] 33.9 [71] 
Quercetin 4.8 [71] 20.9 [71]    34 [68] 
  33.5 [73]  EGC  >400 [68] 
Quercetagetin  9.7 [73]  GCG  6.3 [68] 
  3.5 (Ki) [73]  CG  35 [68] 
(-)-Epicatechin 
(EC)  290 [68]
  Other   
Flavanones    Ellagic acid 3.2 [71] 12.1 [71] 
Naringenin >50 [71] No effect [71]   7.5 (Ki) [76] 13.4(Ki) [76] 
Hesperitin No effect [71] No effect [71]  Gallic acid No effect [71] No effect [71] 
Eriodictyol No effect [71] No effect [71]   3900(Ki)[76] 1730(Ki) [76]  
Isoflavones    Caffeine  130 [77] 
Daidzein No effect [71] No effect [71]     
Genistein >50 [71] No effect [71]     
 
The most favourable flavonoid inhibitors of GP discussed are shown in Figure 3 where 
the substitution patterns exhibit diversity. While initially it was believed that flavonoids 
may exert their inhibitory potential through binding at the same GP binding site, it is 
now clear due to recent work [68, 73, 75] that their mode of action/binding site is 
extremely sensitive to the structural class and/or substitution patterns. The binding site 
of most flavonoids is unknown (c.f., for example in Fig. 3.3). 
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quercetin quercetagetin hypolaetin 
IC50(GPa) = 4.8 [71] IC50(GPb) = 9.7 [73], (3.5(Ki)) [73] IC50(GPb) = 15.7 [73] 
IC50GPb = 20.9 [71], (33.5) [73], 
(34.8)f Binding site: allosteric Binding site: unknown 
Binding site: quercetin   
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6-hydroxyluteolin cyanidin delphinidin 
IC50(GPb) = 11.6 [71] IC50(GPa) = 3.0 [71] IC50(GPa) = 3.1 [71] 
Binding site: unknown IC50(GPb) = 9.0 [71] IC50(GPb) = 10.7 [71] 
 Binding site: unknown Binding site: unknown 
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Figure 3.2 - Most potent flavonoid inhibitors of GP known to date. 
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3.4 - Flavonoid Binding Sites 
 
3.4.1 - Inhibitor Site 
The GP inhibitor site (Figure 3.1), which is also known as the caffeine binding site (Ki ~ 
0.1 mM) [78, 79], is located on the surface of GP at the entrance to the catalytic site 
(some 12 Å from it). It is a hydrophobic binding pocket and when in the T state 
conformation, Phe285 from the 280s loop is stacked close to Tyr613 with these two 
aromatic residues forming the core of the inhibitor site. When inhibitors bind at this site, 
they stabilize the GP T-state conformation and block access to the catalytic site, thereby 
inhibiting the enzyme. Inhibition at this site is synergistic with glucose, suggesting that 
inhibition could be regulated by blood glucose levels and would decrease as 
normoglycaemia is reached and diminish the risk of hypoglycemia. Purines, 
nucleosides, nucleotides [49], some indirubins [80-82] and flavonoids [75] together 
with flavopiridol [74, 75] are known to bind at this site, by exploiting π-π stacking 
interactions of their aromatic rings between the side chains of Phe285 and Tyr613.  
 
Figure 3.3 - Binding of the flavone chrysin at the GP inhibitor site as determined using 
X-ray crystallography (PDB code: 3EBO) [75]. The key interactions are shown in (a) 
with the compound sandwiched between the Phe285 and Tyr613 residues exploiting π-π 
stacking interactions and a number of water bridging (blue) protein-ligand interactions. 
In (b), the hydrophobic pocket lined by Phe771, Tyr573 and Ile380 in the vicinity of the 
flavonoid ring B is highlighted. 
 
The binding of chrysin at the inhibitor site (PDB code: 3EBO) [75] is shown in Figure 
3.3. As first thought, the main characteristic feature for chrysin binding to GPb is the 
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stacking interactions between the two aromatic residues, Phe285 (from the 280s loop) 
and Tyr613. When chrysin binds to GPb, it forms a few polar/polar interactions and 
exploits numerous van der Waals contacts dominated by the substantial contacts made 
to Phe285 and Tyr613 by the aromatic ring [83]. Of particular significance to binding of 
flavonoids at this site is the hydrophobic pocket formed by Phe771, Tyr573 and Ile380, 
as highlighted in Figure 3.3(b). It has been postulated that flavonoids with polar OH 
substituents on ring B and in particular at position 4’ are unfavorable for inhibitor site 
binding on the basis of quantum mechanics – molecular mechanics / Poisson Boltzmann 
surface area (QM/MM-PBSA) binding free energy (ΔGbind) calculations [75].  In 
support of this, calculated ΔGbind values for quercetagetin with 3’ and 4’ OH 
substituents suggested poor binding at the site, in agreement with multiple inhibition 
studies using Dixon plots which suggest that quercetagetin binds at the allosteric site 
[73]. The hypothesis was further corroborated by the recent discovery of the quercetin 
binding site discussed below [67]. 
The most potent natural compound currently known to bind at the inhibitor site is 
ellagic acid. Kyriakis et al. recently published a comprehensive kinetics and 
crystallographic study on the binding properties of gallic acid and its dimer ellagic acid 
to GP [76]. Ellagic acid was found to bind with Ki’s of 7.5 and 13.4 μM for GPa and 
GPb, respectively [76]. In comparison, the binding of gallic acid displays weaker Ki’s of 
3.9 and 1.7 mM, respectively. Ellagic acid (but not gallic acid) binds in a strongly 
synergistic mode with glucose. The inhibition behavior of both compounds was 
additionally investigated with respect to caffeine and allosteric activator AMP. Multiple 
inhibition studies using Dixon plots revealed that the binding of ellagic or gallic acid 
and caffeine is mutually exclusive, that is, they compete for the same binding site. 
Similar analysis using AMP which binds at the allosteric site revealed that gallic or 
ellagic acids and AMP are not mutually exclusive. The experiments, therefore, indicated 
that gallic and ellagic acid bind to the inhibitor binding site. The reported crystal 
structures of the RMGPb-gallic acid (PDB code: 4Z5X) and RMGPb-ellagic acid (PDB 
code: 4YUA) confirmed binding at the site. The binding modes of both ligands are 
similar. As expected, the characteristic binding feature is stacking interactions between 
Phe285 and Tyr613, as shown in Figure 3.4 for the RMGPb - ellagic acid complex. 
Ellagic acid exploits nearly twice as many van der Waals interactions with GPb 
compared to gallic acid; it forms one direct hydrogen bond to the Asn282 sidechain 
(ND atom) but has a number of protein-ligand water bridged interactions with Asp283, 
Ile570, Ala610, Gly612, His614 and Met615. On binding at the inhibitor site, solvent 
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accessible surface area calculations indicate that ~ 74% of both ligands become buried, 
almost all from non-polar groups.  Kyriakis et al. found an approximate correlation 
between ligand binding affinities acting at the inhibitor site and total buried surface 
areas (protein + ligand). 
 
Figure 3.4 - Binding of the ellagic acid at the GP inhibitor site as determined using X-
ray crystallography (PDB code: 4YUA) [76].  
 
The most potent compounds binding at the inhibitor site discovered to date are 
flavopiridol (a synthetic flavonoid) [74, 75] and flavopiridol analogues [84] (Table 3.3). 
While flavopiridol has a Ki of ~1.2 µM, analogues of flavopiridol with a flattened 
tetrahydro-pyridine ring and halogen substituted phenyl ring B have revealed potencies 
ranging from 0.83–2.75 µM. The most favorable substitution in this series is the 3-Cl 
analogue. Halogen substitution and binding effects through the σ-hole phenomenon are 
now widely recognized and exploited in rational drug design [85], a successful example 
of which can also be found for the design of GP catalytic site inhibitors [39]. 
Replacement of the B phenyl ring of the flavopiridol derivatives by a methyl (Ki = 241 
µM) or a tert-butyl (no inhibition) group was found to be detrimental to potency [84].  
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Table 3.3. The chemical structures of the most potent inhibitors known to bind at the GP 
inhibitor site together with their Ki’s for RMGPb inhibition 
Flavopiridol Ki (µM)  
Flavopiridol 
derivatives 
R Ki (µM) 
O
N
O H
C H 3
O H
OH
O H
Cl
 
1.16 
[74] 
 
O H
O
O H
N
C H 3
OH
R
 
H 1.28 [84]
 
1.24 
[75] 
 2-Cl 0.99 [84]
 
  3-Cl 0.83 [84]
 
  4-Cl 1.89 [84]
 
  2-F 2.75 [84]
 
  2-Br 1.50 [84]
 
  3,5-
diCl 
2.50 [84] 
 
 
 
The crystal structure of flavopiridol in complex with RMGPb (PDB codes: 1C8K, 
3EBP) has been solved [74, 75] and the structural features of inhibition compared to 
those of chrysin (PDB ID: 3EBO) [75]. The common cores of flavopiridol and chrysin 
superimpose quite well [75] stacked between Phe285 and Tyr613. Flavopiridol, the 
binding of which is shown in Figure 3.6 makes a few polar/polar interactions with water 
molecules and has numerous van der Waals contacts. The chlorophenyl ring B extends 
towards the hydrophobic pocket lined by Phe771, Tyr573 and Ile380 (as highlighted in 
Figure 3.3(b)) but the chlorine atom does not form a strong halogen bond with GPb and 
is mainly involved in van der Waals interactions. 
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Figure 3.5 - Binding of flavopiridol at the GP inhibitor site as determined using X-ray 
crystallography (PDB code: 3EBP) [75].  
 
3.4.2 - Quercetin Binding Site 
Recent screening of thirteen polyphenolic extracts obtained from the vinification 
byproducts of Vitis vinifera that displayed significant inhibitory potency for RMGPb in 
vitro (IC50 values in the range of low µg/mL) revealed that the most active ingredient of 
these extracts is the flavonoid quercetin [67].  Quercetin was found to bind to a novel 
binding site, which was unknown at the time.  This new site is 15 Å away from the 
active site, 43 Å from the allosteric site and 32 Å from the inhibitor site [67]. The site is 
a shallow groove, created by Lys544, Arg551, Lys655, and Tyr548 on one side and 
Glu120 and Glu123 on the other side. Quercetin, upon binding to GP, forms hydrogen 
bond and van der Waals interactions with Arg551, Lys544. It is also involved in water-
bridging interactions with Glu121, Lys655, Leu494, Cys495, and Glu654 (Fig. 3.7). 
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Figure 3.6 - Binding of quercetin at the GP inhibitor site as determined by X-ray 
crystallography (PDB code: 4MRA) [67].  
 
3.4.3 - Allosteric and New Allosteric Sites 
As stated earlier, quercetagetin binds at the allosteric site on the basis of multiple 
inhibition studies using Dixon plots [73]. With respect to the new allosteric site, binding 
of gallocatechin gallate (GCG) (Ki = 6.3 µM for RMGPb) at this site has been proposed 
also on the basis of multiple inhibition studies using Dixon plots [68]. The new 
allosteric site is located inside the central cavity formed by the association of the two 
GP subunits, 15 Å from the allosteric site, 33 Å from the catalytic site and 37 Å from 
the inhibitor site. 
 
 
3.5 – Flavonoid Anti-Oxidant Effects 
 
Multiple studies have been conducted investigating flavonoid antioxidant and 
antiradical activities. Reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) are both beneficial and harmful to cells [86]. However, when there is an 
imbalance between free radical production and antioxidant capacity, a state of oxidative 
stress arises. Oxidative stress plays an important role in the pathogenesis of a number of 
disorders such as cardiovascular disease, inflammation, and neurodegenerative diseases 
[87, 88]. Elevated ROS levels have also been connected to T2D [89, 90] and the 
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resulting oxidative stress is a major cause of hyperglycemia-induced diabetic 
complications [89-93]. Hyperglycemia stimulates the formation of ROS/RNS from 
sources such as the mitochondrial complex II, oxidative phosphorylation, glucose 
autooxidation, NAD(P)H oxidase, lipooxygenase, cytochrome P450 monooxygenases 
and nitric oxide synthases (NOSs). NADPH oxidases produce superoxide and/or 
hydrogen peroxide as intermediates of redox reactions [94]. Multiple independent 
strategies that can alleviate mitochondrial ROS production were shown to prevent some 
of the typical secondary complications that arise from type 2 diabetes, including the 
activation of protein kinase C or NF-kB and the formation of advanced glycation end 
products. Superoxide is also generated by glucose auto-oxidation which is related to the 
formation of glycated proteins in the plasma of diabetic patients [95, 96]. The 
interaction of these advanced glycated proteins with their corresponding cell surface 
receptors further stimulates ROS production and reduces intracellular glutathione levels 
[97]. Furthermore, hyperglycemia boosts cell-mediated low-density lipoprotein (LDL) 
peroxidation in endothelial cells [98].  
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Figure 3.7 - Antioxidant (AO) and antiradical (AR) activities of flavonoids [99] as discussed 
in the text. % AO activity was calculated as % inhibition of oxidation with versus without 
flavonoid present (β-carotene and linoleic acid system). The scavenging of free radicals 
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using DPPH assay (% AR activity) was also measured versus a reference without flavonoid 
as described in the original reference [99].   
 
Treatment with antioxidants has been shown to alleviate many diabetic complications 
[100-103], although the benefits of antioxidant supplements are controversial [104]. 
Flavonoids have been reported as scavengers of a wide range of ROS and RNS, as well 
as inhibitors of lipid peroxidation [105, 106]. The number of hydroxyl groups, a C2-C3 
double bond (C ring) and a 3-OH group have been referenced as conditions for 
favourable antioxidant and antiradical activities [99, 107-109]. Burda et al. additionally 
highlighted the importance of a flavonol structure or 4’-OH substituent to antiradical 
activity [99]. In a study of 42 structurally diverse flavonoids for their antioxidant and 
antiradical activities [99] measured by heat-induced oxidation in a β-carotene and 
linoleic acid system and by 1,1-diphenyl-2-picrylhydrazyl (DPPH) decoloration test, 
respectively, among the most active that also exhibits potent GP inhibition was 
quercetin (63.6% antioxidant (AO) activity; 89.8% antiradical (AR) activity). Other 
examples of flavonoids which revealed both good antioxidant and antiradical activities 
(Fig. 3.8) were kaempferol (65.3% AO; 93.5% AR), galangin (64.9% AO; 91.8% AR), 
morin (63.5% AO; 96.5% AR), robinetin (61.7% AO; 82.3% AR) and fisetin (61.6% 
AO; 79% AR). All of these compounds are flavonols and have a 3-OH substituent. 
Flavonols with a free 3-OH were very effective antioxidants and also had high activities 
towards scavenging DPPH radicals. Blockage of the 3-OH group by glycosylation or 
methylation resulted in a complete loss of antioxidant activity, consistent with other 
studies [110]. Flavonoids without hydroxyl groups or with hydroxyls only at C-5 and/or 
C-7 had no effect on scavenging of free radicals; the effect of a 4’-OH substituent on the 
hand, as mentioned above, was significant. It would be interesting to test robinetin and 
fisetin for their GP activity to establish the importance of the 5-OH group to potency, 
and morin because of the 3’-OH and 5’-OH disubstitution on ring B. Galangin, with its 
unsubstituted B ring, is potentially a potent GP inhibitor acting at the inhibitor site.   
 
3.6 - Conclusion 
The development of antidiabetic medication from natural products has recently begun to 
receive considerable attention. A number of studies have highlighted the benefits of 
polyphenolic natural compounds with hypoglycemic effect and their importance in the 
management of diabetic complications. These compounds can have nutraceutical 
potential and/or can provide scaffolds for the development of more effective 
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pharmaceuticals for T2D treatment. This section highlights the potential 
antihyperglycaemic effects of natural flavonoids acting through inhibition of GP, a 
validated target for T2D treatment. A number of these compounds are low µM 
inhibitors and the structural basis of the potency as currently known has been analyzed, 
providing information for further structure based inhibitor design efforts. These 
substances can also serve as lead compounds with sufficient structural diversity to be of 
considerable importance in the development of new antihyperglycaemic agents. Some 
of the compounds also exhibit anti-oxidant effects relevant to prevention of diabetic 
complications [111]. 
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Chapter 4 - Computational Approaches to Drug Design 
 
4.1 - Introduction 
Medicines are often derived from natural sources such as plants as described in detail 
for flavonoids targetting GP in the previous chapter. Even though this is a continued 
area of study, there is now the potential to synthesise a large array of compounds which 
aren't currently found in nature. Combine this with the endless possibilities of 
derivatives and sub groups creates a vast library of potential drugs. However, this is not 
practical, as manually synthesising these compounds, then taking them through to 
human-trails is incredibly expensive and time consuming. This enormous library can be 
reduced, through target based screening during the early stages of drug discovery, which 
is far more cost-effective than physically testing each compound. Key to this process in 
modern day drug design efforts is the application of molecular modelling methods with 
the benefit significantly savings in terms of both time and money. These methods have 
become an integral part of drug discovery projects both in academia and industry. There 
are two main types of drug design: structure-based drug design (SBDD) and ligand-
based drug design (LBDD). In SBDD, the structure of the target is known and can be 
exploited to guide ligand design efforts. For LBDD, the structure of the target is 
unknown and relies on binding data being available for a set of ligands which can then 
be compared and modifications suggested exploiting methods such as quantitative 
structure activity relationship (QSAR) analysis. When a set of actives (compounds 
which have activity against the target site) are known for a given target, pharmacophore 
modelling  can also be used to identify common structural features (and distances 
between them) such as hydrogen bond donors, hydrogen bond acceptors, halogen 
groups, aromatic groups and hydrophobic group positions that are crucial to activity. 
The pharmacophores can then be used to search many of the available on-line databases 
such as ZINC (www.zinc.docking.org) [112], the database we have employed in the 
current study. For SBDD, docking is the most commonly applied method, whereby 
ligand binding to the receptor is explicity predicted exploiting the many known 
biological macromolecular targets solved and deposited in the RCSB Protein Database 
(www.pdb.org). This can be used to screen and identify potential hit compounds from 
different sources and the on-line databases previously mentioned. Although primarily 
used for hit identification, docking accuracy has increased dramatically in recent years 
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such that docking may now also help in lead optimization efforts, suggesting 
modifications that have the potential to improve activity [113].  
 
In the current work, targeting the inhibitor site of GP, the core interactions in the 
binding site are π-stacking interactions between the flavonoid(s) and Phe285 and 
Tyr613. Accurate modelling of these interactions are currently beyond the scope of 
docking methods due to their electronic nature, so that we employ docking with 
constraints only to generate initial potential binding poses for all our predicted flavone 
analogues but then more accurately describe the protein-ligand binding using quantum 
mechanics (QM). As it would be impossible to describe the full system using QM, only 
the active site is modelled using QM, with the rest of the protein modelled using 
molecular mechanics (MM) in a method known as QM/MM. The current chapter will 
describe the foundations of the key computational approaches used in this work, 
specifically docking (with an emphasis on Glide) and the quantum mechanics methods 
we used to describe the active site binding process (based on density functional theory - 
DFT).   
 
4.2 - Molecular Docking 
Ligand-protein docking is an in silico approach and an extremely important step in drug 
design. The aim is to structurally predict the most likely binding modes and 
energetically the binding affinities between a small molecule and its target (Figure 4.1). 
Docking mimics the way in which a ligand can bind to the target site of a protein and 
will then generate multiple binding geometries, referred to as poses. 
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Figure 4.1 - A basic workflow showing the generalised proccess of docking 
A scoring function then predicts the binding energies between the ligand and receptor 
for each of these generated poses. These are then evaluated and ranked based on their 
binding energies; the top ranked pose, in theory, should be the most favourable 
conformation of the ligand in the binding site. 
There are two types of docking, rigid and flexible. In rigid docking, the protein and 
ligand are treated as rigid, restricting the search space. The ligand is pre built before-
hand. An image of the target binding site is built up from multiple overlapping spheres 
of different sizes, which have been mapped from the molecular surface of the target 
protein conformation and structure. With this map, the ligand is then overlaid with the 
centre of generated spheres (Fig 4.2). If the conformation fits the ligand is then placed 
into the target site, minimised (the conformation is adjusted so that the structure is at the 
lowest energy), and the position is scored.  
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Figure 4.2 – A diagram showing how the overlapping spheres build the active site, then 
how important atoms on the ligand are orientated to fit within the newly generated site. 
 
Flexible docking however, generates different conformations of each ligand ‘on-the-fly’ 
using a search algorithm. This style is much more effective, and is much more 
commonly used. This is because when conformational change becomes a bigger factor, 
the accuracy of rigid docking decreases; for example, hydrogen bonds and large scale 
features, such as hydrocarbon chains, might be missed due to a lack of flexibility. Also, 
many flexible ligands may be incorrectly dismissed if they are docked as rigid bodies in 
the wrong conformation.[114] The docking process starts by breaking down the 
molecule into its conformationally flexible and its rigid fragments. An example of a 
flexible docking protocol is shown in Figure 4.3. This is done to save time, as the rigid 
fragment can be left in place, rather than running multiple calculations on the ‘same’ 
conformation. Then the orientated fragments are determined producing n ligand 
conformations, and are joined onto the different rigid placements, so, for each rigid 
orientation, n different conformations will be created.  
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Figure 4.3 - Overview of rigid docking ligand ensemble method. A: rigid atoms are 
fixed in position and the conformational space of the rest of the molecule is 
systematically sampled at 60° or 120° increments. B: The rigid fragment is orientated in 
the target site. C: All n flexible fragments of the molecule are scored in the orientation 
of the rigid fragment. 
 
4.3 - Scoring Functions 
Scoring functions are in place to distinguish whether or not poses are correct or 
incorrect, or whether the ligand is active or inactive. This is achieved by calculating the 
binding affinity for the particular pose, if a ligand is deemed active it means that it is 
predicted to have biological activity.  
Scoring functions take into account the various contributions of free energy binding as 
an additive equation. For example 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑏𝑏𝑠𝑠 + ∆𝐺𝐺𝑐𝑐𝑠𝑠𝑏𝑏𝑐𝑐 + ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑠𝑠 + ∆𝐺𝐺𝑟𝑟𝑠𝑠𝑠𝑠 + ∆𝐺𝐺𝑠𝑠/𝑟𝑟 + ∆𝐺𝐺𝑠𝑠𝑏𝑏𝑏𝑏 
where ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑏𝑏𝑠𝑠 is how the solvent effect arises from the interactions between the 
solvent and the ligand, protein and intermolecular complex.  ∆𝐺𝐺𝑐𝑐𝑠𝑠𝑏𝑏𝑐𝑐 arises from 
conformational changes within the protein and in the ligand. In the majority of cases, 
the protein does not change significantly on binding and most docking methods assume 
a rigid receptor. However, the ligand changes from a large variety of conformations in 
solution to a single dominant conformation in the bound state. Where ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑠𝑠 is the free 
energy due to specific protein-ligand interactions. ∆𝐺𝐺𝑟𝑟𝑠𝑠𝑠𝑠 is the free energy loss 
associated with holding internal rotations of the protein and the ligand in place. Where 
∆𝐺𝐺𝑠𝑠/𝑟𝑟 is the loss in translational and rotational free energy due to two bodies (the ligand 
and the receptor forming a single body) known as the intermolecular complex. This is 
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usually assumed to be the same for all ligands and so is ignored if you are only 
interested in the relative binding strengths of different ligands to a certain protein. ∆𝐺𝐺𝑠𝑠𝑏𝑏𝑏𝑏 
is the free energy due to changes in vibrational modes. This contribution is hard to 
calculate and so is generally ignored [115].  
There are three classes of scoring functions: Classical force-field-based, Empirical and 
knowledge-based potentials. 
Classical force-field based: These functions are developed based on physical atomic 
interactions. These interactions include van der Waals interactions, electrostatic 
interactions and bond stretching, bending, torsional forces, between the ligand and the 
ligand-receptor complex. The docking is scored based on terms of molecular mechanics 
forcefields. 
Empirical: Empirical scoring functions are derived to reproduce data obtained from 
experimentally determined complex structures [116]. This approach is useful, but is 
hindered by the requirement for experimentally obtained analytical data. 
Knowledge-based potentials: (also referred to as statistical-potential based scoring 
functions) employ energy potentials which are derived from the structural information 
embedded in experimentally determined atomic structures [117]. 
 
4.4 - Glide Docking and Scoring Functions 
Glide, the program we employ in this work, uses a funnel like system of hierarchical 
filters to search for possible conformations of the ligand in the active-site of the target 
receptor. (Figure 4.4)  
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Figure 4.4 - Glide docking "funnel" stages, showing the glide docking hierarchy. 
The shape and properties of the receptor are mapped on a grid, which is prepared in the 
pre-processing steps, by different sets of fields that provide progressively more accurate 
scoring of the ligand pose. The next step produces a set of initial ligand conformations. 
These are then subjected to initial screens into the entire phase space to find promising 
ligand poses, skipping poses that sterically clash with the receptor. These poses are then 
taken forward and are minimised using the OPLS-AA minimisation forcefield, with a 
small amount of the lowest energy poses being subjected to a Monte Carlo procedure 
which randomly adjust some of the torsional angles, and then minimises them, to find 
potentially better poses. Finally the minimised poses are re-scored with Schrödinger’s 
GlideScore scoring function, which ranks the successful poses. GlideScore (GS) (2.5) is 
derived from modifying the ChemScore function, as follows: 
GS = (vdW) + (Coul) + (Lipo) + (H-bonds) + (Metal) + (Rewards) + (RotB) + (Site) 
Where (vdW) is the van der Waals evergy taking into account non-bonding interactions. 
Where (Coul) is the Coulumbic term, which accounts for electron-electron repulsion. 
(Lipo) is the lipophilic term which is derived from experimental data. (Metal) is for any 
metal-ligand interactions that may be present. (Rewards) takes into account favourable 
bindings whilst penalising polar groups in regions of hydrophobicity. (RotB) stands for 
rotatable bonds, scoring lower for non-moving rotatable ligand binding bonds. Finally 
(Site) gives higher scores for non-hydrogen bonding areas of hydrophobicity. 
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4.5 - Quantum Mechanics Methods 
4.5.1-Introduction 
Electrons are very light particles, they display both wave and particle characteristics, 
and must be described in terms of wavefunction, Ψ.  Quantum mechanics explicitly 
represents the electrons in the calculation, so it is possible to derive properties that 
depend upon the electronic distribution. The term ab intio is Latin for "from the 
beginning", so ab initio methods relate to methods derived from first principles, purely 
based on theory and with no input from experiment. Most ab initio methods try to solve 
the time-independant Schrödinger Wave equation (SWE), which is given as:  
�−
ħ2
2𝑚𝑚
∇2 + 𝑉𝑉�Ψ(𝑟𝑟) = 𝐸𝐸Ψ(𝑟𝑟)       Eq. (4.1) 
Where E is the energy of the particle. The equation can be written in shorthand form 
with (equation Ĥ Ψ = E Ψ). Where Ĥ is the Hamiltonian operator: 
Ĥ = − ħ2
2𝑚𝑚
∇2 + 𝑉𝑉       Eq. (4.2) 
 V in this equation represents the potential energy.  Whereas the first term in the 
equation is the kinetic energy operator with ∇ having the following form:  
∇2= 𝜕𝜕2
𝜕𝜕𝜕𝜕2
+ 𝜕𝜕2
𝜕𝜕𝜕𝜕2
+ 𝜕𝜕2
𝜕𝜕𝜕𝜕2
       Eq. (4.3) 
The Hamiltonian operator Ĥ acts on the wave function Ψ, which characterizes the 
particle's motion. It contains all the measurable information about the particle. The 
wavefunction represents the probability amplitude for finding a particle at a given point 
in space at a given time, where |Ψ|2 is the probability distribution of the particles, the 
integration of the probability of finding the particle over space must be 1:  
∫Ψ∗Ψ𝑑𝑑𝑑𝑑 = 1        Eq. (4.4) 
The wavefunction of a complete system is commonly composed of a set of single-
particle orbitals [118] 
The Hamiltonian can be written in full as: 
Ĥ = ∑ −ħ2
2𝑚𝑚𝑒𝑒
∇𝑏𝑏
2 +𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠𝑟𝑟𝑠𝑠𝑏𝑏𝑠𝑠𝑏𝑏 ∑ −ħ22𝑚𝑚𝐴𝐴 ∇𝐴𝐴2 + ∑ ∑ −𝑠𝑠2𝑍𝑍𝐴𝐴𝑟𝑟𝑖𝑖𝐴𝐴 +𝑏𝑏𝑛𝑛𝑐𝑐𝑠𝑠𝑠𝑠𝑏𝑏𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠𝑟𝑟𝑠𝑠𝑏𝑏𝑠𝑠𝑏𝑏𝑏𝑏𝑛𝑛𝑐𝑐𝑠𝑠𝑠𝑠𝑏𝑏𝐴𝐴                                                  ∑ 𝑠𝑠2
𝑟𝑟𝑖𝑖𝑖𝑖
𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠𝑟𝑟𝑠𝑠𝑏𝑏𝑠𝑠
𝑏𝑏>𝑗𝑗 +∑ 𝑠𝑠2𝑍𝑍𝐴𝐴𝑍𝑍𝐵𝐵𝑟𝑟𝐴𝐴𝐵𝐵𝑏𝑏𝑛𝑛𝑐𝑐𝑠𝑠𝑠𝑠𝑏𝑏𝐴𝐴>𝐵𝐵        Eq. (4.5) 
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Where the consecutive terms in the equation represents: 
• Kinetic energy of the electrons (𝑇𝑇𝑠𝑠) 
• Kinetic energy of the nuclei (𝑇𝑇𝑏𝑏) 
• Electrostatic interaction between the electrons and the nuclei (𝑉𝑉𝑠𝑠−𝑏𝑏) 
• Electrostatic interaction between the electrons (𝑉𝑉𝑠𝑠−𝑠𝑠) 
• Electrostatic interactions between the nuclei (𝑉𝑉𝑏𝑏−𝑏𝑏) 
 
4.5.2 - Variational Theorem 
According to the Variational Theorem, the expectation value of the Hamiltonian is the 
variational energy according to Eq 4.6: 
∫Ψ∗ĤΨ𝑏𝑏𝑑𝑑
∫Ψ∗Ψ𝑏𝑏τ
= 𝐸𝐸𝑠𝑠𝑣𝑣𝑟𝑟 ≥ 𝐸𝐸𝑠𝑠𝜕𝜕𝑣𝑣𝑐𝑐𝑠𝑠       Eq.  (4.6) 
where an approximate wavefunction for a molecular system, when substituted into the 
Schrödinger equation, will always yield a higher energy than the actual energy of the 
system. The more precise the wavefunction that is chosen, the closer the calculated 
energy will be to the true energy. The computational method using this principle to 
obtain approximations to correct wavefunctions is called the Variational Method. [119] 
 
4.5.3 - The Born-Oppenheimer Approximation 
Since exact solutions to the SWE are not available for systems consisting of more than 
two particles, only approximate solutions may be obtained. One of the first 
approximations to be introduced, the Born-Oppenheimer Approximation, concerns the 
mobility of the nuclei in a system. Since the masses of the nuclei are much greater than 
those of the electrons, we can consider the nuclei stationary and the Schrödinger 
equation can be solved for the electrons moving in the stationary potential generated by 
the fixed nuclei approximation. This means that the Hamiltonian operator may be 
approximately written in terms of two separate operators, the nuclear operator Ĥ𝑏𝑏𝑛𝑛𝑐𝑐 and 
the electronic operator Ĥ𝑠𝑠𝑠𝑠 may be expressed as: 
Ĥ𝑠𝑠𝑠𝑠 = 𝑇𝑇𝑠𝑠 + 𝑉𝑉𝑏𝑏−𝑏𝑏 + 𝑉𝑉𝑠𝑠−𝑠𝑠 + 𝑉𝑉𝑠𝑠−𝑏𝑏      Eq. (4.7) 
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4.5.4 – Hartree-Fock Approximation 
Another key approximation is the Hartree Approximation, this assumes that a many 
electron wavefunction can as written as a product of one electron functions, in other 
words the all electron wave function Ψ is described as a simple product of one electron 
wavefunctions 𝜓𝜓(𝑟𝑟𝑏𝑏) (just under 2.11), i.e, the orbital functions. 
Ψ = Ψ(𝑟𝑟1, 𝑟𝑟2, 𝑟𝑟3, … … 𝑟𝑟𝑁𝑁) ≈ 𝜓𝜓1(𝑟𝑟1)𝜓𝜓2(𝑟𝑟2)𝜓𝜓3(𝑟𝑟3) … …𝜓𝜓𝑁𝑁(𝑟𝑟𝑁𝑁)    Eq. (4.8) 
If we use the variational energy, solving the many electron Schrödinger equation is 
reduced to solving a series of one electron Schrödinger equations, each electron 
interacts with the average distribution of other electrons. An effective Hamiltonian 
operator ℎ(𝑖𝑖) can be defined to act only on the electron 𝑖𝑖 and the problem can be 
rewritten as a system of one electron wave functions: 
ℎ𝑏𝑏𝜓𝜓𝑏𝑏(𝑟𝑟𝑏𝑏) = 𝜀𝜀𝑏𝑏𝜓𝜓𝑏𝑏(𝑟𝑟𝑏𝑏)       Eq. (4.9) 
However, the Hartree Approximation makes no distinctions with respect to spin, and the 
one electron wavefunctions have to be described not only in terms of the position of the 
electron, 𝑟𝑟𝑏𝑏 but also in terms of the spin, 𝑠𝑠𝑏𝑏. 𝑠𝑠𝑏𝑏can be one of two orthogonal spin states 
𝛼𝛼(𝜔𝜔) or 𝛽𝛽(𝜔𝜔), corresponding to “spin up”   𝜔𝜔 = + 1
2
 and “spin down”  𝜔𝜔 = −1
2
 
respectively. The single electron wavefunction is therefore written more correctly in the 
form of a so called one electron spin orbital (Molecular Orbital, MO): 
𝜒𝜒(?⃗?𝑥) = 𝜒𝜒(𝑟𝑟, 𝑠𝑠) = �𝜓𝜓(𝑟𝑟)𝛼𝛼(𝜔𝜔)𝑜𝑜𝑟𝑟
𝜓𝜓(𝑟𝑟)𝛽𝛽(𝜔𝜔)      Eq. (4.10) 
However, an N electron wavefunction expressed as a function of N spin orbitals: 
Ψ = Ψ(𝑟𝑟1, 𝑟𝑟2, 𝑟𝑟3, … … 𝑟𝑟𝑁𝑁) ≈ 𝜒𝜒1(𝑟𝑟1)𝜒𝜒2(𝑟𝑟2)𝜒𝜒3(𝑟𝑟3) … …𝜒𝜒𝑁𝑁(𝑟𝑟𝑁𝑁)    Eq. (4.11) 
is still unacceptable, as it does not have the property of antisymmetry. The Pauli 
Exclusion principle states that a many electron wavefunction must be antisymmetric 
with respect to the interchange of the coordinates ?⃗?𝑥 (both space  (𝑟𝑟) and spin(𝑠𝑠)) of any 
two electrons. What is needed therefore, is an approximation which is as easy to handle 
as the Hartree one and also respects Pauli's Principle. One solution to this lies in the use 
of Slater Determinants suggested by Fock. The simplest antisymmetric wavefunction 
which can be used to describe the ground state of an N electron system is a single Slater 
determinant.  
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Ψ(?⃗?𝑥1, ?⃗?𝑥2, … … ?⃗?𝑥𝑁𝑁) = Φ = 1√𝑁𝑁! ��𝜒𝜒𝑏𝑏(?⃗?𝑥1) 𝜒𝜒𝑗𝑗(?⃗?𝑥1) ⋯𝜒𝜒𝑏𝑏(?⃗?𝑥2) 𝜒𝜒𝑗𝑗(?⃗?𝑥2) ⋯⋮
𝜒𝜒𝑏𝑏(?⃗?𝑥𝑁𝑁) ⋮𝜒𝜒𝑗𝑗(?⃗?𝑥𝑁𝑁) ⋱⋯   
𝜒𝜒𝑘𝑘(?⃗?𝑥1)
𝜒𝜒𝑘𝑘(?⃗?𝑥2)
⋮
𝜒𝜒𝑘𝑘(?⃗?𝑥𝑁𝑁)��  Eq. 
(4.12) 
Where Φ represents the Slater determinant. The mathematical properties of the Slater 
determinant guarantee the above mentioned property that is necessary for any 
multielectron wavefunction: antisymmetry. Antisymmetry, the exchange of the 
positions and spins of any two electrons, is equivalent to the exchange of two rows in 
the determinant and results in a change of sign in Ψ. [120] 
 
Hartree-Fock theory is based on the variation principle in quantum mechanics. If we 
take Hartree-Fock wave function, equation (4.13) 
     Ψ = |𝜒𝜒1𝜒𝜒2 …𝜒𝜒3|       Eq. (4.13) 
and put it into the variational energy expression (4.6), and minimise the energy with 
respect to changes in the orbitals        
     𝜕𝜕𝐸𝐸 𝜕𝜕𝜙𝜙𝑏𝑏 = 0⁄         Eq. (4.14) 
this yields the Hartree-Fock equation 
𝑓𝑓(𝑖𝑖)𝜒𝜒𝑏𝑏(?⃗?𝑥𝑏𝑏) = 𝜀𝜀𝑏𝑏𝜒𝜒𝑏𝑏(?⃗?𝑥𝑏𝑏)       Eq. (4.15) 
𝑓𝑓(𝑖𝑖) represents the one electron Fock operator for electron 𝑖𝑖. The eigenvalues 𝜀𝜀𝑏𝑏 are 
interpreted as molecular orbital energies. These orbital energies have a simple physical 
interpretation: they give the amount of energy necessary to take the electron out of the 
molecular orbital, which corresponds to the negative of the experimentally observable 
ionization potential (Koopmans' theorem). 
The essence of the Hartree-Fock approximation is that it reduces the many electron 
problem into a single electron problem and explicit electron-electron interaction can be 
replaced with the Hartree-Fock potential, 𝜐𝜐𝐻𝐻𝐻𝐻(𝑖𝑖), which can be understood as the 
average "field " or average potential experienced by the 𝑖𝑖-th electon due to all other 
electrons. This can be written mathematically as: 
𝜐𝜐𝐻𝐻𝐻𝐻(𝑖𝑖) = ∑ �𝐽𝐽𝑏𝑏𝑗𝑗 − 𝐾𝐾𝑏𝑏𝑗𝑗�𝑁𝑁𝑗𝑗=1       Eq. (4.16) 
 
47 
 
and the all electron Fock operator F� expressed as: F� = T� + V�NE + Ĵ − K�       Eq. (4.17) 
with Ĵ representing the Coulomb operator for electron-electron repulsion and K� the 
exchange operator which is purely quantum mechanical rising from the fact that the 
wave function must change sign when exchanging two electrons 
K�𝜒𝜒𝑏𝑏 = �∑ ∫𝜒𝜒𝑗𝑗𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠𝑟𝑟𝑠𝑠𝑏𝑏𝑠𝑠𝑗𝑗 𝑠𝑠2𝑟𝑟𝑖𝑖𝑖𝑖 𝜒𝜒𝑏𝑏𝑑𝑑𝑑𝑑� 𝜒𝜒𝑗𝑗       Eq. (4.18) 
 
The negative sign in eq 4.17 reminds us that spin correlation keeps the electrons apart 
and so reduces the classical Coulumbic repulsion. 
Solving the Hartree-Fock equation requires an iterative approach known as the self 
consistent field (SCF) method. direct solution of the Hartree-Fock equations is not a 
practical proposition for molecules. The most popular strategy is to write each spin 
orbital as a linear combination of single electron orbitals (atomic orbital, LCAO):  
𝜒𝜒𝑏𝑏 = ∑ 𝑐𝑐𝜇𝜇,𝑏𝑏𝜇𝜇 𝜙𝜙𝜇𝜇      Eq. (4.19) 
Where 𝑐𝑐𝜇𝜇,𝑏𝑏 is the molecular orbital coefficient and 𝜙𝜙𝜇𝜇is the one-electron orbitals which 
are commonly called basis functions and often correspond to the atomic orbitals. 
The objective is to determine the set of coefficients that gives the lowest energy of the 
system 
𝜕𝜕𝐸𝐸 𝜕𝜕𝑐𝑐𝜇𝜇,𝑏𝑏⁄ = 0       Eq. (4.20) 
 
4.5.5 - Roothaan-Hall Equations 
For a closed-shell system with N electrons in N/2 orbitals, the derivation of the Hartree-
Fock equations was first proposed by Roothaan and independently by Hall (1951). They 
recast the Fock equations in matrix form, which can be solved using standard 
techniques and can be applied to systems of any geometry.  
𝐹𝐹𝐶𝐶𝑏𝑏 = 𝜀𝜀𝑏𝑏𝑆𝑆𝐶𝐶𝑏𝑏     Eq. (4.21) 
Where 𝐹𝐹 is the Fock matrix, 𝐶𝐶𝑏𝑏 is the column vector of the molecular orbital 
coefficients, 𝜀𝜀𝑏𝑏 is the orbital energy, 𝑆𝑆 is the overlap matrix. Hartree-Fock can predict 
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lots of properties with reasonable accuracy, e.g., equilibrium structures and relative 
energies. The one significant drawback to Hartree-Fock Theory is that it only treats 
electron correlation in an average, not instantaneous sense. In fact, the motions of 
electrons are correlated and they tend to avoid each other, giving rise to a lower energy.  
Their motion must be "correlated". For a given basis set, the correlation energy is: 
𝐸𝐸𝑐𝑐𝑠𝑠𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑣𝑣𝑠𝑠𝑏𝑏𝑠𝑠𝑏𝑏 = 𝐸𝐸𝑠𝑠𝜕𝜕𝑣𝑣𝑐𝑐𝑠𝑠 − 𝐸𝐸𝐻𝐻𝐻𝐻        Eq. (4.22) 
 
Neglect of instantaneous electron-electron interactions, gives rise to errors and is 
particularly relevant in accounting for dispersion interactions of significant importance 
to the current study. [118] 
 
4.5.6 - Density Functional Theory 
Density Functional Theory (DFT) is an approach to solve the electronic structure of 
atoms and molecules which has enjoyed an increasing interest since the late 1980s and 
1990s. Its advantages include less demanding computational effort and less computer 
time and in many cases better agreement with experiment than is obtained from Hartree-
Fock based methods. DFT replaces the wave function (which is the function of 3n co-
ordinates, where n is the number of electrons) with the electron density (𝜌𝜌) (which is a 
function of only 3 co-ordinates) as the fundamental unknown. 
The 'functional' part of the name comes from the fact that the energy of the molecule is 
a function of the electron density, and the electron density is itself a function of the 
positions of the electrons 𝜌𝜌(𝑟𝑟1). 
Whereas in the Hartree-Fock method, the expression for energy is  
𝐸𝐸𝐻𝐻𝐻𝐻(Ψ) = 𝑇𝑇𝑠𝑠 + 𝑉𝑉𝑏𝑏𝑠𝑠 + 𝐽𝐽𝑠𝑠𝑠𝑠 − 𝐾𝐾𝑠𝑠𝑠𝑠�����𝑉𝑉𝑒𝑒𝑒𝑒        Eq. (4.23) 
Where 𝑇𝑇𝑠𝑠 is the electronic kinetic energy, 𝑉𝑉𝑏𝑏𝑠𝑠 is the potential energy due to the nuclear-
electronic Coulumbic attraction. The last two terms on the right hand side correspond to 
the classical Coulumb repulsion of the electrons (𝐽𝐽𝑠𝑠𝑠𝑠) and non-classical (𝐾𝐾𝑠𝑠𝑠𝑠) due to the 
quantum nature of the electrons. The difference between these terms accounts for the 
electron-electron repulsion, 𝑉𝑉𝑠𝑠𝑠𝑠. In 1964, P. Hohenberg and W. Kohn were able to prove 
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that the exact ground-state energy of a molecule is uniquely determined by its electron 
probability density. They showed it is possible to write  
𝐸𝐸[𝜌𝜌] = 𝐸𝐸𝑐𝑐𝑠𝑠𝑣𝑣𝑠𝑠𝑠𝑠𝑏𝑏𝑐𝑐𝑣𝑣𝑠𝑠[𝜌𝜌] + 𝐸𝐸𝜕𝜕𝑐𝑐[𝜌𝜌]       Eq. (4.24) 
where 𝐸𝐸𝑐𝑐𝑠𝑠𝑣𝑣𝑠𝑠𝑠𝑠𝑏𝑏𝑐𝑐𝑣𝑣𝑠𝑠[𝜌𝜌] is the sum of contributions of K.E., electron-nuclear interactions and 
the classical electron-electron potential energy, and 𝐸𝐸𝜕𝜕𝑐𝑐[𝜌𝜌] is the exchange-correlation 
energy. This term takes into account all the non-classical electron-electron effects due to 
spin and applies small corrections to the K.E. part of 𝐸𝐸𝑐𝑐𝑠𝑠𝑣𝑣𝑠𝑠𝑠𝑠𝑏𝑏𝑐𝑐𝑣𝑣𝑠𝑠  that arise from electron-
electron interactions. The DFT expression for the energy is now: 
𝐸𝐸𝐷𝐷𝐻𝐻𝐷𝐷[𝜌𝜌] = 𝑇𝑇𝑠𝑠[𝜌𝜌] + 𝑉𝑉𝑁𝑁𝑠𝑠 + 𝐽𝐽𝑠𝑠𝑠𝑠 + 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌]      Eq. (4.25) 
where the exact Hartree-Fock exchange is replaced by the XC energy density functional 
that accounts for both the exchange and the correlation energy and can be written as:  
𝐸𝐸[𝜌𝜌] = 𝑇𝑇[𝜌𝜌] + ∫𝜌𝜌𝑉𝑉𝑏𝑏𝑛𝑛𝑐𝑐𝑠𝑠𝑠𝑠𝑏𝑏 + ∫ 𝜌𝜌(𝑟𝑟)𝜌𝜌�𝑟𝑟′�|𝑟𝑟−𝑟𝑟′| 𝑑𝑑𝑟𝑟𝑑𝑑𝑟𝑟′ + 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌]      Eq. (4.26) 
where 𝑇𝑇[𝜌𝜌] is the Kinetic energy, ∫𝜌𝜌𝑉𝑉𝑏𝑏𝑛𝑛𝑐𝑐𝑠𝑠𝑠𝑠𝑏𝑏 is the electron-nuclei attraction, 
∫
𝜌𝜌(𝑟𝑟)𝜌𝜌�𝑟𝑟′�|𝑟𝑟−𝑟𝑟′| 𝑑𝑑𝑟𝑟𝑑𝑑𝑟𝑟′ is the electron-electron repulsion and 𝐾𝐾𝑋𝑋𝑋𝑋[𝜌𝜌] is the exchange / 
correlation.  While the Hohenberg-Kohn theorem just mentioned guarantees, the 
existence of 𝐾𝐾𝑋𝑋𝑋𝑋[𝜌𝜌] but like so many existing theorems in mathematics, it gives no clue 
as to how it should be calculated. The relevant equations were deduced by Kohn and 
Sham in 1965 who showed that 𝜌𝜌(𝑟𝑟) can be expressed as a contribution of each electron 
present in the molecule and written as: 
𝜌𝜌(𝑟𝑟) = ∑ |𝜓𝜓i(r)|2𝑏𝑏         Eq. (4.27) 
where 𝜓𝜓𝑏𝑏 is called a Kohn-Sham orbital and the density of the system is the sum of the 
square moduli of a set of one-electron orthonormal orbitals.  T is also unknown but can 
be approximated if the density is associated with a wavefunction. Kohn and Sham 
introduced the orbital concept into DFT 
𝑇𝑇[𝜌𝜌] = ∑ ∫𝜓𝜓𝑏𝑏(𝑟𝑟) �− ∇22 �𝜓𝜓𝑏𝑏(𝑟𝑟)𝑑𝑑𝑟𝑟𝑏𝑏        Eq. (4.28) 
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We need to define 𝐾𝐾𝑋𝑋𝑋𝑋 which can be approximated in various different ways exactly the 
same ansatz is used as Hartree-Fock, the only difference is in the Fockian operator  
𝐹𝐹�𝐻𝐻𝐻𝐻 = ∑ ℎ�𝑏𝑏 (𝑖𝑖) + �∑ 2𝑗𝑗𝑗𝑗𝑠𝑠𝑐𝑐𝑐𝑐 𝐽𝐽𝑗𝑗 − 𝐾𝐾�𝑗𝑗�  
𝐹𝐹�𝐾𝐾𝐾𝐾 = ∑ ℎ�𝑏𝑏 (𝑖𝑖) + �∑ 2𝑗𝑗𝑗𝑗𝑠𝑠𝑐𝑐𝑐𝑐 𝐽𝐽𝑗𝑗� + 𝐸𝐸�𝜕𝜕𝑐𝑐        Eq. (4.29)  
 
Where the first term of each of the above equations represents the one-electron operator 
for kinetic energy for each electron and electron-nuclear interaction. As with Hartree-
Fock the Kohn-Sham orbitals are expressed as linear combination of atomic-centred 
basis functions, solved iteratively and self consistently (SCF method):  
    𝜓𝜓𝑏𝑏(𝑟𝑟) = ∑ 𝑐𝑐𝑠𝑠𝑏𝑏𝜙𝜙𝑠𝑠𝑠𝑠             Eq. (4.30) 
 
The 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] can be written as 
    𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] = 𝐸𝐸𝑋𝑋[𝜌𝜌] + 𝐸𝐸𝑐𝑐𝑠𝑠𝑟𝑟𝑟𝑟[𝜌𝜌]                  Eq. (4.31) 
where 𝐸𝐸𝑋𝑋[𝜌𝜌] represents the exchange energy density and 𝐸𝐸𝑐𝑐𝑠𝑠𝑟𝑟𝑟𝑟[𝜌𝜌] the correlation energy 
density functional. 
 
4.6 - Conclusion 
Computational chemistry is an extremely powerful tool in the design of potential drugs 
and an extremely valuable tool in modern day drug discovery efforts throughout 
medicine. Its effectiveness to narrow down a library of ligands which have potential 
activity on the GP enzyme has already been demonstrated with a number of 
computationally driven success stories [43, 121]. Using these methods, we can find a 
few select ligands which are likely to bind at the inhibitor site, without the lengthy and 
expensive process of synthesising inactive compounds and then physically testing them.  
And with advances in computer technology, more powerful and lengthy computational 
methods can be used, for more accurate binding predictions reducing the chances of 
false positive predictions. 
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Chapter 5 –Synthetic Methods 
 
5.1 - Introduction 
Type-2 Diabetes (T2D) has become a considerable threat to human health on a global 
scale, and a massive social and economic burden [122]. Multiple problems arise from 
T2D, including an increase in the risk of patients developing other health concerns 
which would otherwise be avoidable, such as angina, cardiac failure, strokes, 
retinopathy, renal replacement therapy and amputations [14]. Diabetes mellitus is 
characterised by hyperglycemia (high levels of glucose in the bloodstream), peripheral 
insulin resistance and low insulin production in the pancreas [123]. Glycogen 
Phosphorylase (GP) has been identified as a key enzyme in T2D, as it catalyses the first 
step in the intracellular degradation of glycogen to give α-D-glucose-1-phosphate (G-1-
P), via the glycogenolysis pathway, as shown in Figure 5.1. This function makes it an 
extremely promising target for T2D treatment, as inhibiting GP would reduce glucose 
production, which would reduce the level of hyperglycemia. It is important to note 
however, that inhibition of GP needs to be temporary, to avoid causing hypoglycaemia 
in the patient (too little glucose in the blood).  
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Figure 5.1 – The glycogenolysis pathway.[33] 
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Figure 5.2 – Basic structure of flavonoids showing ring and atom labelling. 
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Flavonoids are polyphenols which are found in nature, which leads to them being 
consumed daily as part of a healthy diet of fruit and vegetables. They are also known for 
their other health benefits, such as antioxidant, antibacterial, anticancer, anti-
inflammatory and antidiabetic properties, as well as protection against cardiovascular 
disease.[59-61, 124] They have a general scaffold of two aromatic rings (A and B) 
which are joined by a benzo-fused dihydropyran (ring C). The flavone structure, which 
is the focus of this project, has two hydroxy groups on the A ring in the 5 and 7 
position, a ketone at the 4 position and a double bond between the 2 and 3 carbons (as 
seen in Fig 5.3) 
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Figure 5.3 – Structure of chrysin 
Flavonoids, including chrysin, have shown promise in T2D, by inhibiting GP via 
binding at the caffeine binding site, which is found on the surface of GP, 12 Å from the 
catalytic site. This is due to the two aromatic residues found within the inhibitor site: 
Phe285 and Tyr613, which can interact with the A & C rings of the flavone skeleton via 
π-stacking interactions. Binding at this site causes inhibition as the T-state conformation 
is stabilised which blocks access to the catalytic site (c.f. Chapter 2) 
This phenolic structure can be synthesised in a number of ways, whilst keeping the 
desired hydroxyl groups on the 5 and 7 position intact, most of which, involve starting 
with the A and B rings, joined by a carbon chain, which is then cyclised into the C ring. 
Examples are given in the following section. 
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5.2 – Synthetic Methods. 
5.2.1 – Baker-Venkataraman Rearrangement 
4 5
5% K2CO3
AcOH, reflux
1 2 3
K2CO3, H2O, benzene
(n-C4H9)4N+Br-
O H OO
O HOH
OH
O H O
O
O O
O HOH
O
O H O
O HOH
Cl
O
+
 
Scheme 5.1 - Synthesis of chrysin via the Baker-Venkataraman rearrangement (step 3-
4). 
Flavone derivatives can be synthesised from commercially available benzoyl chlorides 
and 2-acetylphenols, by exploiting the Baker-Venkataraman rearrangement [125]. 
Chrysin can be made via this route by using 2,4,6-hydroxyacetophenone (2) and 
benzoyl chloride (1) as starting materials. These have been experimentally observed to 
react under multiple conditions, where Zhiwei Chen et al [125] at Zhejiang University 
have observed a reaction when combining the two reactants with K2CO3, H2O and 
benzene with (n-C4H9)4N+Br- as a phase-transfer catalyst stirring at reflux. The use of 
benzene is potentially dangerous, however, but creates a biphase layer, which requires 
the (n-C4H9)4N+Br- to act as a phase-transfer catalyst which needs removal afterwards. 
This can be avoided by the use of dry pyridine as a solvent and base, as observed by 
Bhawna Yvas et al [126]  at Punjabi University, which is stirred at reflux then poured 
onto ice with hydrochloric acid to yield the solid product. The process can also be done 
in acetone, with the K2CO3 as base under reflux, as proven by Xing Zheng et al [127] at 
the University of South China. All three of these methods require basic conditions for 
the condensation to be achievable, as a base is needed for the formation of the enolate 
intermediate. 
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An intermediate product from this reaction is an ester, which can undergo the Baker-
Venkataraman rearrangement to form the diketone as seen in Scheme 5.2. 
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Scheme 5.2 – Baker-Venkataraman rearrangement of (7) to form the diketone 
intermediate, (9). 
Cyclisation of the diketone to yield the flavone structure can be achieved by a variety of 
methods, for example, Zhiwei Chen et al [125] found that heating the diketone at reflux 
in 5% aqueous potassium carbonate for 6 hours then treating with acetic acid closed the 
C ring to form the flavone. Whereas Bhawna Yvas et al [126] did not use basic 
conditions but used strong acidic conditions for ring closure. Bhawna Yvas et al [126] 
used glacial acetic acid and concentrated sulphuric acid at reflux for 1 hour, which was 
then poured onto crushed ice to precipitate the flavone product. However, this process 
may be problematic due to the dangerous nature of concentrated sulphuric acid, so, 
Xing Zheng et al [127] overcame this by completing this reaction with the same glacial 
acetic acid, but instead mixed with anhydrous sodium acetate.  
 
5.2.2 – Microwave Synthesis 
George W. Kabalka et al [128] took the diketone structure (9) and synthesised a variety 
of flavones by using microwave assisted methods. This was achieved by adding 1.0 
mmol of the diketone compound and 0.1 mmol of CuCl2 in 3 ml of ethanol, then 
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subjecting the mixture to microwave at 80°C at 100W for 5 minutes. This mixture was 
extracted and purified by flash column chromatography to yield flavones in up to 98% 
yield. Julio A. Seijas et al [129] also created the flavone structure via the diketone 
pathway by using microwave techniques. However, this was achieved without the use 
of solvent. This varies slightly to the techniques discussed earlier as this method uses 
ethyl benzoylacetate (Fig 5.4) with 1,3,5-trihydroxybenzene, rather than the benzoyl 
chloride and 2-acetylphenol method in Scheme 5.1. However, without solvent, this 
meant that the microwave was set to 240°C at 800W, which is substantially more 
powerful than that used by George W. Kabalka et al. 
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Figure 5.4 – Structure of ethyl benzoylacetate. 
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Scheme 5.3 – Microwave assisted synthesis of chrysin in solvent free conditions. 
 
Though a mechanism was not provided, it is assumed that the mechanism follows a path 
similar to Scheme 5.4. 
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Scheme 5.4 – Proposed mechanism for the microwave assisted synthesis of chrysin. 
 
This has an advantage over traditional ‘wet’ methods, as there are no harmful solvents, 
acids, or bases used during the synthesis. Julio A. Seijas et al [129] also recorded 
extremely high yields using this method, of 96% when synthesising chrysin. Microwave 
synthesis also has the added advantage of taking much less time in comparison to 
traditional methods, the reaction mentioned above (Scheme 5.3) requires 3 minutes of 
irradiation time, whereas wet methods can take longer than 24 hours. This in turn, 
means less energy is needed to power apparatus for long periods of time. 
 
5.2.3 – Single Ketone Synthesis 
Many reaction pathways in the synthesis of flavones form a single ketone as an 
intermediate, which are derivatives of 1-(2-hydroxyphenyl)-3-phenyl-2-propenone (Fig 
5.5) or 2′-hydroxychalcone (Fig 5.6). These structures can undergo the 
cyclocondensation required to form the C ring (c.f. Fig 5.2) to create the desired flavone 
structure.  
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Figure 5.5 – Structure of 1-(2-
hydroxyphenyl)-3-phenyl-2-propenone. 
Figure 5.6 – Structure of 2′-
hydroxychalcone. 
 
Both of these can be synthesised under basic conditions, 1-(2-hydroxyphenyl)-3-phenyl-
2-propenone was synthesised by Abhay S. Zambare et al [130] using sodium hydroxide 
in ethanol at 15-20°C to undergo an aldol condensation, as seen in Scheme 5.5. 
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Scheme 5.5 – Synthesis of 1-(2-hydroxyphenyl)-3-phenyl-2-propenone. 
 
Koneni V. Sashidhara et al [131] synthesised 2’-hydroxychalcone by reacting 
salicylaldehyde (16) and acetophenone (17) together with 10% aq. KOH and ethanol at 
reflux (see Scheme 5.5) via a variant of the aldol reaction, the Claisen-Schmidt 
condensation. 
 
1716 13
KOH/Ethanol
reflux
O O H
O H
O
H
O
+
 
Scheme 5.6 – Synthesis of 2’-hydroxychalcone. 
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The use of 1-(2-hydroxyphenyl)-3-phenyl-2-propenone has been investigated in the 
synthesis of flavones, with positive results in many different systems. Surender Kumar 
et al [132] cyclised 1-(2-hydroxyphenyl)-3-phenyl-2-propenone to form flavone in 
DMSO and sodium tellurite (Na2TeO3) at 130-140°C with yields of 80% (Scheme 5.6)  
Na2TeO3, DMSO
18
OO H
O
O
12  
Scheme 5.7 – Synthesis of flavone from the cyclocondensation of 1-(2-hydroxyphenyl)-
3-phenyl-2-propenone using sodium tellurite in DMSO. 
 
Kalvi Hemanth Kumar et al [133] found that using iron(III) chloride hexahydrate 
(FeCl3.6H2O) in methanol at reflux was also a viable method of cyclocondensing 1-(2-
hydroxyphenyl)-3-phenyl-2-propenone to form flavone (Fig 5.7), this method was also 
found to be effective in ethanol, but unsuccessful in non-alcoholic solvents 
(DMF,DMSO, ethyl acetate, THF and toluene). This method did give lower yields in 
comparison to previously mentioned methods; FeCl3.6H2O in methanol gave only 55% 
yields, and also took 10 hours for completion, which is longer than the previously 
discussed microwave methods. 
FeCl3.6H2O
methanol
18
OO H
O
O
12  
Scheme 5.8 - Synthesis of flavone from the cyclocondensation of 1-(2-hydroxyphenyl)-
3-phenyl-2-propenone using iron(III) chloride hexahydrate. 
Ethanol has been used repeatedly for the cyclocondensation step for the formation of the 
C ring; Abhay S. Zambare et al [130] used 10 mol% oxalic acid in ethanol to give the 
cyclised flavone with excellent yields of 95% over 6 hours. Alcoholic solvents were 
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also tested and methanol gave yields of 92% over 6.5 hours, which backs up the 
previously mentioned solvent choice [133]. However, unlike the iron(III) chloride 
hexahydrate route, using oxalic acid as a catalyst allowed a wider range of solvents to 
be used, with acetonitrile over 12 hours giving 85% yield and THF over 10 hours giving 
88% yield. This makes the oxalic method far more favourable than the iron(III) chloride 
hexahydrate method. However, this is still unfavourable in comparison to the 
microwave assisted methods mentioned earlier. 
Abu T. Khan et al [134] also managed to achieve the cyclised product by exploiting 
ammonium bromide and vanadium pentoxide alongside hydrogen peroxide (Scheme 
5.9) 
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Scheme 5.9 – Synthesis of 8-bromochrysin derivative from 2'-hydroxy-4',6'-
dimethoxychalcone. 
 
Unfortunately, this method only gave an overall yield of 62%; which means this method 
is not optimal, as the yields are poor in comparison to previously mentioned methods, 
and also introduces an undesired bromine at the 8-position, which would need further 
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work to remove, such as exploiting a Pt(III) surface for hydrodebromination 
methods.[135] The methyl groups on the hydroxyl groups would also need to be 
removed via de-methylation techniques, such as HBr with AcOH at reflux for 24 hours 
as reported by Chavi Yenjai et al [136] in which they achieved a 95% yield. 
Koneni V. Sashidhara et al [131] investigated the cyclocondensation of 2′-
hydroxychalcone with the use of different catalysts (Table 5.1) and solvents (Table 5.2).  
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Scheme 5.10 – Synthesis of 2-(4-methylphenyl)-4H-chromen-4-one. 
 
Table 5.1 – Optimisation of reaction conditions for the synthesis of 2-(4-
methylphenyl)-4H-chromen-4-one. 
Entry Catalyst Time (h) Yield (%) 
1 AlCl3 2.5 28 
2 ZnCl2 3.0 10 
3 BF3.OEt2 3.0 0 
4 SnCl2.2H2O 2.0 54 
5 HgCl2 3.0 5 
6 FeCl3 3.0 5 
7 SnCl4 3.0 0 
8 I2 1.5 74 
 
It was reported that iodine gave the best results under these conditions, they also 
reported that the use of 10 mol % of iodine was optimal. More surprisingly however, is 
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the use of solvent; as no solvent achieved yields close to performing the synthesis neat, 
as seen in Table 5.2. 
 
Table 5.2 – Optimisation of reaction solvents for the synthesis of 2-(4-
methylphenyl)-4H-chromen-4-one. 
Entry Solvent Yield 
1 1,4-Dioxane 56 
2 Acetonitrile 0 
3 Ethanol 33 
4 Methanol 12 
5 THF 15 
6 DMSO 20 
7 Neat 74 
 
Using iodine as a catalyst with no solvent at 110-130°C for 1.5h gives a 74% yield for 
the 2-(4-methylphenyl)-4H-chromen-4-one, and also gives a 72% yield for flavone. 
Sashidhara [131] suggested a plausible mechanism, as shown in Figure 5.10: 
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Figure 5.7 – Proposed mechanism of reaction of flavones using iodine as a catalyst. 
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5.2.4 – Synthesis Using a Metallic Catalyst  
An alternative method involves the use of palladium-based catalyst to synthesise the 
flavone compound. Hua Miao et al [137] at Harvard University achieved high yields 
under basic conditions under a carbon dioxide atmosphere, as shown in Scheme 5.11. 
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Scheme 5.11 - Mechanistic interpretation for the synthesis of flavones using a 
palladium based catalyst. 
 
Unlike other methods mentioned, this approach starts with iodophenol (24), which 
undergoes oxidative addition to form the organo metallic intermediate (25), then the 
carbon monoxide is inserted to give the carbon monoxide insertion product (26). With 
base and the desired R group attached to an alkyne carbon-carbon bond (27). For the 
synthesis of flavones, the R group needs to be aromatic. Compound (27) can then 
undergo 6-endo-dig cyclisation to directly form the desired flavone (30). Alternatively, 
(27) can undergo a Michael addition, to attach the NR''R''' diethylamine group, forming 
the alkene compound (28) which can undergo 6-endo-trig cyclisation (29) which 
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spontaneously rearranges to form the flavone (30). There is a major drawback with this 
method, as compound (27) can rearrange to form a palladium compound. This 
regioselective problem has been resolved by Torii and Kalinin by using an excess of 
diethylamine to competitively form compound (28). However, the conditions required 
are 120°C and under pressure of 20kg/cm2, which is impractical compared to other 
methods discussed previously. 
 
5.3 - Conclusion 
T2D is a chronic and widespread illness, affecting millions of patients. With the 
promising approach of inhibition of the GP enzyme using flavone derivatives, better 
treatment for T2D is achievable. The synthetic methods presented in this chapter are all 
viable options for the synthesis of flavones, which in turn means they can be considered 
for the synthesis of chrysin and it’s analogues. Due to it’s synergy with the 
computational methods and using benzoyl chlorides with the Zinc Docking Database, 
and also due to the previous expertise within the group, to follow the synthetic route via 
the Baker-Venkataraman rearrangement, via the 2,4,6-hydroxyacetophenone and the 
benzoyl chloride. The synthesised analogues can then be taken forward to kinetics 
experiments, to test whether or not they have activity against GP. These results will help 
influence the next step, as structure activity relationships will be performed, comparing 
the computational results to the kinetic experiments. These results will then be used to 
refine and suggest further more ligands, for synthesis aiming for greater activity.  
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Chapter 6 - Computational Screening for New Flavonoid Derivatives 
Targeting the Inhibitor Site 
 
6.1 - Introduction 
Type-2 Diabetes (T2D) is a chronic heterogeneous disease which is characterised by 
hyperglycaemia. T2D is caused by a disorder of insulin secretion, insulin resistance, and 
by the production of hepatic glucose in the liver, of which, 70% comes from the 
breakdown of glycogen by the GP enzyme in the glycogenolysis pathway.[138] This 
means that GP is an extremely promising target for inhibition in the treatment of T2D. 
GP has several different binding sites: the allosteric, the catalytic, the inhibitor, the new 
allosteric, the quercetin binding and the glycogen storage site. The inhibitor site is the 
main focus in this study, and how flavone derivatives can bind to the site by exploiting 
the π-stacking interactions. The inhibitor site of GP is found on the surface of the 
enzyme, roughly 12 Å from the catalytic site. When the enzyme is in the less active T 
state, Phe285, which is on the 280s loop (residues 282-287) is stacked close to Tyr613, 
which is on the α19 helix (residues 613-631). These two aromatic residues form the core 
of the inhibitor site. The ligands that bind to this site are heavily influenced by these 
residues, this is because of π-stacking interactions between the Phe285 and the Tyr613 
sidechains, forming a sandwich-like complex. This promotes the T state conformation 
of the enzyme via stabilisation of the closed position of the 280s loop, which in turn 
blocks access to the catalytic site. When the enzyme is converted from the T state to the 
R state, the 280s loop changes its shape, which opens a channel that allows Arg569 to 
enter the catalytic site in place of Asp283, creating the recognition site for the substrate 
phosphate. It is this transition which enables the glycogen substrate to reach the 
catalytic site [40]. Inhibition of the binding site is usually synergistic with glucose, 
which suggests that inhibition could be regulated by blood glucose levels, and would 
decrease as normoglycaemia is achieved without causing hypoglycaemia [139].  
Because of this property, design of inhibitors targeting the “inhibitor site” is particularly 
attractive from a drug design perspective. Additionally, as we have discussed previously 
(Chapter 3), natural products such as flavonoids provide a proven scaffold for design of 
potent GP inhibitors but to date the only flavonoid ligands confirmed to bind at the site 
are chrysin (by crystallography, PDB code 3EBO) and  quercetagetin (multiple 
inhibition studies).  
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Figure 6.1 - Structure of chrysin and 5,7-dihydroxy-2-(naphthalen-2-yl)-4H-chromen-
4-one 
In this chapter, we present the virtual screening of a library of compounds exploiting the 
Zinc database (http://zinc.docking.org) [112] using 5,7-dihydroxy-4H-chromen-4-one as 
a core scaffold (Figure 6.1). Initial screening was performed using both Glide-SP and –
XP but combining the results in a consensus scoring approach so as to potentially 
reduce false positive results. Two GP protein conformations were used for this purpose, 
one taking the solved GP protein conformation directly from its complex with chrysin 
(PDB code 3EBO) and the other from an induced fit docking of 5,7-dihydroxy-2-
(naphthalen-2-yl)-4H-chromen-4-one (Figure 6.1) to 3EBO so as to expand the 
hydrophobic pocket (key residues Leu380, Tyr573 and Phe771; c.f. Figure 3.3 in 
Chapter 3) to allow binding of ligands with larger B ring substituents extending into the 
hydrophobic pocket.  QM/MM-PBSA binding free energy calculations were then 
performed on the predicted best inhibitors that were also considered to be synthetically 
viable. Filters were employed so that the final most accurate QM/MM-PBSA 
predictions only considered the best possible ligands. The whole process is 
demonstrated in the flowchart shown in Figure 6.3 (on page 71). 
 
6.2 - Computational Details 
6.2.1 - Protein Preparation 
The GPb receptor (PDB code: 3EBO) was prepared for calculations using Schrödinger’s 
Protein Preparation Wizard [140]. This receptor was chosen as it is the solved structure 
with the lead compound chrysin bound at the inhibitor site. The waters within 5 Å of 
chrysin were retained, bond orders assigned and hydrogens added, with protonation 
states for basic and acidic residues based on pKa’s at a pH of 7. Finally, the system was 
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softly minimised using OPLS-AA (2005) forcefield with the root-mean-square 
deviation (RMSD) of heavy atoms kept within 0.3 Å of the crystallographic positions. 
6.2.2 - Ligand Database Preparation 
Using the Zinc docking database (http://zinc.docking.org/), benzoyl chloride derivatives 
were selected using criteria so that the final compounds would follow Lipinski’s ‘rule of 
five’ [141] for oral bioavailability. To ensure this, the search for benzyl chlorides was 
given the following search criteria: 0 ≤ MW ≤ 386 amu, ≤ 3 hydrogen bond donors and 
≤ 7 hydrogen bond acceptors. There was also a limit on the number of rotatable bonds 
of the downloaded compounds to < 3 (5 rotatable bonds in total for final compounds 
limiting flexibility) and the formal charge to be 0 (to make the final ligand more suitable 
for synthesis).  These restrictions gave 1169 benzoyl chloride derivatives. These were 
joined to the 5,7-dihydroxy-4H-chromen-4-one core using CombiGlide 3.9,[140] which 
exploits the program LigPrep, as shown in Figure 6.2. This process yielded 1239 
minimised structures including tautomers (occurring only for the B ring), which were 
now ready to be employed in the docking studies. 
 
 
Figure 6.2 – The chrysin core and the benzyl chloride substructure used for searching 
the ZINC docking database and then being bound together with CombiGlide to form the 
final ligands for screening. 
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6.2.3. Docking  
Docking of all ligand was performed to the “Original GPb Receptor” conformation 
from it complex with chrysin (c.f. 6.2.1) and also to an “Induced-fit GPb Receptor” GP 
conformation prepared so as to allow the binding of bulkier ligands.  
 
Docking to Original GPb Receptor 
In the docking calculations with Glide 6.9 [140, 142], the shape and properties of the 
inhibitor binding site were mapped onto grids with dimensions of 23.1 x 23.1 x 23.1 Å 
centred on the native chrysin ligand. Standard parameters were applied including van 
der Waals scaling for non-polar atoms (by 0.8) to include modest ‘induced-fit’ effects. 
Core constraints (maximum RMSD of 0.10 Å for core atoms positions) were applied on 
the A and C ring atoms (c.f. Figure 6.1) as well as 5 and 7 hydroxyl atoms. Docking 
calculations were performed using both Glide standard-precision (SP) and extra-
precision (XP), both of which included post-docking minimization with strain 
correction. Intramolecular hydrogen bonds were also rewarded. 1 pose per ligand (each 
tautomer) was saved for both docking calculations. This Glide-SP and -XP docking 
produced 457 and 499 protein-ligand poses, respectively.  
 
Docking to Induced-fit GPb Receptor 
To expand the inhibitor site’s hydrophobic pocket, induced fit docking (IFD) was 
initially performed. Using the 5,7-dihydroxy-2-(naphthalen-2-yl)-4H-chromen-4-one 
(Fig 6.1) as the ligand, a model for GP was obtained that would be able to accommodate 
larger substituents in the hydrophobic pocket in rigid-receptor docking calculations 
[143]. In Stage 1 of the IFD, 5,7-dihydroxy-2-(naphthalen-2-yl)-4H-chromen-4-one was 
docked to the inhibitor site using Glide-SP with 20 poses per ligand saved. The core of 
the ligand (rings A and C atoms) involved in the π-stacking was restrained to its original 
position using core constraints (tolerance 0.1 Å). The Leu380 sidechain was trimmed 
for this stage, as well as scaling of the van der Waals radii of non-polar atoms by 0.5. 
Stage 2 was a Prime refinement, with residues Phe771 and Leu380 sidechain positions 
in the hydrophobic pocket refined. For Stage III, up to 20 protein conformations within 
30 kcal/mol of the lowest-energy structure were used for Glide-SP re-docking.  
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Using the top-ranked IFD pose based on IFDscore, the original 1169 ligands from the 
CombiGlide process, were redocked into the new induced-fit receptor using Glide-SP 
and Glide-XP using the exact same settings as for the “Original GP Receptor” and 
which gave 740 and 790 poses, respectively. 
 
Consensus Scoring 
Ligands were ranked using Consensus Scoring with a Simple Sum Rank of the Glide-SP 
and –XP ranks (based on GlideScore) for each receptor, “Original GP Receptor” and 
“Induced-fit GPb Receptor” (Eq. 6.1).  In the case of ligands with tautomers only the 
best scoring tautomer was ranked in each case so that each ligand received only one 
rank. This gave more reliable ranks, by taking all calculations into account [144, 145].      
𝑠𝑠𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 = (𝐺𝐺𝑠𝑠𝑖𝑖𝑑𝑑𝑠𝑠 − 𝑆𝑆𝑆𝑆 𝑆𝑆𝑐𝑐𝑜𝑜𝑟𝑟𝑠𝑠) + (𝐺𝐺𝑠𝑠𝑖𝑖𝑑𝑑𝑠𝑠 − 𝑋𝑋𝑆𝑆 𝑠𝑠𝑐𝑐𝑜𝑜𝑟𝑟𝑠𝑠)        Eq. (6.1) 
We then compared the RMSDs of all atoms for ligands that gave poses for both SP and 
XP. This was to see if SP and XP gave similar poses for the same receptor [145]. A 
RMSD cut-off less than 0.7 Angstroms was considered similar. Additionally, the 
ligands were manually investigated in detail and based on intuition, compounds that 
were not feasible with the Baker-Venterman re-arrangement, or if they had bulky or 
polar para substituents, were deleted, as these would be unfavourable. This process left 
373 novel compounds. Based on this, the top 200 ligands for each of the two receptor 
conformations (with some ligands in top 200 for both receptors) proceeded to more 
accurate QM/MM-PBSA binding free energy calculations.  
 
6.2.4 - QM/MM-PBSA Calculations 
The best 200 SP poses for each receptor were used as input for QM/MM-PBSA binding 
free energy calculations. QM/MM interaction energies (∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄) were calculated 
directly for each of the poses, considering the bound and unbound states of the predicted 
protein-ligand complexes: 
∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 = 𝐸𝐸𝑐𝑐𝑠𝑠𝑚𝑚𝑐𝑐𝑠𝑠𝑠𝑠𝜕𝜕 − 𝐸𝐸𝑟𝑟𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑟𝑟 − 𝐸𝐸𝑠𝑠𝑏𝑏𝑙𝑙𝑣𝑣𝑏𝑏𝑏𝑏         Eq. (6.2) 
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Ligand binding free energies were then calculated using QM/MM-PBSA according to 
the following equation:  
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 + ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝑇𝑇∆𝑆𝑆𝑄𝑄𝑄𝑄                    Eq. (6.3) 
All calculations employed DFT with the M06-2X functional  [146] and the all electron 
LACVP*+ basis set [140] was used for the QM region (ligand, Phe 285 and Tyr 613 
sidechains); this method was previously shown to be effective for halogen substituted 
ligands in studies of this type [39]. The GP enzyme (except for Phe285 and Tyr613 
sidechains) was described using MM with the OPLS-AA(2005) forcefield [147]. No 
cut-off for non-bonded interactions was employed. Effectively, the MM region polarizes 
the QM region, with electrostatic interactions between QM wavefunction, and the van 
der Waals interactions between QM and MM atoms accounted for [147]. Bulk solvation 
effects were included using Poisson-Boltzmann Surface Area (PBSA), allowing 
∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠to be calculated. The default solute (internal) dielectric constant of 1.0 was used. 
An estimate for the loss of ligand entropy (∆𝑆𝑆𝑄𝑄𝑄𝑄) on binding was calculated using MM 
with the OPLS-AA(2005) forcefield [147]  and the Rigid Rotor Harmonic Oscillator 
(RRHO) approximation. Using this method, the change in vibrational, rotational and 
translational entropy of the ligands on binding was considered. All QM/MM and 
QM/MM-PBSA calculations were performed using Qsite 6.9 [140]. RRHO calculations 
were performed using MacroModel 11.0 [140]. We then compared the ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values of 
ligands from both receptors results; the best  ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 value was taken as the “true” value 
and the corresponding receptor-ligand pose considered (corresponding either to 
“Original GP receptor” or “Induced-fit receptor”). Ligands were ranked by ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
values and those with a value more negative than -11 kcal/mol taken forward (58 
ligands) for even more accurate QM/MM-PBSA calculations following a Prime 
refinement of the corresponding receptor-ligand pose. 
 
6.2.5 - Prime Minimisation 
To prepare complexes for the more accurate QM/MM-PBSA calculations, Prime 4.2 
[140] minimisation was used to refine the protein-ligand complexes using the preferred 
GPb conformation (either the “Original GPb receptor” or the “Induced-fit GPb 
Receptor” model) for each of the 58 ligand candidates. The chosen GPb model was 
based on the protein conformation which gave the best ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 value in the original 
QM/MM-PBSA calculations. For this Prime “protein refinement” minimization, 
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standard settings were employed with the OPLS3 forcefield [148] and VSGB solvation 
model.[149] Refined residues were the sidechains of amino acids: Asp283, Asn284, 
Glu382, Leu380, Hie571, Glu572, Tyr573, Arg770 and Phe771, which are all within the 
hydrophobic pocket and are also in close proximity to bound ligands. While the 5,7-
dihydroxy-4H-chromen-4-one ligand core of each ligand was constrained using a force 
constant of 200 kcal/(mol.Å2) (maintaining the π-stacking distances with Phe285 and 
Tyr613), the B ring groups were additionally refined (free) in the hydrophobic cavity 
with the aforementioned residues. 
 
6.2.6 - Second stage QM/MM-PBSA Calculations 
The more accurate QM/MM-PBSA binding free energies of these refined complex 
poses were determined using the Prime output files as input. Two sets of calculations 
with different QM regions were run for each refined protein-ligand complex:  
1) post-Prime QM/MM-PBSA(1) – ligand, Phe285, Tyr613 as QM region  
2) post-Prime QM/MM-PBSA(2) – ligand, Phe285, Tyr613 and additionally 
Asp283, Asn284, Glu382, Leu380, Hie571, Glu572, Tyr573, Arg770 and 
Phe771 as QM region  
As before, DFT with the M06-2X functional and the all electron LACVP*+ basis set 
was used for the QM region, with the rest of the GP receptor was described using MM 
with the OPLS-AA (2005) forcefield, and ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values calculated according to Eq. 
6.3.  
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Figure 6.3 – Flowchart representing the computational process for identification of 
ligand candidates. 
Protein Preparation 
     Protein Preparation Wizard 
PDB code: 3EBO (GPb-chrysin)                     
“Original GPb receptor” 
Protein Preparation – Induced 
Fit 
Stage 1: Glide-SP docking 
Stage 2: Prime refinement 
Stage 3: Glide-SP re-docking 
Receptor model based on best 
 
   
 
Zinc Database 
1169 benzoyl chlorides 
CombiGlide 3.9 with LigPrep 3.6 
1239 minimised structure (refer to Figure 
 
Docking 1: Glide-SP & -XP 
SP poses = 457; XP poses = 499 
Docking 2: Glide-SP & -XP 
SP poses = 740; XP poses = 790 
 
Consensus Scoring Separately for Docking 1 and 2 
Ranking of Predicted Potencies: Simple Sum Rank (SP & XP) 
Geometries: 0.7Å RMSD cut-off (SP & XP). 
Ligands filtered based on intuition/synthetic viability 
Gave 373 ligands 
Post-docking QM/MM-PBSA Calculations 
Top 200 ligands from Docking 1 (“Original GPb 
Receptor) 
+ 
Top 200 ligands from Docking 2 (“Induced-fit 
receptor”) 
Best Protein-Ligand pose = Best ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 value    
         
 
 
 
Prime 4.2 Minimization 
Best 58 ligands:                                                                       
Protein-ligand complex with best ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 value 
 
QM/MM-PBSA (2) 
Refined complexes subjected to 
more accurate QM/MM-PBSA 
calculations 
(Large QM region: ligand, Phe285, 
Tyr613 and hydrophobic pocket) 
 
QM/MM-PBSA (1) 
Refined complexes subjected to 
more accurate QM/MM-PBSA 
calculations 
(Standard QM region: ligand, 
Phe285 & Tyr613) 
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6.3 – Results and Discussions 
6.3.1 – Docking Results 
 
Docking to “Original GPb Receptor” 
 
The aim of docking was to be able to screen a wide range of compounds to predict their 
relative binding affinities to the inhibitor site of GPb. Using the Zinc Database and 
CombiGlide we generated 1239 structures including tautomers, which were docked into 
the prepared GP protein (PDB code: 3EBO) using Glide –SP and –XP which gave 457 
and 499 poses, respectively.  The ligands were first ranked by best GlideScore (GS) of 
Glide-SP then –XP. This was to identify ligands with predicted binding free energies 
greater than chrysin. GSs revealed that 79 ligands using Glide-SP were better than 
chrysin and using Glide-XP, 131 ligands were better than chrysin. Then the ranks from 
Glide-SP and –XP were combined using the Simple Sum Rank (Eq. (6.1)). This 
consensus scoring was again used to identify ligands with predicted binding free 
energies greater than chrysin, but considered more accurate due to the known benefits of 
combining results from different dockings to reduce the chance of false positives [41]. 
This yielded 79 ligands predicted as more potent than chrysin. The ligands that ranked 
well (Table 6.1) had halogenated substituents on the B ring, especially fluorine and 
chlorine at the meta position (3’ and 5’, refer to Figure 6.1 for numbering Scheme). 
Hydroxyl groups in the ortho position (2’ and 6’) also appear to give extremely good 
binding affinities in these early docking studies. 
 
 
 
 
 
 
 
 
 
Table 6.1 – Top ligands by simple sum rank from Glide-SP & -XP results from “Original 
73 
 
GPb Receptor”(a) 
Simple Sum Rank: 3 Simple Sum Rank: 6 Simple Sum Rank: 12 
R
O H
OH
 
R
O H
F
 
R
O H
O H
F
 
ZINC34207034 ZINC39056429 ZINC39056876 
GlideScore –SP: -9.311 (1) GlideScore –SP: -8.889 (2) GlideScore –SP: -8.756 (3) 
GlideScore –XP: 9.590 (2) GlideScore –XP: -9.168 (4) GlideScore –XP: -8.610 (9) 
   
   
Simple Sum Rank: 26 Simple Sum Rank: 29 Simple Sum Rank: 33 
R O H
O H
F
 
R O
O
 R O H
O H
Cl
 
ZINC39056879 ZINC38350563 ZINC39057341 
GlideScore –SP: -8.549 (11) GlideScore –SP: -8.730 (4) GlideScore –SP: -8.447 (19) 
GlideScore –XP: -8.494 (15) GlideScore –XP: -8.373 (25) GlideScore –XP: -8.526 (14) 
   
   
Simple Sum Rank: 36 Simple Sum Rank: 47 Simple Sum Rank: 49 
R
O H
 
R
N H 2
 
R
N H 2
Cl
 
ZINC39056727 ZINC34160328 ZINC39056853 
GlideScore –SP: -8.372 (28) GlideScore –SP: -8.705 (6) GlideScore –SP: -8.314 (42) 
GlideScore –XP: -8.643 (8) GlideScore –XP: -7.847 (41) GlideScore –XP: -8.749 (7) 
   
   
Simple Sum Rank:52 Simple Sum Rank:56 Simple Sum Rank: 63 
R
NH 2
 
R F
OH
 R
O
F
F
 
ZINC39056307 ZINC39056495 ZINC39712909 
GlideScore –SP: -8.725 (5) GlideScore –SP: -8.327 (36) GlideScore –SP: -8.463 (18) 
GlideScore –XP: -7.790 (47) GlideScore –XP: -8.416 (20) GlideScore –XP: -7.812 (45) 
   
(a) Docking ranks shown in brackets. 
 
 
 
 
Table 6.1(continued) – Top ligands by simple sum rank from Glide-SP & -XP results from 
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“Original GPb Receptor”(a) 
 
   
Simple Sum Rank: 66 Simple Sum Rank: 67 Simple Sum Rank: 71 
R N H 2
 
R
O H
F
 
R
FF
NO 2
 
ZINC34207038 ZINC39056475 ZINC79387399 
GlideScore –SP:  -8.287 (47) GlideScore –SP: -8.491 (13) GlideScore –SP: -8.587 (10) 
GlideScore –XP: -8.443 (19) GlideScore –XP: -7.696 (54) GlideScore –XP: -7.596 (61) 
   
   
Simple Sum Rank: 77 Simple Sum Rank: 83  Simple Sum Rank: 84  
R
O
F
F 3 C
 R
O H
Cl
Cl
 
R N H 2
Cl F
 
ZINC71867286 ZINC39375152 ZINC39057333 
GlideScore –SP: -8.391 (25) GlideScore –SP: -8.346 (32) GlideScore –SP:  
GlideScore –XP: -7.729 (52) GlideScore –XP: -7.749 (51) GlideScore –XP:  
   
   
Simple Sum Rank: 86 Simple Sum Rank: 87 Simple Sum Rank:  
R
Cl F
F
 
R
O HF
O H
 
R
 
ZINC02540168 ZINC39056878 Chrysin 
GlideScore –SP: -8.443 (21) GlideScore –SP: -8.181 (82) GlideScore –SP: -8.193 (79) 
GlideScore –XP: -7.574 (65) GlideScore –XP: -9.117 (5) GlideScore –XP: -7.255 (128)  
   
(a) Docking ranks shown in brackets. 
 
 
Docking to “Induced-fit GPb Receptor” 
An induced fit receptor was then created, by relaxing the residues inside the 
hydrophobic pocket to allow for larger substituents on the B-ring to be able to fit into 
the cavity. Using the same parameters as the original Glide-SP and –XP, all 1239 
ligands were docked into this new receptor. This gave 740 poses and 790 poses for 
Glide-SP and –XP respectively. The docking GSs revealed that 398 ligands using Glide-
SP were better than chrysin and 214 ligands using Glide-XP were better than chrysin. 
These poses were then rescored using the Simple Sum Rank of Glide-SP and –XP ranks 
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(Eq 6.1). 257 ligands were found to bind better than chrysin in the “Induced fit 
receptor”. The ligands that gave good poses with Glide-SP and –XP were fluorine and 
chlorine in the para position (4’), halogens in the meta position (3’ and 5’) also appear 
to give greater binding affinities. Similar to the original GPb receptor, hydroxyl groups 
in the ortho (2’ and 6’) position seemed to favour binding. As anticipated, the Induced 
Fit Receptor allowed slightly larger substituents on the B ring to be docked into the 
hydrophobic pocket, due to the more relaxed open cavity, which is also why the 
“Induced Fit Receptor” yielded more results than the original. Chrysin, as somewhat 
expected, was found to go down the ranking for this receptor with the GPb 
conformation adjusted from the native GPb-chrysin complex conformation of the solved 
crystallographic complex (PDB code: 3EBO).   
 
 
6.3.2 - QM/MM-PBSA Results 
The best 200 Glide-SP poses for each receptor were taken forward and used as input for 
preliminary QM/MM-PBSA binding free energy calculations. More accurate QM/MM-
PBSA binding free energy calculations were employed on ligands that gave values more 
negative than -11 kcal/mol in the original QM/MM-PBSA calculation (58 protein-
ligand complexes with receptor conformation either from “Original GPb receptor” or 
“Induced-fit receptor”). Accuracy was improved by using Prime 4.2 minimisation to 
refine the protein-ligand complexes, so that the complexes were theoretically closer to 
the “true” complex structures. These QM/MM-PBSA(1) and QM/MM-PBSA(2) results 
should in theory give more accurate results than the preliminary QM/MM-PBSA 
calculations on the “Original GPb Receptor” and the “Induced Fit Receptor” due to the 
relaxed receptor from Prime, as the residues around the ligand were in more optimal 
positions to the specific ligands. The results from the faster QM/MM-PBSA(1) 
calculations (smaller QM region) after the Prime minimisation gave more negative 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values than the original QM/MM-PBSA calculations, whereas the slower 
QM/MM-PBSA(2) calculations gave in general less negative ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values. 
The first set of QM/MM-PBSA(1) tests (small QM region, results shown in Table 6.2) 
employed the ligand and the two aromatic π-stacking residues Phe285 and Tyr613 as 
the QM region, leaving the rest of the receptor in the MM region. This has a greater 
number of more negative ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏  values compared to the slower QM/MM-PBSA(2) 
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with a larger QM region. The QM/MM-PBSA(1) calculations showed that 36 ligands 
gave better ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values than chrysin. Out of these 36 ligands, 26 also performed 
better in the preliminary QM/MM-PBSA calculations.  Of the total 58 ligands, the 
QM/MM-PBSA(1) calculations did, however, give five ligands with values below the -
11 kcal/mol cut off, which was the threshold value used for selection of candidates from 
the preliminary QM/MM-PBSA calculations. Encouragingly, the overall outcomes does 
suggest that multiple ligands are more potent than chrysin. From Table 6.1 considering 
all 58 ligands, generally the ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 values dominate, with values between -79.51 and 
-54.46 kcal/mol. The ligand with a value of -79.51 kcal/mol has hydroxyl groups in the 
2’ and 3’ position, whilst the ligand with a value of -54.46 kcal/mol has two fluorines at 
the ortho positions. This suggests that more polar substituents give better ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 
values. As for halogenated ligands, for example, Zinc code 39712934 (2’,6’=F, 4’=Cl) 
gave a value of -54.50 kcal/mol and ligand 02381665 (2’,6’=F, 3’=Cl) gave a value of -
54.51 kcal/mol. Whilst total solvation free energies range from 21.23 and 45.98 
kcal/mol, the ligand that gave the worst result of 45.98 kcal/mol has two hydroxyl 
groups on the meta positions of the B ring, whilst the best result of 23.35 kcal/mol has 
two flourines at the ortho positions, the same which gave the poor ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 result. This 
highlights the sensitive balance between ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄and ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 required to design an 
effective potent inhibitor. Entropy values range from -15.99 to -13.37 kcal/mol, whilst 
chrysin has a value of -13.64 kcal/mol, which means that the entropy loss of chrysin 
upon binding is less than all but one of the ligands, which has a fluorine in the meta 
position. This low entropy value is a contributing factor to its competitive ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 value. 
The greatest entropy loss value of -15.99 kcal/mol has hydroxyls on the 2’ and 3’ 
positions, which is the same ligand that gave the best ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 result. This suggests 
that hydroxyl groups on the B ring have less favourable entropy contributions, as other 
ligands with hydroxyl groups have also poor TΔS values, whilst the more favourable 
entropy contributions tend to come from ligands that have only one substituent, of either 
fluorine or chlorine, the two smaller halogens, especially at the ortho position, such as 
ligand 01609560 (2’=Cl) with a value of -13.85 kcal/mol and 01699267 (2’=Br) with a 
value of -13.90 kcal/mol. 
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Table 6.2: Table illustrating the varied contributions to the terms in  Eq. 6.3  
to the QM/MM-PBSA binding free energies for four different ligands.a 
Structure 
O
OO H
OH
Cl
 
O H
O
O
OH
Br
 
Zinc Code 01609560 01699267 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
 -13.60 -11.20 
∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 -51.95 -52.84 
∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 24.50 27.74 
𝑇𝑇∆𝑆𝑆 -13.85 -13.91 
Structure 
O H
O
O
OH
Cl
F
F
 
O H
O
O
OH
ClF
F
 
Zinc Code 02381665 39712934 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
 -10.58 -4.93 
∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 -51.91 -51.70 
∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 27.13 31.85 
𝑇𝑇∆𝑆𝑆 -14.20 -14.93 
Structure 
O H
O
O H
OH
O
OH
 
O H
O
O
OH
 
Zinc Code 34207036 02041164 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
 -5.92 -12.35 
∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 -66.76 -51.44 
∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 45.98 25.45 
𝑇𝑇∆𝑆𝑆 -14.86 -13.64 
aAll Values in table refer to results from the QM/MM-PBSA (2) in kcal/mol. 
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Table 6.3: QM/MM-PBSA(1) results showing the breakdown of ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏. 
Rankc Ligand Zinc Code 
2'
3'
4'
5'
6'
OH
O H
O
O
 
Simple Sum Rank QM/MM-PBSA 
2’ 3’ 4’ 5’ 6’ aa bb ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄d ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃𝐵𝐵 d ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝐾𝐾𝐴𝐴 d ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑣𝑣𝑠𝑠d 𝑇𝑇∆𝑆𝑆d ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏c,d 
               
1(28) 01566597 H H Br H H 671 (346) 442 (146) -59.29 26.09 -4.86 21.23 -14.69 -23.37 (-13.84) 
2(15) 01997104 H H H H OH 137 (51) 573  (242) -70.83 38.18 -4.78 33.40 -14.69 -22.74 (-15.37) 
3(41) 01609560 H H H H Cl 229 (95) 759 (416) -57.88 27.20 -4.98 22.21 -13.85 -21.82 (-12.32) 
4(10) 20248556 F H H Br H 412 (198) 364 (103) -59.96 28.66 -4.93 23.73 -14.73 -21.50 (-15.90) 
5(26) 05782628 H H H CH3 OH 483 (232) 119 (23) -65.72 34.82 -4.96 29.86 -14.96 -20.89 (-13.99) 
6(18) 11804354 NH2 H H Cl H 89 (23) 20 (4) -65.65 35.80 -4.58 31.22 -15.14 -19.29 (-15.06) 
7(27) 01699267 H H H H Br 269 (119) 837 (464) -59.07 30.53 -4.55 25.98 -13.90 -19.18 (-13.88) 
8(50) 02506767 H H Cl H F - 432 (140) -57.08 28.14 -4.69 23.45 -14.49 -19.13 (-11.48) 
9(4) 01995213 H H H F H 426 (207) 343 (95) -56.08 28.45 -4.76 23.69 -13.37 -19.02 (-16.98) 
10(14) 01845844 H H F Br H 127 (44) 157 (36) -60.71 32.43 -5.14 27.29 -14.55 -18.87 (-15.45) 
11(13) 02560120 H H F Cl H 212 (81) 104 (16) -59.63 31.45 -4.79 26.66 -14.24 -18.73 (-15.55) 
12(8) 02140809 H H F H F 188 (75) 297 (78)  -57.21 29.59 -4.47 25.13 -13.69 -18.39 (-16.15) 
13(21) 02243102 F H H I H 591 (289) 500 (175) -57.34 29.39 -5.06 24.33 -14.63 -18.38 (-14.79) 
14(11) 02382083 F H H Cl H 458 (225) 212 (52) -57.07 29.55 -4.95 24.60 -14.32 -18.15 (-15.89) 
15(2) 20248548 OH H H Cl H 166 (67) 107 (18) -71.17 43.26 -5.11 38.15 -15.24 -17.78 (-17.79) 
a: “Original GPb Receptor”. b: “Induced Fit Receptor”. c: Values in brackets from preliminary QM/MM-PBSA calculations. d: (kcal/mol) Chrysin highlighted in 
red.  
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Table 6.3 (continued): QM/MM-PBSA(1) results showing the breakdown of ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏. 
16(55) 13481417 H H H OH OH 95 (28) 299 (80) -79.51 50.38 -4.61 45.77 -15.99 -17.74 (-11.14) 
17(34) 02140813 H H Cl Cl H 258 (112) 201 (49) -59.11 32.04 -4.91 27.13 -14.79 -17.19 (-12.84) 
18(3) 03860261 H H H Cl H 544 (272) 479 (164) -56.89 30.59 -4.94 25.66 -14.11 -17.12 (-17.70) 
19(46) 34207038 H H H NH2 H 66 (13) 435 (141) -59.52 32.78 -4.69 28.09 -14.42 -17.01 (-11.57) 
20(16) 01847456 H H F H H 129 (45) 530 (211) -59.04 32.80 -4.76 28.04 -14.07 -16.93 (-15.33) 
21(9) 14989302 H Br H F H 284 (125) 389 (120) -56.32 29.18 -4.42 24.76 -14.64 -16.93 (-15.91) 
22(51) 01662293 H H H Br H 608 (300) 410 (131) -57.31 31.07 -4.76 26.31 -14.11 -16.89 (-11.40) 
23(7) 02022413 H H H H F 353 (168) 609 (269) -56.43 30.63 -4.39 26.24 -13.64 -16.54 (-16.19) 
24(42) 02539282 H H F F H 162 (66) 76 (12) -58.70 33.86 -5.03 28.83 -14.00 -15.87 (-12.24) 
25(30) 16159637 H H H Br F 557 (274) 366 (108) -56.23 30.86 -4.73 26.13 -14.33 -15.76 (-13.66) 
26(45) 20248536 H H Cl H OH - 277 (69) -71.56 45.10 -4.62 40.48 -15.43 -15.65 (-11.85) 
27(52) 34207036 H OH H OH H 284 (126) 182 (42) -71.88 46.16 -4.67 41.49 -14.86 -15.53 (-11.29) 
28(29) 67800103 F H H Br F 428 (209) 360 (101) -55.13 30.35 -4.92 25.43 -14.43 -15.27 (-13.75) 
29(38) 02539342 H F H F H 144 (54) 403 (127) -55.03 30.39 -4.60 25.79 -14.20 -15.03 (-12.41) 
30(5) 60084043 F H F CH3 H 392 (189) 512 (188) -59.81 34.58 -4.96 29.62 -15.33 -14.87 (-16.87) 
31(43) 02539281 F H H F H 327 (154) 220 (53) -56.20 32.22 -4.86 27.36 -13.98 -14.86 (-12.09) 
32(25) 02390497 Cl H H Br H 198 (78) 414 (133) -58.38 33.94 -4.85 29.09 -14.64 -14.65 (-14.14) 
33(54) 14443449 H H H OH H 235 (99) 601 (266) -70.06 45.21 -4.67 40.54 -15.07 -14.45 (-11.16) 
34(6) 39056287 CHO H H H H 232 (98) - -58.52 34.48 -4.67 29.81 -14.36 -14.36 (-16.37) 
35(22) 02382234 H H H Cl F 424 (206) 287 (76) -55.62 31.98 -4.92 27.06 -14.27 -14.29 (-14.56) 
36(12) 01604094 H H H I H 622 (308) 529 (210) -57.39 33.50 -4.71 28.79 -14.34 -14.25 (-15.85) 
37(40) 02041164 H H H H H 207 (80) 590 (258) -56.24 33.30 -4.82 28.48 -13.64 -14.12 (-12.35) 
38(58) 36533250 H H Br H CH3 528 (259) 509 (187) -60.45 35.98 -4.96 31.03 -15.36 -14.06 (-11.02) 
39(31) 39056301 Et H H H H 286 (127) 995 (557) -58.65 34.99 -4.74 30.25 -14.36 -14.04 (-13.32) 
a: “Original GPb Receptor”. b: “Induced Fit Receptor”. c: Values in brackets from preliminary QM/MM-PBSA calculations. d: (kcal/mol) Chrysin highlighted in 
red.  
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Table 6.3 (continued): QM/MM-PBSA(1) results showing the breakdown of ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏  
40(37) 02582858 H NS N H H  339 (93) -62.86 38.77 -4.82 33.95 -14.88 -14.03 (-12.58) 
41(57) 02140810 F H H H F 326 (153) 721 (374) -54.46 31.04 -4.74 26.30 -14.22 -13.94 (-11.04) 
42(56) 02527758 H Cl H F H 262 (115) 222 (54) -55.62 32.12 -4.67 27.45 -14.46 -13.71 (-11.07) 
43(17) 39056676 OH H H CHO H 122 (39) 524 (204) -72.85 48.59 -4.64 43.95 -15.45 -13.44 (-15.18) 
44(24) 02381665 F H H Cl F 400 (192) 271 (66) -54.51 31.82 -4.93 26.90 -14.20 -13.41 (-14.25) 
45(48) 04262390 F H F F H 136 (49) 63 (8) -57.47 34.51 -4.59 29.93 -14.21 -13.34 (-11.52) 
46(44) 39057325 CH2Cl H F H H 179 (72) 284 (74) -62.70 39.64 -4.52 35.12 -14.41 -13.17 (-11.97) 
47(19) Chrysin_BC1-1 H H H H H 511 (252) 750 (403) -59.68 37.41 -5.15 32.26 -14.58 -12.84 (-14.84) 
48(32) 02545260 F H F H F 272 (120) 226 (57) -55.62 33.43 -5.01 28.43 -14.36 -12.83 (-12.89) 
49(1) 39056475 H H F H OH 67 (14) 351 (97) -71.96 47.17 -2.55 44.61 -14.86 -12.48 (-18.73) 
50(23) 02584346 H H H F F 255 (110) 235 (61) -54.52 33.06 -4.91 28.16 -14.11 -12.26 (-14.44) 
51(53) 39057324 CH2Cl H H F H 134 (48) 361 (102) -61.60 39.94 -4.82 35.12 -14.37 -12.11 (-11.21) 
52(47) 39056678 CH2O CH3 
H H H H 170 (69) 617 (278) -61.37 39.98 -4.68 35.30 -14.43 -11.65 (-11.53) 
53(36) 39056429 F H H H OH 6 (2) 371 (110) -67.43 45.37 -4.38 40.98 -15.00 -11.45 (-12.67) 
54(49) 02560325 CH3 H H F H 230 (96) 348 (96) -56.80 36.89 -5.03 31.86 -14.22 -10.72 (-11.51) 
55(39) 39712934 F H Cl H F - 398 (125) -54.50 33.85 -4.73 29.11 -14.93 -10.45 (-12.37) 
56(20) 39056495 OH H H F H 56 (11) 270 (65) -69.97 49.81 -5.16 44.65 -15.08 -10.23 (-14.80) 
57(33) 02600074 H H H CF3 F - 467 (154) -56.54 35.70 -4.74 30.96 -15.56 -10.03 (-12.87) 
58(35) 02382119 H H F Cl F 304 (145) 113 (20) -58.24 40.40 -4.60 35.80 -14.37 -8.07 (-12.76) 
- 01627231 H CH3 H H H - - -57.77 34.64 -4.86 29.78 -14.52 -13.47 
- 02040256 H H CH3 H H - - -50.53 28.42 -4.59 23.83 -14.68 -12.01 
a: “Original GPb Receptor”. b: “Induced Fit Receptor”. c: Values in brackets from preliminary QM/MM-PBSA calculations. d: (kcal/mol) Chrysin highlighted in 
red.  
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The second set of QM/MM-PBSA(2) tests (large QM region, results shown in Table 
6.4) employed the ligand, the two aromatic π-stacking residues Phe285 and Tyr613 and 
the residues inside the hydrophobic pocket (Asp283, Asn284, Glu382, Leu380, Hie571, 
Glu572, Tyr573, Arg770 and Phe771) as the QM region, with the remainder of the 
receptor being the MM region. This has a greater number of less negative ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏  
values compared to the fast QM/MM-PBSA(1) with a smaller QM region. The 
QM/MM-PBSA(2) calculations revealed that 20 ligands gave better ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values than 
chrysin. Out of these 20 ligands, 14 also performed better in the preliminary QM/MM-
PBSA calculations. Of the total 58 ligands, the QM/MM-PBSA(2) calculations did 
however give 28 ligands with values worse than the -11 kcal/mol cut-off, which was the 
threshold value used for selection of candidates from the preliminary QM/MM-PBSA 
calculations. Generally, the ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 values dominate, with values between -76.98 and 
-50.11 kcal/mol, the ligand with a value of -76.98 kcal/mol has hydroxyl groups in the 
2’ and 3’ position, whilst the ligand with a value of -50.11 kcal/mol has two ortho 
flourines. An increase in polarity correlates with better ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 values. Whilst total 
solvation free energies range from 23.35 and 45.98 kcal/mol, the ligand that gave the 
least favourable value of 45.98 kcal/mol has two hydroxyl groups on the meta positions 
of the B ring, whilst the best result of 23.35 kcal/mol has two flourines at the ortho 
positions, consistent with the values from the QM/MM-PBSA(1) calculations. The non-
polar contributions to solvation are similar as well, consistently around -4 to -5 
kcal/mol, with the polar contributions dominating. Entropy values for QM/MM-
PBSA(2) in Table 6.3 are identical to the values for QM/MM-PBSA(1) in Table 6.1 due 
to the nature of the calculations using the same input pose, which favour smaller 
halogenated derivatives and the ortho position on the B ring. In summary and in 
general, therefore, the results from QM/MM-PBSA(1) and QM/MM-PBSA(2) appear to 
be quite consistent, adding credibility to the predictive nature of these calculations.
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Table 6.4: QM/MM-PBSA(2) results showing the breakdown of ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
Rankc Ligand Zinc Code 
2'
3'
4'
5'
6'
OH
O H
O
O
 
 
Simple Sum Rank QM/MM-PBSA (kcal/mol) 
2’ 3’ 4’ 5’ 6’ aa bb ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄d ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃𝐵𝐵 d ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝐾𝐾𝐴𝐴 d ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑣𝑣𝑠𝑠d 𝑇𝑇∆𝑆𝑆d ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏c,d 
               
1(26) 05782628 H H H CH3 OH 483 (232) 119 (23) -62.93 31.70 -4.81 26.88 -14.96 -21.09 (-13.99) 
2(15) 01997104 H H H H OH 137 (51) 573 (242) -65.59 37.47 -4.55 32.93 -14.69 -17.98 (-15.37) 
3(55) 13481417 H H H OH OH 95 (28) 299 (80) -76.98 48.44 -4.72 43.72 -15.99 -17.26 (-11.14) 
4(14) 01845844 H H F Br H 127 (44) 157 (36) -55.75 29.18 -4.94 24.24 -14.55 -16.97 (-15.45) 
5(51) 01662293 H H H Br H 608 (300) 410 (131) -53.73 28.26 -4.59 23.67 -14.11 -15.95 (-11.40) 
6(25) 02390497 Cl H H Br H 198 (78) 414 (133) -53.78 28.44 -4.79 23.64 -14.64 -15.49 (-14.14) 
7(28) 01566597 H H Br H H 671 (346) 442 (146) -55.03 29.99 -4.65 25.34 -14.69 -15.00 (-13.84) 
8(16) 01847456 H H F H H 129 (45) 530 (211) -53.45 29.30 -4.76 24.54 -14.07 -14.84 (-15.33) 
9(22) 02382234 H H H Cl F 424 (206) 287 (76) -52.91 29.29 -4.65 24.64 -14.27 -13.99 (-14.56) 
10(29) 67800103 F H H Br F 428 (209) 360 (101) -52.78 29.56 -5.05 24.51 -14.43 -13.84 (-13.75) 
11(9) 14989302 H Br H F H 284 (125) 389 (120) -52.57 28.65 -4.42 24.22 -14.64 -13.71 (-15.91) 
12(41) 01609560 H H H H Cl 229 (95) 759 (416) -51.95 28.85 -4.35 24.50 -13.85 -13.60 (-12.32) 
13(45) 20248536 H H Cl H OH - 277 (69)  -67.98 43.23 -4.24 38.99 -15.43 -13.56 (-11.85) 
14(2) 20248548 OH H H Cl H 166 (67) 107 (18) -67.39 43.69 -4.93 38.76 -15.24 -13.40 (-17.79) 
15(21) 02243102 F H H I H 591 (289) 500 (175) -52.39 29.20 -4.61 24.59 -14.63 -13.17 (-14.79) 
a: “Original GPb Receptor”. b: “Induced Fit Receptor”. c: Values in brackets from preliminary QM/MM-PBSA calculations. d: (kcal/mol) Chrysin highlighted in 
red. 
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Table 6.4 (continued): QM/MM-PBSA(2) results showing the breakdown of ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
16(35) 02382119 H H F Cl F 304 (145) 113 (20) -54.62 31.67 -4.58 27.09 -14.37 -13.17 (-12.76) 
17(57) 02140810 F H H H F 326 (153) 721 (374) -50.11 28.26 -4.91 23.35 -14.22 -12.54 (-11.04) 
18(46) 34207038 H H H NH2 H 66 (13) 435 (141) -55.90 33.63 -4.61 29.03 -14.42 -12.46 (-11.57) 
19(8) 02140809 H H F H F 188 (75) 297 (78) -51.24 29.36 -4.22 25.14 -13.69 -12.41 (-16.15) 
20(10) 20248556 F H H Br H 412 (198) 364 (103) -55.35 33.39 -5.13 28.26 -14.73 -12.36 (-15.90) 
21(40) 02041164 H H H H H 207 (80) 590 (258) -51.44 29.92 -4.47 25.45 -13.64 -12.35 (-12.35) 
22(13) 02560120 H H F Cl H 212 (81) 104 (16) -54.57 33.00 -4.81 28.19 -14.24 -12.14 (-15.55) 
23(54) 14443449 H H H OH H 235 (99) 601 (266) -66.42 43.80 -4.53 39.27 -15.07 -12.07 (-11.16) 
24(42) 02539282 H H F F H 162 (65) 76 (12) -52.80 31.45 -4.65 26.80 -14.00 -12.00 (-12.24) 
25(34) 02140813 H H Cl Cl H 258 (112) 201 (49) -56.07 34.44 -5.15 29.29 -14.79 -11.99 (-12.84) 
26(5) 60084043 F H F CH3 H 392 (189) 512 (188) -55.03 32.76 -4.53 28.23 -15.33 -11.47 (-16.87) 
27(37) 02582858 H NS N H H - 339 (93) -59.89 38.03 -4.45 33.58 -14.88 -11.43 (-12.58) 
28(27) 01699267 H H H H Br 269 (119) 837 (464) -52.84 32.19 -4.46 27.74 -13.91 -11.20 (-13.88) 
29(36) 39056429 F H H H OH 6 (2) 371 (110) -63.56 42.05 -4.60 37.45 -15.00 -11.11 (-12.67) 
30(48) 04262390 F H F F H 136 (49) 63 (8) -52.21 31.24 -4.33 26.91 -14.21 -11.10 (-11.52) 
31(32) 02545260 F H F H F 272 (120) 226 (57) -51.28 30.37 -4.36 26.01 -14.36 -10.91 (-12.89) 
32(4) 01995213 H H H F H 426 (207) 343 (95) -50.65 31.38 -4.87 26.51 -13.37 -10.77 (-16.98) 
33(11) 02382083 F H H Cl H 458 (225) 212 (52) -52.87 32.46 -4.62 27.84 -14.32 -10.72 (-15.89) 
34(1) 39056475 H H F H OH 67 (14) 351 (97) -66.13 44.80 -4.14 40.66 -14.86 -10.60 (-18.73) 
35(24) 02381665 F H H Cl F 400 (192) 271 (66) -51.91 31.93 -4.80 27.13 -14.20 -10.58 (-14.25) 
36(50) 02506767 H H Cl H F - 432 (140) -52.69 32.26 -4.30 27.96 -14.49 -10.23 (-11.48) 
37(12) 01604094 H H H I H 622 (308) 529 (210) -53.08 33.67 -4.91 28.77 -14.34 -9.97 (-15.85) 
38(7) 02022413 H H H H F 353 (168) 609 (269) -51.04 31.95 -4.48 27.47 -13.64 -9.92 (-16.19) 
39(58) 36533250 H H Br H CH3 528 (259) 509 (187) -56.48 35.95 -4.68 31.27 -15.36 -9.85 (-11.02) 
a: “Original GPb Receptor”. b: “Induced Fit Receptor”. c: Values in brackets from preliminary QM/MM-PBSA calculations. d: (kcal/mol) Chrysin highlighted in 
red. 
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Table 6.4 (continued): QM/MM-PBSA(2) results showing the breakdown of ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
40(47) 39056678 CH2O CH3 
H H H H 170 (69) 617 (278) -57.14 37.83 -4.75 33.08 -14.43 -9.63 (-11.53) 
41(30) 16159637 H H H Br F 557 (274) 366 (108) -53.78 35.00 -4.92 30.08 -14.33 -9.36 (-13.66) 
42(18) 11804354 NH2 H H Cl H 89 (23) 20 (4) -60.41 40.39 -4.41 35.99 -15.14 -9.28 (-15.06) 
43(17) 39056676 OH H H CHO H 122 (39) 524 (204) -70.22 50.72 -4.81 45.91 -15.45 -8.86 (-15.18) 
44(33) 02600074 H H H CF3 F - 467 (154) -55.13 35.34 -4.59 30.75 -15.56 -8.83 (-12.87) 
45(3) 03860261 H H H Cl H 544 (272) 479 (164) -53.07 35.16 -4.91 30.25 -14.11 -8.71 (-17.70) 
46(23) 02584346 H H H F F 255 (110) 235 (61) -50.63 32.55 -4.62 27.93 -14.11 -8.59 (-14.44) 
47(31) 39056301 Et H H H H 286 (127) 995 (557) -53.55 35.40 -4.79 30.61 -14.36 -8.57 (-13.32) 
48(43) 02539281 F H H F H 327 (154) 220 (53) -51.14 33.30 -4.31 28.99 -13.98 -8.18 (-12.09) 
49(20) 39056495 OH H H F H 56 (11) 270 (65) -65.26 47.21 -4.68 42.53 -15.08 -7.65 (-14.80) 
50(38) 02539342 H F H F H 144 (54) 403 (127) -50.61 33.66 -4.86 28.80 -14.20 -7.62 (-12.41) 
51(56) 02527758 H Cl H F H 262 (115) 222 (54) -51.76 34.44 -4.57 29.88 -14.46 -7.43 (-11.07) 
52(49) 02560325 CH3 H H F H 230 (96) 348 (96) -51.51 34.63 -4.64 29.98 -14.22 -7.31 (-11.51) 
53(52) 34207036 H OH H OH H 284 (126) 182 (42) -66.76 50.80 -4.83 45.98 -14.86 -5.92 (-11.29) 
54(53) 39057324 CH2Cl H H F H 134 (48) 361 (102) -56.65 41.70 -4.71 37.00 -14.37 -5.29 (-11.21) 
55(39) 39712934 F H Cl H F - 398 (125) -51.70 36.78 -4.93 31.85 -14.93 -4.93 (-12.37) 
56(6) 39056287 CHO H H H H 232 (98) - -53.46 39.32 -4.91 34.41 -14.36 -4.69 (-16.37) 
57(44) 39057325 CH2Cl H F H H 179 (72) 284 (74) -57.29 42.95 -4.72 38.23 -14.41 -4.65 (-11.97) 
58(19) Chrysin_BC1-1 H H H H H 511 (252) 750 (403) -54.32 41.35 -5.33 36.01 -14.58 -3.73 (-14.84) 
- 01627231 H CH3 H H H - - -54.05 27.50 -4.55 30.61 -14.52 -12.04 
- 02040256 H H CH3 H H - - -48.52 25.96 -4.64 32.05 -14.68 -7.87 
a: “Original GPb Receptor”. b: “Induced Fit Receptor”. c: Values in brackets from preliminary QM/MM-PBSA calculations. d: (kcal/mol) Chrysin highlighted in 
red. 
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Consensus QM/MM-PBSA ranking 
Using ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 as a new rank system for the preliminary QM/MM-PBSA, the faster 
QM/MM-PBSA(1) and the slower QM/MM-PBSA(2), we combined the results using a 
Simple Sum Rank of the ligands to decide which ligands performed the best across the 
board [144]. This revealed that 13 ligands achieved a higher Simple Sum Rank than the 
benchmark chrysin, as shown in Table 6.5. Out of the 13 ligands which achieved a 
higher Simple Sum Rank than the benchmark chrysin, two ligands scored better than 
chrysin in every QM/MM-PBSA calculation, both of which have a single hydroxyl 
group in the ortho position. Out of the top 13 ligands, 7 of them contain fluorine atoms, 
mostly in ortho and para positions. Generally, the position that seems to dominate the 
most for substitutions is the meta position, with 8 of the 13 ligands displaying 
substituents at this position. For example, ligand with Zinc code 4989302 has a fluorine 
and bromine at the meta positions. The only other substituent to appear here is a non-
polar methyl group. The lack of polarity at the meta position suggests that polarity here 
leads to poor binding due to the hydrophobic pocket, consistent with previous 
suggestions [83]. The highest scoring ligand (Zinc code 13481417) that displays 
polarity (hydroxyl) at the meta position has a sum rank of 74, which is 9 places lower 
than the benchmark chrysin. This lack of polarity inside the pocket is even more 
apparent for the para position, as none of the ligands that made it past the filtering 
stages has para polar substituents such as hydroxyls. This is also consistent with 
previous work [83]. For the top 13 compounds, apart from ligand Zinc code 01566597 
with a para-bromine substituent and whose binding is shown in Fig 6.4(a), only fluorine 
appears in the para position. This may be due to it’s size; being the smallest 
hydrophobic substituent present in these results. The ortho position shows different 
preferences. This allows substituents to be more polar, as they do not project as deeply 
into the hydrophobic pocket. Three of the best 13 ligands display hydroxyl groups at the 
ortho position, and all three give high ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏values. Ligand Zinc code 01997104 which 
has only one substituent, a hydroxyl at the ortho position, scored the highest in regards 
to the Simple Sum Rank. One reason that the hydroxyls bind well when at the ortho 
position is that the hydrogen forms a hydrogen bond to the oxygen on the Glu572, 
which can be seen with ligands Zinc codes 01997104 (ortho = OH) and 20248548 
(ortho = OH; meta = Cl), and whose binding is shown in Figures 6.4(c) and 6.4(d), 
respectively. The ligand 01997104 (Fig 6.4(c)) hydroxyl forms a hydrogen bond with a 
donor angle of 155° and a distance of 1.94 Å; these values imply the hydrogen bond 
between the two is strong. The same trend is observed for Zinc code 20248548 (Fig 
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6.4(d)), with values of 1.81 Å and 161°. Ligand Zinc code 01609560 (Fig 6.4(b)) with a 
chloro ortho substituent is also predicted to be favourable. When this ligand binds, the 
chlorine may form halogen bonding to the same Glu572 oxygen; the distance between 
the chlorine and oxygen is 3.22 Å, which is close to the optimal value of 3.12 Å [150]. 
This halogen bond is a key contributor factor to the favourable ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 value. Ligands 
with halogen substituents show a trend with less favorable ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 contributions, 
whilst polar groups have more negative and favourable ∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 values. However, due 
to the polarity, these ligands require more energy to desolvate, which is shown in the 
∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑃𝑃𝐵𝐵  values; polar ligands have much higher values, which brings down the overall 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 of the ligand. On the other hand, non-polar halogen substituents with less  
∆𝐸𝐸𝑄𝑄𝑄𝑄/𝑄𝑄𝑄𝑄 contributions to binding do not get as heavily penalised by high ∆𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃𝐵𝐵  
results, due to them not interacting with solvents as strongly. 
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Table 6.5 – Predicting the best ligands for GPb inhibition by exploiting consensus scoring the values obtained for QM/MM-PBSA calculations. 
Rank  
By Simple 
Sum 
Rank 
Ligand 
2'
3'
4'
5'
6'
OH
O H
O
O
 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
Preliminary 
(Kcal/mol) 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
Preliminary 
rank 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
QM/MM-
PBSA(1) 
(Kcal/mol) 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
QM/MM-
PBSA(1) 
rank 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
QM/MM-
PBSA(2) 
(Kcal/mol) 
∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 
QM/MM
-PBSA(2) 
rank 
Simple 
Sum 
Rank 
2’ 3’ 4’ 5’ 6’ 
1 01997104 H H H H OH -16.98 4 -22.74 2 -17.98 2 8 
2 01566597 H H Br H H -14.85 19 -23.37 1 -15.00 7 27 
3 01609560 H H H H Cl -15.85 12 -21.82 3 -13.60 12 27 
4 20248548 OH H H Cl H -17.79 2 -17.78 15 -13.40 14 31 
5 05782628 H H H CH3 OH -13.99 27 -20.89 5 -21.09 1 33 
6 20248556 F H H Br H -15.90 10 -21.50 4 -12.36 20 34 
7 14989302 H Br H F H -15.91 9 -16.93 21 -13.71 11 41 
8 01845844 H H F Br H -13.88 28 -18.87 10 -16.97 4 42 
9 01847456 H H F H H -15.45 14 -16.93 20 -14.84 8 42 
10 01995213 H H H F H -15.33 16 -19.02 9 -10.77 32 57 
11 02390497 Cl H H Br H -14.56 23 -14.65 32 -15.49 6 61 
12 60084043 F H F CH3 H -16.87 5 -14.87 30 -11.47 26 61 
13 02243102 F H H I H -12.84 35 -18.38 13 -13.17 15 63 
14 02041164 H H H H H -16.19 7 -14.12 37 -12.35 21 65 
15 02140810 F H H H F -16.15 8 -13.94 41 -12.54 17 66 
16 02560120 H H F Cl H -12.89 33 -18.73 11 -12.14 22 66 
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Table 6.5 (continued) - Predicting the best ligands for GPb inhibition by exploiting consensus scoring the values obtained for QM/MM-PBSA calculations. 
17 101804354 NH2 H H Cl H -15.06 18 -19.29 6 -9.28 42 66 
18 67800103 F H H Br F -13.75 30 -15.27 28 -13.84 10 68 
19 01662293 H H H Br H -12.32 42 -16.89 22 -15.95 5 69 
20 02506767 H H Cl H F -14.14 26 -19.13 8 -10.23 36 70 
21 02140809 H H F H F -12.35 41 -18.39 12 -12.41 19 72 
22 02382083 F H H Cl H -14.25 25 -18.15 14 -10.72 33 72 
23 13481417 H H H OH OH -11.14 55 -17.74 16 -17.26 3 74 
24 02022413 H H H H F -15.37 15 -16.54 23 -9.92 38 76 
25 04262390 F H F F H -17.70 3 -13.34 45 -11.10 30 78 
26 02382234 H H H Cl F -12.76 36 -14.29 35 -13.99 9 80 
27 34207038 H H H NH2 H -11.57 47 -17.01 19 -12.46 18 84 
28 39056475 H H F H OH -18.73 1 -12.48 49 -10.60 34 84 
29 20248536 H H Cl H OH -11.85 46 -15.65 26 -13.56 13 85 
30 02382119 H H F Cl F -15.89 11 -8.07 58 -13.17 16 85 
31 01699267 H H H H Br -11.40 51 -19.18 7 -11.20 28 86 
32 02539282 H H F F H -12.09 44 -15.87 24 -12.00 24 92 
33 39056287 CHO H H H H -16.37 6 -14.36 34 -4.69 56 96 
34 16159637 H H H Br F -13.66 31 -15.76 25 -9.36 41 97 
35 03860261 H H H Cl H -12.87 34 -17.12 18 -8.71 45 97 
36 02140813 H H Cl Cl H -11.04 57 -17.19 17 -11.99 25 99 
37 02381665 F H H Cl F -14.79 22 -13.41 44 -10.58 35 101 
38 01604094 H H H I H -13.84 29 -14.25 36 -9.97 37 102 
39 39056676 OH H H CHO H -15.18 17 -13.44 43 -8.86 43 103 
40 14443449 H H H OH H -11.16 54 -14.45 33 -12.07 23 110 
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Table 6.5 (continued) - Predicting the best ligands for GPb inhibition by exploiting consensus scoring the values obtained for QM/MM-PBSA calculations. 
41 02582858 H NS N H H -11.51 49 -14.03 40 -11.43 27 116 
42 02545260 F H F H F -12.41 39 -12.83 48 -10.91 31 118 
43 39056301 Et H H H H -13.32 32 -14.04 39 -8.57 47 118 
44 39056429 F H H H OH -12.67 37 -11.45 53 -11.11 29 119 
45 02560325 CH3 H H F H -15.55 13 -10.72 54 -7.31 52 119 
46 02539342 H F H F H -12.24 43 -15.03 29 -7.62 50 122 
47 02600074 H H H CF3 F -14.44 24 -10.03 57 -8.83 44 125 
48 Chrysin_BC1-1 H H H H H -14.85 20 -12.84 47 -3.73 58 125 
49 39056495 OH H H F H -14.80 21 -10.23 56 -7.65 49 126 
50 34207036 H OH H OH H -11.29 52 -15.53 27 -5.92 53 132 
51 02584346 H H H F F -12.58 38 -12.26 50 -8.59 46 134 
52 36533250 H H Br H CH3 -11.02 58 -14.06 38 -9.85 39 135 
53 02539281 F H H F H -11.07 56 -14.86 31 -8.18 48 135 
54 39056678 CH2O CH3 
H H H H -11.53 48 -11.65 52 -9.63 40 140 
55 2527758 H Cl H F H -11.48 50 -13.71 42 -7.43 51 143 
56 39057325 CH2Cl H F H H -11.97 45 -13.17 46 -4.65 57 148 
57 39712934 F H Cl H F -12.37 40 -10.45 55 -4.93 55 150 
58 39057324 CH2Cl H H F H -11.21 53 -12.11 51 -5.29 54 158 
- 01627231 H CH3 H H H -8.90 - -13.47  -12.04   
- 02040256 H H CH3 H H 3.18 - -12.01  -7.87   
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Figure 6.4 – Predicted binding of four of the best candidates at the inhibitor site of 
GPb. With displayed ribbons. Hydrogen bonds are shown in black, non-polar hydrogens 
are hidden for clarity. Zinc Codes (a) 01566597, (b) 01609560, (c) 01997104 and (d) 
20248548. 
 
 
6.4 - Conclusion 
Computational drug design has extremely useful applications regarding the inhibition of 
GP for treatment of T2D. By aligning the core of the flavone structures between the two 
aromatic residues Phe285 and Tyr613 and modelling binding of different ligand groups 
occupying the hydrophobic cavity formed by key residues Leu380, Tyr573 and Phe771, 
we can clearly see potential for more effective inhibitor candidates. The computational 
predictions favour substituted phenyl B rings with ortho-substituted hydroxyl groups 
d 
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and halogenated substituents at the meta and para positions, whilst polar groups which 
enter the hydrophobic pocket give much poorer results.   Also, even when they are non-
polar, bulky groups appear to be too sterically demanding when entering the 
hydrophobic cavity. Of the top 13 ligands based on consensus scoring of QM/MM-
PBSA results, five, seven and one were mono-, di- and tri-substituted, respectively. 
These results can help guide the decision which ligands would be the most ideal for 
synthesis; the four ligands: 01566597 (Fig 6.4(a)), 01609560 (Fig 6.4 (b)), 01997104 
(Fig 6.4(c)) and 20248548 (Fig 6.4(d)) would be the most ideal and provide a range of 
substituents. Ligand Zinc code 01566597 has a halogen in the para position, which 
would show whether non-polar groups do bind well in the hydrophobic pocket. Whilst 
the ligand with Zinc code 01997104 would be able to confirm that hydroxyl groups at 
the ortho position interacting with Glu572 gives strong binding. Likewise, the ligand 
with Zinc code 01609560 has a chlorine in the ortho position, to see whether halogen 
bonds can compete with hydrogen bonds in this position. The ligand with Zinc code 
20248548 has both a hydroxyl in the ortho position and a halogen inside the 
hydrophobic pocket, which would be able to show whether these two interactions can 
work in synergy with each other, to give strong binding to GPb. A methyl substitution 
in the meta position also appears twice (Zinc codes 05782628 and 60084043), 
indicating that ligands of this type are worthy of synthetic consideration, to start with, 
however, meta and para methyl substitutions are considered due to likely less synthetic 
complications and to optimise a synthetic protocol. These ligands demonstrated 
competitive ∆𝐺𝐺𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 values in the QM/MM-PBSA calculations here compared to those 
calculated for chrysin. 
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Chapter 7 – Synthetic Methods 
 
7.1 - Introduction 
Type-2 Diabetes (T2D) is a chronic illness which is characterised by three factors: 1) a 
resistance of insulin action on glucose uptake, 2) relatively low production of insulin in 
the pancreas, and 3) impaired insulin action to inhibit the hepatic glucose production 
[123]. One way of combatting T2D is by inhibiting the glycogen phosphorylase (GP) 
enzyme, which is a key enzyme in glycogenolysis (breakdown of glycogen to glucose), 
and is responsible for 70% of the glucose production in the liver. It is well reported that 
flavonoids can bind to multiple sites. Flavonoids are polyphenols and ubiquitous 
components in both food of plant origin, found throughout nature and consumed daily 
as part of a healthy balanced diet. Studies in diabetic and non-diabetic rats have shown 
that flavonoids do have anti-hyperglycemic properties due to their effect on glycogen 
metabolism,[151-153] and have been shown to bind at multiple sites on GP (c.f. Chapter 
3.4). The synthesis of a variety of flavonoids has been reported. But the focus of this 
work is on the specific group of flavonoids known as flavones (Fig 7.1), and the effects 
that different substituents at the B ring have on the inhibition of GP at the caffeine 
binding site. 
A C
B
3
45
6
7
8
2'
3'
4'
5'
6'
O
O
 
Figure 7.1 – Basic structure of flavones. 
 
There are multiple synthetic routes and methods to yield the flavone structure with the 
desired substituents. For inhibition of GP, hydroxyl groups on the 5 and 7 position (see 
Fig 7.1) are required to increase bioavailability, which is important to remember when 
designing synthetic routes to these compounds so that the hydroxyl groups do not 
interfer with the desired reactions. As such, multiple synthetic methods were 
considered, (c.f. Chapter 5) including the Baker-Venkataraman rearrangement, 
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microwave methods, synthesis via 2’-hydroxychalcone, Claisen-Schmidt and the use of 
metal catalysts. 
 
7.2 - Synthetic Approach to Chrysin (6a). 
General procedure: 
3a: (R1 = R2 = H)  
3b: (R1 = H, R2 = CH3) 
3c: (R1 = CH3, R2 = H) 
CH3COOH
Δ
3a: (R1 = R2 = H)  
3b: (R1 = H, R2 = CH3) 
3c: (R1 = CH3, R2 = H) 
4a: (R1 = R2 = H)  
4b: (R1 = H, R2 = CH3) 
4c: (R1 = CH3, R2 = H) 
4a: (R1 = R2 = H)  
4b: (R1 = H, R2 = CH3) 
4c: (R1 = CH3, R2 = H) 
5a: (R1 = R2 = H)  
5b: (R1 = H, R2 = CH3) 
5c: (R1 = CH3, R2 = H) 
6a: (R1 = R2 = H)  
6b: (R1 = H, R2 = CH3) 
6c: (R1 = CH3, R2 = H) 
CH3COOH
Δ
1 2a: (R1 = R2 = H)  
2b: (R1 = H, R2 = CH3) 
2c: (R1 = CH3, R2 = H) 
i) K2CO3, H2O, PhMe, 60°C
ii) (nC4H9)4N+Br- 
5% K2CO3, reflux
OH O H
OO H
Cl
O
O
O
O
O
O OO H
O
O
O
O
O OO H
O
O
O
OOO
O
O
O
OOO
O H
O
O
O
O
OH
O H O
O
R 1
R 2
R 1
R 2 R 2
R 1
R 1
R 2
R 1
R 2 R 2
R 1
R 1
R 2
R 1
R 2
R 1
R 2
R 2
R 1
R 1
R 2
R 2
R 1
R 2
R 1
R 2
R 1
R 2
R 1
R 2
R 1
+
 
Scheme 7.1 – Synthesis of 5,7-dihydroxyflavone analogues (6a-c) via the Baker-
Venkataraman rearrangement. 
2,4,6-Trihydroxyacetophenone (1) was added to benzoyl chloride (2a) in a mixture of 
toluene, saturated potassium carbonate and tetrabutylammonium bromide and stirred, 
upon which an orange solution of (3a) was formed. To this solution, 5% potassium 
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carbonate was added and the reaction stirred at reflux. A dark orange/brown sticky solid 
formed in the orange liquid, which was decanted off and added to glacial acetic acid 
with heat and stirring. When added to ice, a cream coloured solid was yielded and 
assigned to be the only partially hydrolysed ester, 5a. 
The 13C DEPT NMR showed that cyclisation had occurred, as no CH2 peak was present 
at approximately 58 ppm. However, confusingly, 1H and 13C NMR, along with LCMS, 
confirmed that there was only trace amounts of (6a) and that the majority of the isolated 
compound was an esterified analogue: shown to be 5-hydroxy-4-oxo-2-phenyl-4H-
chromen-7-yl benzoate (5a) as seen in Fig 7.2. 
5a
O
O
O
OO H
 
Figure 7.2 – The unexpected partially hydrolysed benzoyl ester of chrysin isolated. 
 
The structure of the ester was realised, since the 1H NMR showed that only one 
hydroxyl peak had formed in the polar region at 12.24 ppm. This was further evidenced 
by the aromatic region, which showed that there were 13 aromatic protons. To confirm 
its identity, LCMS analysis showed a major peak at m/z = 359 which is consistent with 
the esterified compound, 5a. Nevertheless, despite not fully hydrolysing, the method did 
show that the Baker-Venkataraman method was effective for forming the flavone 
structure. After some time, and further attempts at its synthesis, due to the commercial 
availability of chrysin, and the trace amounts of compound left after analysis, the 
decision was made to purchase chrysin and move onto the synthesis of simple 
hydrophobic chrysin analogues. 
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7.3 - Synthesis of 5,7-dihydroxy-2-(3-methylphenyl)chromen-4-one (6b) 
 
2,4,6-Trihydroxyacetophenone (1) was added to 3-methylbenzoyl chloride (2b) in a 
mixture of toluene, saturated potassium carbonate and tetrabutylammonium bromide 
and stirred; an orange solution of (3b)  was formed. The reaction was left until 
completion, as determined by TLC. The organic layer was separated and washed, then 
added to potassium carbonate and heated at reflux with stirring to form (4b), which was 
heated at reflux in glacial acetic acid to yield the final compound (4b), which was 
purified by flash column chromatography. Again, despite attempting alternative 
conditions for ester hydrolysis (increased time, base and temperature), the same 
problem occurred, with small amounts of the desired product (6b) being isolated, but 
forming large quantities of (5b). Furthermore, extra attempts at ester hydrolysis of the 
isolated product (5b) also failed, such as, a screen of bases, the use of nucleophilic 
solvents, such as methanol, and extended reaction times. Depsite these attempts, the 
presence of the ester was confirmed by 1H NMR and MS in each case, demonstrating 
the surprising resilience in the hydrolysis of this ester. 
 
7.4 - Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-one (6c) 
This second synthesis aimed to create another methyl-chrysin analogue with the methyl 
in the para-position of the B ring, using slight changes to the synthetic method as above, 
in the hope that the para-substituted analogue would be less resilient to hydrolysis. In 
the event, (1) and (2c) were mixed together using the same molar ratios as used 
previously, but more time was given for each step to complete, in an attempt to achieve 
a higher yield and purity. Once the reaction was deemed complete by a TLC of 1:5 ethyl 
actete: petroleum ether, it was isolated and analysed by 1H NMR to check for impurities 
and unreacted starting materials. Unfortunately, the 1H NMR was extremely complex, 
with no identifiable products having been formed. Due to the lack of success with the 
previous synthetic attempts, and again here, it was decided to try a different approach, 
to achieve higher quality compounds for biological evaluation. 
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7.5 - Second Attempt at Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-
one (6c) 
General procedure: 
8
3c2c
i) K2CO3, H2O, PhMe, 60°C
X
ii) (nC4H9)4N+Br- 
5% K2CO3, reflux
Cl
O
OH
O
O
O
O
O
O OO H
Scheme 7.2 – Hydrolysis of p-toluoyl chloride (2c) to form p-toluic acid (8) 
This reaction was an attempt at the previous synthesis with the para-positioned methyl 
group on the B ring, but under different conditions, such as longer reaction times, extra 
catalyst and higher concentrations of base. However the benzoyl chloride reacted with 
water to form the carboxylic acid, not the desired product (3c). 
 
7.6 - Second attempt of synthesis of chrysin (6a). 
 
Due to the trace amounts of desired methylated-chrysin found in the second synthesis 
above, attempts turned back to create chrysin itself with further alterations to the 
literature conditions, in the hope of achieving higher yields. This involved using 
dichloromethane as solvent instead of the previously used toluene, since Shabnam 
Saxena and co-workers had found that doing so could produce higher yields [154]. In 
the event, the reaction was evaluated by 1H NMR of the crude mixture to determine how 
successful the solvent change had been. However, 1H NMR of what was expected to be 
the intermediate (3a) showed a very complex mixture, and so it was concluded that 
dichloromethane was not suitable here and that toluene would be used for all remaining 
attempts. 
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7.7 - Third Attempt of Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-
one (6c). 
 
Returning to toluene as solvent, the first step was performed the same as previously 
attempted, except that less catalyst was used and the reaction was left for a longer time. 
It was hoped that with less catalyst, the desired intermediate would be easier to isolate 
pure with improve yield. It was also decided not to wash the organic layer with aqueous 
solutions, but instead, isolate the organic compound directly from the organic layer, in 
the hope that there would be less chance of the desired product being lost. Performing 
this altered work-up yielded the purified esterified product (5c) in 15% yield. Once 
isolated, separate attempts to cleave the esters using acetonitrile/H2O and potassium 
hydroxide, were performed and the purified product again revealed hydrolysed benzoic 
acid and unhydrolysed ester.   
 
 
7.8 - Fourth Attempt of Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-
one (6c). 
3c1 2c
DCM, DMAP, 36°C
X
TEA 
Cl
O
OH O H
OO H
O
O
O
O
O OO H
+
 
Scheme 7.3 - Unsuccesful synthesis of (6c) using alternated conditions. 
 
As all attempts with the method proposed by Shabnam Saxena et al [154] were 
unsuccessful, a step-wise approach was taken, using dichloromethane, 4-
dimethylaminopyridine and trimethylamine to form and isolate the ester intermediate, 
rather than telescope all steps into one process. However, the initial reaction (DCM, 
DMAP, TEA, rt→reflux) showed no change by TLC, and when pyridine was added and 
heat was applied, there was still no significant change, so this method was not taken 
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further, despite such conditions being successful on other compounds in the Snape 
group. 
7.9 - Fifth Attempt of Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-
one (6c). 
 
Successive failures at this reaction encouraged a new approach to be adopted whereby 
each step was closely monitored, isolated and purified where possible to determine 
where and why the literature procedure was failing. Therefore, reverting back to the 
method using dichloromethane as a solvent instead of toluene, once the reactants had 
fully reacted by TLC, the first product was analysed by 1H NMR, which revealed that 
there was a large mixture of aromatics and methyl groups, which were expected due to 
the three arylmethyl groups on the intermediate, and the excess unreacted p-toluoyl 
chloride. So, the mixture was purified via flash column chromatography, which 
revealed six products. The fractions that were separable were isolated and analysed, 
revealing that one of the products was the ester (5c) seen previously, as identified by a 
single hydroxyl peak at 13.06 ppm, instead of the expected two peaks. The other two 
fractions gave inseparable mixtures and were not taken forward.   
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7.10 - Sixth Synthesis of 2-(4-Methylphenyl)-4H-chromen-4-one (6c). 
Enol B (11)
9 7
Enol A (10)
i) K2CO3, H2O, PhMe, 60°C
ii) (nC4H9)4N+Br- 
Cl
O
O H
O O H
O O H
O H
O H O
+
 
Scheme 7.4 - Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-one via the 
Baker-Venkataraman rearrangement forming the two stabilised enols. 
 
To confirm that the continued reaction reaction failure was due to the two extra 
hydroxyl groups in the starting matieral, and not due to human error, the synthesis was 
attempted again, but without the hydroxyl groups at positions 5 and 7 (Scheme 7.4), to 
form 2-(4-Methylphenyl)-4H-chromen-4-one (c.f. Figure 7.3). By using the same 
conditions, the diketone intermediate was formed, which stabilised itself as two enolic 
forms (enol A and enol B, see Scheme 7.4), which were confirmed by 1H NMR. 
Pleasingly, these products confirm that these reaction conditions do work, and that it is 
the two hydroxyls that are interfering with the synthesis. Unfortunatley, the additional 
hydroxyl groups are essential for biological activity (c.f. Chapter 3), meaning that it was 
necessary to persevere with the failed syntheses. As such, the synthesis in Scheme 7.4 
was not taken further as it lacked the essential hydroxyls, and much more promising 
progress had been made in parallel experiments, the details of which are shown in the 
following section.  
O
O
 
Figure 7.3 – Structure of 2-(4-Methylphenyl)-4H-chromen-4-one 
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7.11 - Alternative Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-one 
(6c) Using Methyl Protecting Groups. 
1312 7
i) K2CO3, H2O, PhMe, 70°C
ii) (nC4H9)4N+Br- 
Cl
O
O H
O
O H
O O
OMe
MeO
MeO
OMe
+
 
Scheme 7.5 - Synthesis of 5,7-dihydroxy-2-(4-methylphenyl)chromen-4-one via the 
Baker-Venkataraman rearrangement. 
 
Unlike the previous methods that exploited an in situ protecting group strategy, which 
subsequently proved difficult to remove, this new method used methyl protecting 
groups on the hydroxyls, to prevent unnecessary esters forming on the 5 and 7 position, 
an approach that had been shown to be successful by Khanapur [155]. Using similar 
methods as previously performed, with toluene as solvent, the method did show 
promise. However, these trial reactions were only performed on a test scale meaning 
that sufficient material was not obtained at first attempt. Nevertheless, after analysis of 
the small scale reaction, promising results were observed. Analysis showed a mixture of 
desired intermediate (13) and unreacted starting material. Nevertheless, these promising 
results for the methylated starting material, meant we were encouraged to test 
alternative conditions using the methyl protected starting material. 
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7.12 - Alternative Synthesis of 5,7-dihydroxy-2-(3-methylphenyl)chromen-4-one 
(6b,6c) Using Methyl Protecting Groups. 
2b: (R1 = H, R2 = CH3) 
2c: (R1 = CH3, R2 = H) 
14b: (R1 = H, R2 = CH3) 
14c: (R1 = CH3, R2 = H) 
15b: (R1 = H, R2 = CH3) 
15c: (R1 = CH3, R2 = H) 
15b: (R1 = H, R2 = CH3) 
15c: (R1 = CH3, R2 = H) 
13b: (R1 = H, R2 = CH3) 
13c: (R1 = CH3, R2 = H) 
13b: (R1 = H, R2 = CH3) 
13c: (R1 = CH3, R2 = H) 
14b: (R1 = H, R2 = CH3) 
14c: (R1 = CH3, R2 = H) 
6b: (R1 = H, R2 = CH3) 
6c: (R1 = CH3, R2 = H) 
THF, NaH
H2SO4, CH3COOH
HBr, CH3COOH
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O
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Scheme 7.6 – Synthesis of 5,7-dihydroxy-2-(3-methylphenyl)chromen-4-one (6b-c) via 
the Baker-Venkataraman rearrangement using the methyl protecting groups. 
During the alternative method, it was decided we would stop at each stage of the 
process to isolate, purify and characterise the products, in attempts to confirm reactions 
and optomise the process, to later achieve higher yields, as seen in Scheme 7.6. This 
method of using protecting groups from the start, not in situ bypassed the problem of 
de-esterification that arose from the previous methods. However, methoxy groups are 
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notoriously difficult to remove and require harsh chemicals to do so, but by carrying out 
this step, the final compound was reached. This method also gave better results 
throughout, determined by in-process analysis, possibly due to the lack of in situ 
protecting groups as intermediates. Unfortunately, after column chromatography and 
also purification with analysis at each step, the yield for this metod was low, and did not 
leave enough material for initial de-methylation attempts. 
 
7.13 - Second Synthesis of 5,7-dihydroxy-2-(3-methylphenyl)chromen-4-one (6b) 
Using Methyl Protecting Groups. 
 
Using the same conditions as the previous attempt, the methylated flavone was created 
with high purity in 35% yield. Literature procedures stated that removal of methyl 
groups from a flavone skeleton could be achieved by the use of boron tribromide, [156] 
as such, this method was attempted with small amounts of the purified compound in 
anhydrous dichloromethane, (boron tribromide is extremely reactive in the presence of 
water, becoming deactivated). Multiple attempts showed little to no activity, so 
alternative methods were investigated. Ranu B. et al explained that a mixture of 
hydrobromic acid and glacial acetic acid can remove the methyl group on such a 
flavonoid core, [157] so this procedure was tested and showed extremely good results, 
which resulted in the highly pure desired compound in its fully deprotected state. 
Although the overall yield was low, it was decided to try this method again, as the 
analysis and purification methods may have affected the yield. Due to the success of the 
meta-substituted analogue we also decided to synthesise the para substituent. 
 
7.14 - Conclusion 
The synthesis of chrysin analogues proved more complicated than first expected, 
despite the recorded literature. However, a viable synthetic route for flavones which 
contain hydroxyl groups at the 5 and 7 position was finally discovered by exploiting 
methyl protecting groups, which proved to be more effective than using in situ esters 
protecting groups as first thought – despite the notorious difficulty in removing methyl 
protecting groups during natural product synthesis. The newly discovered route did 
succesfully lead to the synthesis of two analogues with hydrophobic methyl groups on 
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ring B, and theoretically, the same methods can be used for hydroxyl and halogenated 
groups, as these show promise from the results of the computational studies (c.f. 
Chapter 6). These synthesised compounds will now be taken forward for kinetic 
experimental analysis to compare the computational results to the actual activity of the 
compounds. Then using this data, a refined search for the ideal ligand can be initiated, 
using the synthetic methods described and optimised above to create more potent 
compounds that bind to GP. 
 
7.15 – Experimental 
7.15.1 – Overview of Materials and Methods 
Reactions were followed by analytical thin layer chromatography (TLC) using plastic-
backed TLC plates coated in silica G/UV254, run in a variety of solvent systems and 
visualised with a UV light at 254 nm, p-anisaldehyde stain and/or potassium 
permanganate stain.  Commercially available solvents and reagents were purchased 
from Fisher, Sigma Aldrich, TCI and Fluorochem and were used without further 
purification unless specified in the syntheses.  Flash column chromatography was 
carried out on Davisil silica 60 Å (40 – 63 µm) under bellows pressure. 1H and 13C 
NMR were carried out on a Bruker Fourier 300 (300 MHz). GCs ran with DSQ II, 
Trace GC Ultra, Triplus, trace1800 GC & ITQ700. LCs ran with Finnigan LCQ 
Advantage Max, Finnigan PDA Plus detector. Infrared spectra were recorded on a solid 
sample using a Thermo Nicolet IR-200 FT-IR.   
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7.15.2 - 5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl benzoate 
5a
O
O
O
OO H
 
2,4,6-Trihydroxyacetophenone (1) (1 g, 5.37 mmol), was added to benzoyl chloride (2) 
(2.49 ml, 21.49 mmol) in a mixture of toluene (40 ml), saturated potassium carbonate 
(40 ml) and the reaction stirred at 60 °C for 1 hour, and monitered by TLC of 1:3 ethyl 
acetate: petroleoum ether. Tetrabutylammonium bromide (2.6 g, 8.06 mmol) was added 
and the mixture stirred at 60 °C for 3 hours, upon which an orange solution of (3a) was 
formed. The reaction was left to cool. To this solution, 5% K2CO3 (25 ml) was added 
and the mixture stirred at reflux (110 °C) for 4 hours. A dark orange solid formed in the 
orange liquid. This liquid was decanted off and added to glacial acetic acid (50 ml) with 
heat and stirring for 10 minutes. The solution was added to ice and a cream coloured 
solid was formed, which was washed with petroleum ether and water. The product was 
purified by flash column chromatography (1:3 Ethyl Acetate: petroleum ether) to yield 
compound (5a) (c.f. Chapter 7, Fig 7.2) (0.20g, 10.4%). 1H NMR (300 MHz, DMSO): 
δH= 12.36 (1H, s, OH), 7.95 (1H, s, Ar CH), 7.92 (1H, s, Ar CH), 6.47 (1H, d, J = 3, Ar 
CH), 6.31 (1H, d, J = 3, Ar-CH), 7.66-7.54 (3H, m, Ar CH), 7.48-7.33 (5H, m, Ar CH). 
13C NMR (75 MHz, DMSO): δC = 192.91 (OC=C), 180.25 (C=O), 165.66 (Ar CO), 
161.86 (Ar C-C), 158.06 (Ar C-O), 136.97 (Ar C-C), 134.70 (Ar C-C), 132.14 (Ar CH), 
131.59 (Ar CH), 129.72 (Ar CH), 129.50 (Ar CH), 129.32 (Ar CH), 128.75 (Ar CH), 
120.62 (Ar C-C), 103.74 (Ar CH), 99.90 (Ar CH), 94.88 (Ar CH). MS (ESI): m/z 359.1 
([M+H]+). 
 
 
 
 
 
 
105 
 
7.15.3 - 5,7-dihydroxy-2-(3-methylphenyl)chromen-4-one 
5b
O
O
O
OO H
 
2,4,6-Trihydroxyacetophenone (1) (1 g, 5.37 mmol) was added to 3-methylbenzoyl 
chloride (2b) (2.84 ml, 21.49 mmol) in a mixture of toluene (40 ml) and saturated 
potassium carbonate (40 ml), and the reaction stirred at 60 °C overnight. 
Tetrabutylammonium bromide (2.6 g, 8.06 mmol) was then added and the mixture 
stirred at 60 °C for 6 hours, and monitered by TLC, upon which an orange solution of 
(7) was formed. The reaction was left to cool over-night. The organic layer was 
separated and washed with 2 x 20 ml of distilled water. The interface and aqueous layer 
was washed with 2 x 20 ml of ethyl acetate, 2 x 20 ml of distilled water and 20 ml of 
brine. The organic layers evaporated, and 5% K2CO3 (50 ml) was added and the reaction 
heated at reflux with stirring for 2 hours to form (8), which was decanted off under 
suction filtration. The solid was transferred to a conical flask and boiled in glacial acetic 
acid (50 ml) for 30 minutes. Water (50 ml) was added, turning solution creamy and 
creating a precipitate, which was suction filtered and dried over night, then washed with 
ethyl acetate to yield the final compound (5b) (1.31 g, 97.58%), which was purified by 
flash column chromatography in 5:2 ethyl acetate: petroleum ether to yield 5b. 5ml of 
MeOH with K2CO3 (100 mg) was added to 8 and the attempted hydrolysis stirred at 30 
°C for 1 hour. TLC showed no change, so more K2CO3 (100 mg) was added and left for 
another hour. TLC showed no change. (5b) = 1H NMR (300 MHz, CDCl3): δH= 12.37 
(1H, s, OH), 7.73 (2H, Ar CH), 7.37 (4H, Ar CH), 7.22 (1H, Ar CH), 6.47 (1H, d, J = 3, 
Ar CH), 6.30 (1H, d, J = 3, Ar CH), 6.03 (1H, Ar CH), 2.37 (3H, s, CH3), 2.31 (3H, s, 
CH3). 13C NMR (75 MHz, DMSO): δC = 192.52 (OC=C), 179.89 (C=O), 165.03 (Ar C-
C), 162.25 (Ar C-O), 161.46 (Ar C-O), 157.61 (Ar C-O), 138.54 (Ar C-C), 138.29 (Ar 
CH), 136.69 (Ar C-C), 134.90 (Ar C-C), 132.32 (Ar-CH), 131.16 (Ar CH), 129.37 (Ar 
CH), 128.92 (Ar CH), 128.73 (Ar CH), 128.70 (Ar CH), 126.63 (Ar CH), 125.53 (Ar C-
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C) 120.31 (Ar CH), 103.40 (Ar C-C), 103.40 (Ar CH), 99.40 (Ar CH), 94.40 (Ar C-C), 
20.90 (Ar-CH3), 20.75 (Ar-CH3). 
 
7.15.4 - p-Toluic acid 
General procedure: 
8
OH
O
 
2,4,6-Trihydroxyacetophenone (1) (1.8 g, 9.67 mmol)  and (2c) p-toluoyl chloride (2 
ml, 15 mmol) were added to 50 ml of pyridine. The solution was stirred for 2 hours and 
poured over crushed ice with 3% HCl (20 ml) and stirred for 1 hour. The reaction was 
suction filtered and washed with methanol (2 x 20ml) and distilled water (2 x 20 ml) 
resulting in a white slurry. The aqueous layer was also washed with diethyl ether (2 x 20 
ml). These washing were combined with the white slurry and washed with 1 M HCl (2 x 
50 ml), distilled water (2 x 50 ml) and brine (50 ml) then dried with MgSO4. The 
resulting white powder was dissolved in pyridine with stirring at 55 °C, then 1 g of 
potassium hydroxide was added which turned the solution yellow. 10% acetic acid (10 
ml) was added with stirring for 1 hour, turning the solution dark. Rotary evaporation if 
the reaction yielded a yellow solid. Sulphuric acid (25 ml) was added with glacial acetic 
acid (25 ml) and the reaction stirred for 1 hour. The reaction was washed with water and 
dried with suction filtration, leaving tan coloured compound. The product was isolated 
by flash column chromatography to yield p-toluic acid (8) (40 %) 1H NMR (300 MHz, 
CDCl3): δH= 12.55 (1H, s, OH), 8.03 (2H, d, J = 9, Ar-H), 7.29 (2H, d, J = 9, Ar-H), 
2.45 (3H, s, CH3). Mp: 176-180 °C (lit: 177-180 °C) 
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7.15.5 – General procedure for the synthesis of B-ring analogues of chrysin 
6b: (R1 = H, R2 = CH3)
6c: (R1 = CH3, R2 = H)
OH O
O H O
R 2
R 1
 
7.15.5.1 – Procedure for the synthesis of 14b and 14c. 
14b: (R1 = H, R2 = CH3) 
14c: (R1 = CH3, R2 = H) 
O
O
O
MeO
OMe
R 1
R 2
 
2′-Hydroxy-4′,6′-dimethoxyacetophenone (1.0 eq.) was added to dichloromethane. m-
Toluoyl chloride (b) and p-toluoyl chloride (c) (1.1 eq.) was then added to the mixture 
with 4-(dimethylamino)pyridine (0.1 eq.) and triethylamine (1.5 eq.). This solution was 
stirred vigorously at room temperature until deemed complete by a TLC of petroleum, 
ether and ethyl acetate (3:1). The product was washed with hydrochloric acid (3 x 25 
ml) and extracted with dichloromethane (2 x 25 ml). The organic layers were combined 
and washed with distilled water (2 x 25 ml) and brine. The solution was evaporated in 
vacuo leaving an oil, which was dried in vacuo for 48 hours. 
14b 
Chromatography solvent, 1:3 ethyl acetate: petroleum ether. 1H NMR (300 MHz, 
CDCl3): δH= 7.94 (2H, Ar-H), 7.39 (2H, Ar-H), 6.40 (1H, AR-H), 6.35 (1H, Ar-H), 3.87 
(3H, O-CH3), 3.82 (3H, O-CH3), 2.48 (3H, C-CH3), 2.42 (3H, Ar-CH3). MS (ESI): m/z 
315.2 ([M+H]+). 
14c 
Chromatography solvent, 1:3 ethyl acetate: petroleum ether. 1H NMR (300 MHz, 
CDCl3): δH= 7.48 (2H, Ar-H), 7.26 (2H, Ar-H), 6.38 (1H, AR-H), 6.36 (1H, Ar-H), 3.81 
(3H, O-CH3), 3.77 (3H, O-CH3), 2.47 (3H, C-CH3), 2.40 (3H, Ar-CH3). MS (ESI): m/z 
315.3 ([M+H]+). 
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7.15.5.2 – General procedure for 13b and 13c 
 
13b: (R1 = H, R2 = CH3) 
13c: (R1 = CH3, R2 = H) 
O H
O O
MeO
OMe
R 2
R 1
 
 
Tetrahydrofuran was added with 4 Å molecular sieves to a dry round bottomed flask 
and stirred for 2 hours at 80 °C. 14b/14c was then added. Sodium hydride (4.0 eq.) was 
added and heated to 90 °C for 3 hours with stirring and left to cool over night. The 
mixture was then filtered and washed with hydrochloric acid until neutral and ethyl 
acetate (2 x 25 ml). The organic layer was washed with distilled water (2 x 25 ml) and 
brine (25 ml) and dried with MgSO4. This was then evaporated in vacuo resulting in a 
black oil. 
13b 
Chromatography solvent, 1:5 ethyl acetate: petroleum ether. 1H NMR (300 MHz, 
CDCl3): δH= 15.54 (1H, Ar-OH), 6.47 (1H, AR-H), 6.44 (1H, Ar-H), 7.98-7.28 (4H, m, 
Ar-H), 3.92 (3H, O-CH3), 3.81 (3H, O-CH3), 3.45 (2H, C-CH3), 2.43 (Ar-CH3). MS 
(ESI): m/z 314.3 ([M+H]+). 
 
13c 
Chromatography solvent, 1:5 ethyl acetate: petrololeum ether. 1H NMR (300 MHz, 
CDCl3): δH= 15.61 (1H, Ar-OH), 8.04-7.19 (4H, m, Ar-H), 6.47 (1H, AR-H), 6.45 (1H, 
Ar-H), 3.88 (3H, O-CH3), 3.82 (3H, O-CH3), 3.47 (2H, C-CH3), 2.42 (Ar-CH3). MS 
(ESI): m/z 314.2 ([M+H]+). 
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7.15.5.3– General procedure for 15b and 15c 
 
15b: (R1 = H, R2 = CH3) 
15c: (R1 = CH3, R2 = H) 
O
OOMe
MeO
R 1
R 2
 
Glacial acetic acid (100 ml per 1g of 2′-hydroxy-4′,6′-dimethoxyacetophenone) was 
added to 13b/13c along with concentrated sulphuric acid (2 ml per 1g of 2′-hydroxy-
4′,6′-dimethoxyacetophenone) and stirred at 110 °C for 4 hours. The hot solution was 
then poured over crushed ice and poured into a separating funnel. The solution was 
washed with sodium hydroxide (1 M) and ethyl acetate (2 x 25 ml), then water (2 x 
25ml) and brine (50ml). The resulting solid was purified by flash column 
chromatography using a solution of 1:9 ethyl acetate: petroleum ether. 
 
15b 
Chromatography solvent, 1:3 ethyl acetate: petroleum ether. 1H NMR (300 MHz, 
CDCl3): δH= 7.67 (2H, Ar-H), 7.34 (2H, Ar-H), 6.67 (1H, AR-H), 6.58 (1H, Ar-H), 6.38 
(1H, Ar-H), 3.96 (3H, O-CH3), 3.92 (3H, O-CH3), 2.44 (3H, Ar-CH3). MS (ESI): m/z 
297.1 ([M+H]+). 
 
15c 
Chromatography solvent, 1:3 ethyl acetate: petroleum ether. 1H NMR (300 MHz, 
CDCl3): δH=7.98 (1H, Ar-H), 7.77 (1H, Ar-H), 7.30 (2H, Ar-H), 6.69 (1H, AR-H), 6.57 
(1H, Ar-H), 6.38 (1H, Ar-H), 3.95 (3H, O-CH3), 3.91 (3H, O-CH3), 2.43 (3H, Ar-CH3). 
MS (ESI): m/z 297.2 ([M+H]+). 
 
 
 
 
110 
 
7.15.5.4 – General procedure for synthesis of 6b and 6c 
 
6b: (R1 = H, R2 = CH3)
6c: (R1 = CH3, R2 = H)
OH O
O H O
R 2
R 1
 
 
The purified solid of 15b/15c was added to a round bottomed flask with hydrobromic 
acid (15 ml per 1g of 2′-hydroxy-4′,6′-dimethoxyacetophenone) and glacial acetic acid 
(15 ml per 1g of 2′-hydroxy-4′,6′-dimethoxyacetophenone)  and stirred at 180 °C for 18 
hours to yield the final demethylated product, which was washed with sodium 
hydroxide until neutral, ethyl acetate (2 x 25 ml), 50 ml water and  50 ml brine, then 
dried with MgSO4. Rotary evaporation yielded the title compound as a pure product. 
 
5,7-Dihydroxy-2-(3-methylphenyl)chromen-4-one (6b).  
(0.14 g, 10.26 %) Chromatography solvent, 1:9 ethyl acetate: petroleum ether. 1H NMR 
(300 MHz, CDCl3): δH= 12.85 (1H, s, OH), 10.96 (1H, s, OH), 7.88 (2H, d, J = 9, Ar-
H), 7.45 (2H, d, J = 6, Ar-H), 6.95 (1H, s, Ar-H), 6.52 (1H, s, Ar-H), 6.22 (1H, s, Ar-
H), 2.41 (3H, s, CH3). 13C NMR (75 MHz, DMSO): δC = 181.90 (C=O), 164.45 (Ar, C-
C), 163.39 (Ar, C-OH), 161.48 (Ar, C-OH), 157.49 (Ar, C-O), 138.64 (Ar, C-C), 132.74 
(Ar, C-C), 130.67 (Ar, CH), 129.07 (Ar, CH), 126.84 (Ar, CH), 123.65 (Ar, CH), 
105.13 (Ar, C-C), 103.98 (Ar, CH), 99.03 (Ar, CH), 94.16 (Ar, CH), 20.98 (CH3). MS 
(ESI): m/z 269.2 ([M+H]+). IR (neat, cm-1) ν = 1649 (C=O), 1100 (O-H), 1117 (O-H), 
1182 (C-O-C). mp: 231-234 °C 
 
5,7-Dihydroxy-2-(4-methylphenyl)chromen-4-one. (6c) 
(0.27 g, 19.79 %) Chromatography solvent, 1:7 ethyl acetate: petroleum ether. 1H NMR 
(300 MHz, CDCl3): δH= 12.27 (1H, s, OH), 10.91 (1H, s, OH), 7.97 (2H, d, J = 8, Ar-
H), 7.38 (2H, d, J = 8, Ar-H), 6.93 (1H, s, Ar-H), 6.51 (1H, s, Ar-H), 6.21 (1H, s, Ar-
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H), 2.39 (3H, s, CH3). 13C NMR (75 MHz, DMSO): δC = 181.89 (C=O), 164.36 (Ar, C-
C), 163.36 (Ar, C-OH), 161.47 (Ar, C-OH), 157.42 (Ar, C-O), 142.37 (Ar, C-C), 129.76 
(Ar, C-C), 127.91 (Ar, CH), 126.39 (Ar, CH), 104.49 (Ar, C-C), 103.93 (Ar, CH), 98.98 
(Ar, CH), 94.12 (Ar, CH), 21.12 (CH3). MS (ESI): m/z 269.1 ([M+H]+). IR (neat, cm-1) 
ν = 1653 (C=O), 1128 (O-H), 1117 (O-H), 1188 (C-O-C). mp: 238-243 °C 
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Chapter 8 - Conclusion and Future Work 
 
Diabetes is one of the largest global health problems of the 21st century, with over 400 
million people suffering from hyperglycemia in some way, and with type 2 diabetes 
being the most prelevant (91% of diabetes in adults in high income countries [158]). 
Although there are currently drugs on the market which aim to make the disease 
manageable, such as metformin, glibenlamide, glimepiride and repaglinide, alongside a 
healthy life style, there are considerable side-effects associated with the current drugs 
including a risk of hypoglycaemia. Hence, there is an immediate need for new, more 
effective treatments to make the lives of patients easier and healthier. Inhibition of 
glycogen phosphorylase, especially at the caffeine binding site, is an extremely 
promising approach to finding a better treatment, as this site can prevent glucose 
production when blood glucose levels are too high, with inhibition at this site being 
more potent under high blood glucose concentrations, whilst being less potent at lower 
blood glucose levels. This balance can prevent hypoglycaemia in patients, which is a 
common risk inolved in current treatments. 
We have exploited computational methods such as docking with Glide SP and XP, 
which generated poses for further claculations. These were then followed by post 
docking calculations such as Prime and QM/MM-PBSA calculations, which minimised 
the poses, and accurately scores the ligands and predicts their free binding energy, as 
described throughout this project. By using these, we have efficiently screened a large 
library of possibly active and novel compounds, which have the potential to bind at the 
inhibitor site of glycogen phosphorylase. After multiple screening, filtering and 
consensus scoring techniques have been used, the computational simulations yielded a 
total of 13 ligands which are predicted to perform better at GP inhibition than the 
benchmark ligand chrysin. All 13 ligands can now be taken forward for synthesis via 
the Baker-Venkataraman re-aarrangement by manipulating methyl protected hydroxyl 
groups. The synthesised ligands will then undergoe further testing of their inhibitory 
function in Greece via kinetic eperiments. The original synthetic process did 
unfortunately take longer to optimise than expected, due to complications with de-
esterification on the A ring of the flavone in the final stages, which were formed in situ. 
Nonetheless, the method has finally been altered and refined to create the desired 
flavone structure with the hydroxyls left intact on the 5 and 7 position of the A ring by 
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using methoxy protecting groups, rather than in situ  protection methods. This 
procedure can now be taken forward and adapted to synthesise many of the investigated 
chrysin analogues which have been discovered via the computational methods. It is 
expected that the conditions throughout the refined synthesis will allow halogens and 
alcohols to be incorporated with minimal adaptation to the method. This is important, as 
the post docking QM/MM-PBSA calculations seemed to favour halogens and hydroxyls 
at the ortho position of the ring, due to binding interactions with the residue glutamate 
572. The synthetic procedure will, in theory, be viable for all ligands produced, as this 
was taken into consideration during the initial screening of ligands. The final 
compounds should also be viable as the halogens will not be reactive and the hydroxyls 
can be synthesised via methyl protecting groups in the same way as the hydroxyls in the 
5 and 7 position of the A ring. Though there will be epected alterations made to the 
synthetic route, such as the need to possibly allow more time for certain stages, changes 
to TLC and flash column chromatography solvent systems and potentially minor ratio 
changes, which can all be discovered in the lab, using simple observational methods and 
intuition.  
Combining the methods used throughout this project has considerable potential for the 
discovery of novel and active compounds in the treatment of type 2 diabetes, as 
thousands of ligands can be rapidly screened for their and potential, then selective 
synthesis of the best ligands can be implemented. Extension of this work has an exciting 
and promising future. With the refinement of the synthetic process, it will now be far 
easier to create the desired ligands which are predicted to have high binding affinities by 
the computational predictions. The computational results have suggested ortho-
substituted halogens and hydroxyl groups in the B ring, which would be considered 
first. Then, using kinetic experimental data from the synthesised compounds, we can 
then feed the information about what works well and what does not, back into the 
computational data to refine the results even further until we can successfully design 
more potent and drug-like inhibitors of glycogen phosphorylase. This structure activity 
relationship process can additionally be used to investigate how changes to the A ring 
affect binding in combination with the results we have for the B ring, until eventually 
we find the most optimal substitution combinations for the flavone to bind strongest. 
Further work would then involve pharmacokinetic and in vivo studies with the ultimate 
aim to achieve a drug that performs better than currently available treatments for this 
worldwide healthcare problem affecting the lives of many. 
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